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Integrating Statement 
I embarked on this professional doctorate program in public health to receive training in the 
skills crucial for leadership roles in public health. I was attracted to the DrPH programme at 
LSHTM as opposed to a PhD as it is designed for students like me whose career plans involve a 
broader range of public health activities and not specially research. For example, as a DrPH 
graduate I might work in international health organisations, national ministries of health, private 
sector providers, not-for-profit organisations, aid agencies, consulting groups, major companies, 
foundations and other donors, as well as research institutions1. 
 
From my first day in September 2010, I found the intellectual and academic standards of the 
DrPH high and demanding. The awarding of the DrPH degree requires successful completion of 
three components: one taught element and two research outputs; 
 
The taught component was delivered in Term 1 of my first year of the DrPH. This consisted of 
two compulsory modules which covered research methods and paradigms, the management of 
effective communications in public health practice and policy and leadership skills in public 
health. These modules are specific and exclusive to the DrPH programme and are delivered and 
assessed at doctoral level1. For example I completed a systematic review of the effectiveness of 
plain cigarette box packaging on reducing tobacco consumption. I was then required to write a 
policy brief for the Minister of Health outlining my scientific findings in a language that could 
be easily understood by a non-scientist for making a policy decision. This assignment 
highlighted the importance of evidence based policy making as well as providing me with the 
skill set to be able to bridge the gap between the “two communities” i.e. researchers and policy 
makers. From a personal perspective “Leadership Management and Personal Development” 
gave me the opportunity to discover my personality type and consequently how to work best in 
teams and in leadership positions. I was required to successfully pass this taught component 
before moving on to the Organisational and Policy Analysis (OPA) project. 
 
The OPA research project provided me with the opportunity to observe and analyse the 
workings of a private sector Fast Moving Consumer Goods (FMCG) company in its attempt to 
execute a public health objective “To increase the rates of hand washing with soap for children 
under five”. This OPA project involved 5 months fieldwork within my host organisation in 
India and Bangladesh. To achieve their public health objective it was essential that the FMCG 
Company form several partnerships with other private sector organisations as well as NGO’s 
and community based groups. I specifically analysed their current partnerships and provided 
recommendations on what was working and how they could improve partnerships that were 
proving difficult. The project was assessed on the basis of a 12,000 word academic written 
report. Upon successful completion of this report, I was then required to present my 
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organisational and policy analysis findings to the host organisation to help them make future 
policy decisions with regard to achieving their public health objective.  This component of the 
DrPH provided me a unique opportunity to explore public private partnerships from both 
perspectives. To remain impartial in my interviewing of both sides and subsequent report for the 
private sector organisation developed in me a new set of communication and writing skills that I 
feel are essential for any future role in public health leadership. 
 
Successful completion of the two compulsory core modules and the OPA project report was 
necessary to commence the current research thesis phase of the DrPH programme. 
The third and final component of the DrPH programme is the DrPH thesis. The scope of the 
thesis topic is broad. It could have been from any LSHTM academic discipline and subject area, 
from life sciences to social sciences and not restricted to public health medicine alone or 
necessarily related in any way to the core taught component subjects or the topic of the OPA 
report. 
 
The duration of my research and the length of the thesis itself are both shorter for the DrPH than 
the PhD, but the process is the same1. For the thesis component of the degree, I was required to 
conduct a literature review, prepare a research protocol and receive approval of my plan from 
my DrPH review Committee (the equivalent of an Upgrading Committee). Following the 
Committee’s approval and subsequent University and local ethics approval I conducted my data 
collection at the St Luke’s Radiation Oncology Network in Ireland, analysed the results and 
prepared this thesis. I did this under the supervision of my Supervisor and Advisory Committee. 
This thesis allowed me to combine my undergraduate degree and practical experience in 
Radiation Oncology with my Postgraduate Masters and DrPH experience in Public health. 
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Abstract 
 
Background: Exercise could have a role in ameliorating some of the adverse effects of External Beam 
Radiotherapy and Androgen Deprivation Therapy (EBRT+ADT) in men with prostate cancer. The primary 
aim of this study was to assess the feasibility (process, resource and management) and efficacy 
(scientific) of a home-based moderate-to-vigorous physical activity (MVPA) walking exercise 
intervention for patients with localised prostate cancer (PCa) undergoing EBRT+ADT in anticipation of a 
future confirmatory RCT. 
Methods:  PCa patients receiving EBRT+ADT were randomized to a home-based MVPA walking 
intervention (n=12) or standard care (n=12) for the duration of their EBRT. Intervention patients were 
prescribed 3000 steps in 30 minutes on 5 days each week, i.e. a cadence of 100 steps/minute. These 
3000 steps/day were prescribed in addition to their pre-determined habitual step/day. Fatigue, health 
related quality of life (HRQoL), anthropometric measures and physical performance were assessed at 
baseline (planning CT), mid EBRT, end of EBRT, and at 1 month post EBRT. Intervention participants’ 
satisfaction with the intervention and barriers/facilitators to exercise during EBRT were also assessed. 
Control group participants’ exercise knowledge, attitudes and practices were assessed post EBRT. The 
feasibility of the intervention’s processes, resources and management were assessed using quantitative 
and qualitative methods. 
Results: The exercise intervention group showed greater improvements in fatigue, quality of life, 
anthropometric measures and physical performance compared to standard care controls. These 
improvements were sustained beyond the intervention period. Exercise convenience and treatment 
centre environment emerged as exercise facilitators. Intervention participants’ average exercise 
convenience and satisfaction ratings were 4.8/5 (SD=0.4) i.e. “extremely convenient” and 4.8/5 (SD=0.4) 
i.e. “extremely satisfied” respectively. A lack of time and poor weather emerged as exercise barriers. 
Standard care controls had poor exercise knowledge, attitudes and practices (KAP) post EBRT, for 
example only 42% of the control group were aware of the correct recommended weekly MVPA 
guidelines.  
Conclusions: This preliminary evidence suggests that a pragmatic home-based MVPA walking exercise 
intervention is feasible and has the potential to evoke improvements in fatigue, in addition to other 
important health outcomes in men with PCa undergoing EBRT+ADT. This pilot study has achieved its six 
feasibility criteria and should proceed to a future confirmatory RCT. 
Impact: This study shows for the first time that a pragmatic home-based MVPA walking exercise 
intervention using evidence based tailored exercise prescriptions is feasible and could have a positive 
impact on fatigue and other key outcomes in men with PCa receiving EBRT+ADT. 
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Definition of a Pilot Study  
Investigations designed to test the feasibility of methods and procedures for later use or to 
search for possible effects and associations that may be worth following up in the subsequent 
future confirmatory study2. 
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1. INTRODUCTION 
1.1. Why Conduct A Pilot Exercise Study? 
In Ireland, prostate cancer (PCa) incidence is increasing3. The number of men living as prostate 
cancer survivors is also increasing thanks to improved treatment and management. This 
simultaneous increase in incidence and survivorship has focused researchers’ and clinicians’ 
efforts on improving the health related quality of life (HRQoL) of both prostate cancer patients 
under active treatment, and prostate cancer survivors. A diagnosis of prostate cancer and 
subsequent treatment with external beam radiotherapy (EBRT) and androgen deprivation 
therapy (ADT) regularly causes patients to experience disease- and treatment-related adverse 
outcomes, such as cancer related fatigue (CRF) and decreased HRQoL and physical 
performance.  There is strong evidence to suggest that physical activity interventions offset 
many of the side effects of EBRT+ADT, with few side effects themselves4,5. 
 
Large Randomised Control Trials (RCTs) are expensive and oncology trial sponsors such as the 
All Ireland Co-operative Oncology Research Group (ICORG) require preliminary evidence 
before supporting research. A pilot study is the best way to provide such evidence. Pilot studies 
assess the feasibility of expensive full-scale studies, and are considered an essential pre-
requisite by the British Medical Council2.  
 
The current prostate cancer research at the St Luke’s Radiation Oncology Network (SLRON) in 
Dublin, Ireland, is a pilot study. Pilot comparative randomised trials that are designed to provide 
preliminary evidence on the clinical efficacy of an intervention are routinely performed in many 
clinical areas2. External pilot studies such as this study, are defined as stand-alone pieces of 
work, planned and carried out independently of  the main future study6. 
 
Methodologically rigorous pilot studies play a crucial role in health research. This study builds 
on the emergent exercise study methodologies in cancer populations and introduces new 
methods to encourage and assess exercise adherence. For example, it is the first home-based 
exercise intervention for PCa patients undergoing EBRT+ADT that A) utilises a tailored step-
based exercise prescription and B) objectively measures physical activity adherence using a 
pedometer. 
 
In addition to exploring the effect of the walking exercise intervention on participants, this pilot 
study enabled us to examine elements of the trials process, resources and management 
including:  recruitment criteria and procedures, consent rate, testing of equipment, 
administration and assessment of the exercise intervention, and coordinating a multicentre trial. 
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It also served to increase our clinical experience with the new intervention for  a potential future 
trial2. Above all it aimed to determine the acceptability of the intervention to patients. To 
comply with best practice for reporting pilot studies, the results of this pilot investigation are 
reported using the CONSORT format2 . CONSORT guidelines also call for precise reporting of 
behaviour change interventions and therefore this intervention will be described according to the 
Behaviour Change Technique Taxonomy (v1)7. 
 
To fully understand the study’s outcomes of interest, objectives and methods; it is first 
important to have an understanding of prostate cancer, its treatment and the adverse effects of 
treatment.  
1.2. The Prostate  
The prostate (Figure 1) is a walnut sized gland found only in men. It is located between the 
bladder and the penis and just in front of the rectum. The urethra runs through the prostate, from 
the bladder to the penis, letting urine flow out of the body. 
 
 
 
Figure 1: The Prostate 
The prostate is part of the exocrine system and starts to develop before birth. It grows rapidly 
during puberty, fuelled by male hormones called androgens. The main androgen, testosterone, is 
made mainly in the testicles and to a much lesser extent in the adrenal glands. Testosterone 
controls the normal growth and development of the reproductive organs and is responsible for 
erectile function and libido. The enzyme 5-alpha reductase converts testosterone into 
dihydrotestosterone (DHT). DHT is the main hormone that signals the prostate to grow8. A 
normal prostate weighs between 20 and 30 grams, while a diseased prostate can weigh more 
than 100 grams8.  
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The vasa deferentia (singular: vas deferens) bring sperm from the testes to the ejaculatory ducts. 
The prostate secretes a milky substance that makes up around 20 to 30 percent of semen. It 
contains various enzymes, zinc and citric acid. Though prostate fluid is slightly acidic, another 
fluid in semen made by the seminal vesicles leaves semen slightly alkaline, or basic. This 
alkalinity helps protect sperm and prolong their life after they are deposited in the acidic 
environment of the vagina9. 
 
The prostate can be affected by a number of disorders, including prostatitis, benign prostate 
hyperplasia, and cancer. If prostate cancer (PCa) develops, testosterone stimulates the PCa cells 
to grow. Similarly if testosterone is inhibited from acting on PCa cells, PCa cells will shrink8. 
 
1.3. Prostate Cancer (PCa) 
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (~13% of all 
deaths) in 200810. The most recent global cancer estimates (2008) report that prostate cancer is 
the second most frequently diagnosed cancer of men (899 000 new cases, 13.6% of the total) 
and the fifth most common cancer overall10.  Nearly three-quarters of the registered cases occur 
in developed countries (644 000 cases). Incidence rates of prostate cancer vary by more than 25-
fold worldwide, the highest reported rates are in Australia/New Zealand, Western /Northern 
Europe, and North America, largely because the practice of prostate specific antigen (PSA) 
testing has become widespread in those regions10. 
 
Prostate cancer had an estimated incidence of 3267 cases and mortality of 563 cases in Ireland 
in 20113. Prostate cancer is the most common malignant cancer diagnosed in Irish men 
accounting for 31.9% of all invasive cancers and is the 3rd most common cause of invasive 
cancer death. It has an incidence rate of 156.4 per 100,000 and mortality rate of 25.5 per  
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Figure 2: NCRI Prostate Cancer Fact Sheet3 
100,000, cumulative lifetime risk of diagnosis of 13.5% and death of 1.1%. The National 
Cancer Registry predicts a 275% increase in cases between 2000 and 202011. Figure 2 below 
shows the age profile, trends in incidence (1994-2011), and 5 year relative survival for prostate 
cancer patients in Ireland.  
 
We do not know exactly what causes prostate cancer (PCa).  Researchers have found some risk 
factors, e.g. age, family history, race and geographic location and are trying to learn how these 
factors cause prostate cells to become cancerous. Essentially, PCa is caused by changes in the 
DNA of a prostate cell. Changes in DNA can cause normal prostate cells to grow abnormally 
and form cancers. DNA changes can either be inherited from a parent or can be acquired during 
a person's lifetime8. 
 
Some genes (linear sequences of nucleotides along a segment of DNA) control when cells grow, 
divide into new cells, and undergo apoptosis (programmed cell death). Certain genes that tell 
cells to grow and divide are called oncogenes. Others that normally slow down cell division or 
cause cells to die at the right time are called tumour suppressor genes. Cancer can be caused in 
part by DNA changes (mutations) that turn on oncogenes or turn off tumour suppressor genes8 
 
Ninety-five percent of PCa are of epithelial tissue with glandular origins (adenocarcinomas); 
other histologies (sarcoma, lymphoma, small cell carcinoma, and transitional carcinoma) are 
very rare. Adenocarcinomas arise in the peripheral zone of the prostate in approximately 70% of 
cases (figure 3). 
 
 
Figure 3: Zonal Predisposition to Prostate Disease 
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1.4. Non-Metastatic Prostate Cancer Treatment (T1-3, NO, MO) 
Cancer that is found within the gland only is called localised or early PCa. Cancer that has 
spread beyond the confines of prostate tissue is known as locally advanced PCa. These cancers 
have not spread to lymph nodes (N0) or to distant tissues (non-metastatic or M0) such as bones. 
In the T stages, the cancer is localised in the prostate gland and surrounding areas i.e. non 
metastatic. Among the treatment option available for non-metastatic PCa are surgery, 
brachytherapy (short range radiation) and the focus of this research; External Beam 
Radiotherapy (EBRT) and Androgen Deprivation Therapy (ADT). 
 
Treating PCa with EBRT and ADT conveys a survival benefit for this group of patients. 
However, a diagnosis of non-metastatic prostate cancer and subsequent EBRT+ADT regularly 
causes patients to experience disease- or treatment-related adverse outcomes, which reduce 
patients’ HRQoL during treatment and in survivorship. 
 
1.4.1. External Beam Radiation Therapy (EBRT) 
Ionising radiation causes wide-ranging molecular damage throughout cells by the production of 
ionised atoms, which cause breakage of chemical bonds, production of free radicals and damage 
to DNA. Most clinically significant effects of EBRT are due to irreparable DNA lesions which 
result in cell sterilisation - a loss of proliferative cells ability for sustained cell division12.  
 
In tumours, sterilisation of proliferative cells is a necessary condition for tumour cure. Partial 
sterilisation of the tumour cell population results in tumour stasis or regression, giving a clinical 
remission, followed by re-growth of the tumour from those cells which have retained their 
proliferative ability12. 
 
In self-renewing normal tissues, sterilisation of proliferative cells leaves the tissue unable to 
provide replacements for cells that are ordinarily being lost at a constant rate from the tissue, 
and initiates a rundown of the mature cells of the tissue. Proliferative sterilisation is often 
referred to as cell kill, with those cells that retain long-term proliferative ability being described 
as survivors12. 
 
In radical EBRT the objective is complete sterilisation of any tumour cells present without 
incurring a high risk of serious injury to normal self-renewing tissues for e.g. bladder and rectal 
tissue. EBRT side effects or “toxicities” can be divided into two categories; Acute- occurring 
during or shortly after EBRT, and Late- toxicities which manifest months or even years after the 
completion of EBRT.  
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The most commonly reported radiation induced acute toxicity of EBRT is Cancer Related 
Fatigue (CRF). EBRT has been reported to induce acute fatigue in up to 80% of patients13. In 
general, CRF usually increases in severity during EBRT, and peaks at the completion of EBRT. 
In up to 30% of cases, radiation-induced fatigue can last long after completion of treatment and 
thus develop into chronic fatigue13,14. Other commonly reported acute effects are listed in table 
1. Rectal bleeding and urinary function toxicities are the most commonly reported late toxicities 
of EBRT; however serious toxicities are very rare. 
 
 
1.4.2. Androgen Deprivation Therapy (ADT) 
Around 50% of men will be undergo Androgen Deprivation Therapy (ADT) as part of their 
treatment15. The purpose of ADT is to reduce levels of the androgens - testosterone and 
dihydrotestosterone (DHT) in the body, or to prevent them from reaching prostate cancer cells. 
Most of the male body’s androgens come from the testicles, but the adrenal glands also make a 
small amount. Androgens stimulate prostate cancer cells to grow. Lowering androgen levels or 
stopping them from getting into prostate cancer cells often makes prostate cancers shrink or 
grow more slowly for a time. However, hormone therapy alone does not cure prostate cancer 
and eventually, it stops controlling the disease16. 
 
There are several clinical situations when ADT may be prescribed16 for example: if patients’ are 
not able to have surgery/EBRT or can't be cured by these treatments because the cancer has 
already spread beyond the prostate gland, if a patient’s cancer remains or comes back after 
treatment with surgery or radiation therapy, or before EBRT to try to shrink the cancer to make 
treatment more effective. 
 
In the current research, we are only concerned with men who receive ADT along with EBRT 
(EBRT+ADT) as their initial treatment. These patients receive EBRT+ADT because they are at 
higher risk of the cancer coming back after treatment. This risk is determined by combining 
three pieces of clinical information about the cancer:  
 
Irritation and inflammation of the 
bladder 
Increased urgency/frequency of urination  
Nocturia (increased night-time urination) 
Dysuria (painful urination)/Haematuria (blood in urine) 
Incontinence 
Urinary tract obstruction or pain,  
Irritation and inflammation of the 
rectum 
Diarrhoea/Constipation 
Proctitis (inflammation of the rectum) 
Rectal pain/bleeding/mucous discharge 
Table 1: Potential Acute Side Effects of EBRT 
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A) Gleason score (pathology), a score given to a prostate cancer based upon its microscopic 
appearance. Cancers with a higher Gleason score are more aggressive and have a worse 
prognosis. 
B) PSA level (blood), and  
C) T-stage (growth of the cancer inside/outside the prostate as assessed clinically by a Digital 
Rectal Exam (DRE) or radiologically by an MRI scan).  
 
Patients with one high risk factor e.g. Gleeson score ≥ 8 or PSA ≥ 20 or T-stage of “3” are 
usually prescribed a short course of ADT i.e. 6 months. Patients with two or more high risk 
factors are normally prescribed long-term ADT i.e. 2-3 years. Patients receiving EBRT+ADT 
are at a greater risk of some treatment induced toxicities due to the combined effects 
EBRT+ADT than if receiving either alone. Patient on long-term ADT are more likely to 
experience adverse effects than those on short-term courses. 
 
Several types of hormone therapy can be used to treat prostate cancer. Some lower the levels of 
testosterone or other androgens. Others block the action of those hormones16. Most patients are 
prescribed a combination of a) luteinizing hormone-releasing hormone (LHRH) analogs and 
antagonists and b) anti-androgens. 
 
a) Luteinizing hormone-releasing hormone (LHRH) analogs and antagonists 
LHRH analogs e.g. Decapeptyl© and Eligard©, and antagonists e.g. Firmagon© lower the amount 
of testosterone made by the testicles. LHRH analogs are injected or placed as small implants 
under the skin. Depending on the drug used, they are prescribed from once a month up to once 
every 6 months. When LHRH analogs are first given, testosterone levels go up briefly before 
falling to very low levels. This effect is called ‘flare’ and results from the complex way in which 
LHRH analogs work. Flare can be avoided by giving drugs called anti-androgens (see anti-
androgens below) for a few weeks when starting treatment with LHRH analogs. LHRH 
antagonists work like LHRH agonists, but they reduce testosterone levels more quickly and do 
not cause tumour flare like the LHRH agonists do. Degarelix is an example of an LHRH 
antagonist.  
 
b) Anti-androgens  
Androgens have to bind to a protein in the cell called an androgen receptor in order to work. 
Anti-androgens e.g. Casodex© stop androgens from working by binding to the receptors so the 
androgens can’t. Drugs of this type, such as flutamide, bicalutamide, and nilutamide, are taken 
daily as pills. Anti-androgens are not often used by themselves. An anti-androgen may be added 
to treatment if an LHRH analog or antagonist is no longer working by itself. An anti-androgen 
is sometimes given for a few weeks when an LHRH analog is first started to prevent a tumour 
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flare. Anti-androgen treatment may be combined with LHRH analogs as first-line hormone 
therapy. This is called combined androgen blockade (CAB). 
 
While ADT has the beneficial effect of slowing down the growth of cancer by reducing the 
production of testosterone, this reduction leads to adverse effects (table 2) involving changes in 
body composition and fatigue that may reduce patients' Health related Quality of Life (HRQoL). 
ADT has some adverse effects in common with EBRT, namely CRF and decreased physical 
performance. It is suggested that 40% of men with biochemically controlled prostate cancer on 
long-term ADT report CRF that interferes with functioning17. 
 
 
Skeletal Decreased bone mass density 
Increased osteoporosis incidence 
Increased fracture risk 
Body Composition Increased body fat 
Decreased lean body mass 
Functional Decreased muscle strength 
Decreased physical performance 
Cardiovascular /Metabolic Increased circulating triglycerides 
Increased high density lipoprotein and total cholesterol 
Increased insulin resistance 
Increased incidence of metabolic syndrome and diabetes 
Increased arterial stiffness 
Sexual Erectile dysfunction 
Loss of Libido 
Gynecomastia 
Other Increased fatigue 
Decreased QoL 
Increased depression 
Decreased Cognitive function 
Vasomotor flushing (Hot Flushes) 
 
Table 2: Adverse effects of ADT18 
 
Since the incidence of PCa is increasing and the number of men living as prostate cancer 
survivors is increasing, research and clinicians’ efforts on improving CRF and overall health 
related quality of life (HRQoL) of both prostate cancer patients under active treatment, and 
prostate cancer survivors is also increasing. Key to this effort is reducing the onset and effects 
of EBRT+ADT treatment related toxicities and consequently reducing the future burden on the 
public health system. 
 9 
 
1.5. Public Health Burden 
Whilst EBRT+ADT convey clear biochemical failure-free survival and overall survival benefits 
for non-metastatic PCa patients CRF and combined EBRT+ADT treatment related changes in 
body composition may lead to diseases and syndromes that are more of a public health burden 
than the prostate cancer itself.15 
  
As prostate cancer patients undergoing  EBRT+ADT are likely to experience a diminished level 
of physical and psychological functioning that persists even after treatment finishes, 
intervention strategies that mitigate the effects of the associated CRF  and overall HRQoL are 
essential 4,5,19,20 and the driving force behind the current research. 
 
The next chapter (Literature review) will discuss in more detail the relationship between PCa 
treatments, Health related Quality of Life (HRQoL), Cancer Related Fatigue (CRF) and their 
implications for the future health of PCa survivors. It will also outline the evidence based 
decision-making process that has led to the conclusion that there is a need assess the feasibility 
(process, resource and management) and efficacy (scientific) of a home-based moderate to 
vigorous physical activity (MVPA) walking exercise intervention for prostate cancer (PCa) 
undergoing EBRT+ADT in anticipation of a future confirmatory RCT at SLRON. 
 10 
 
2. LITERATURE REVIEW 
This review of the literature is divided into four sections. Section 2.1 explores the relationship 
between Prostate cancer treatment, HRQoL and CRF, followed by a review of the literature 
regarding interventions designed to ameliorate HRQoL and CRF. 
Section 2.2 systematically reviews the literature regarding physical activity interventions for 
men with prostate cancer actively undergoing treatment with EBRT+ADT  
Section 2.3 examines the literature regarding best practices for prescribing exercise and 
enhancing adherence to the exercise prescription and finally section 2.4 draws theses sections 
together to conclude the literature review and contextualise the present study and provide 
justification for its research objectives. 
2.1. Prostate Cancer Treatment - Health Related Quality Of Life and Fatigue 
A diagnosis of prostate cancer and subsequent external beam radiotherapy (EBRT) and 
androgen deprivation therapy (ADT) regularly causes patients to experience  disease- or 
treatment-related adverse outcomes or both15, which reduce health related quality of life 
(HRQoL).   
Although there is no universally accepted definition of HRQoL, there is a consensus that it is a  
patient-reported, multidimensional construct5 with four major domains; physical function, 
psychological function, economic and social function, and spiritual wellbeing. HRQoL also 
encompasses the negative aspects of the disease or treatment such as fatigue21.Common 
psychological and emotional adverse outcomes include depression, anxiety, stress, reduced self-
esteem, loss of sense of control, and reduced psychological and emotional well-being5,20,22,23. 
The physical and functional adverse outcomes of prostate cancer and its treatment include 
diminished cardiovascular and pulmonary function, decreased strength and lean body mass, 
weight change, interrupted sleep patterns and, most notably for patients, cancer related fatigue 
(CRF)5,20,22,23. These physical and functional adverse outcomes are considered more clinically 
significant by clinicians and cancer researchers alike than social/family or emotional wellbeing 
adverse outcomes. 
2.1.1. External Beam Radiotherapy  
Cancer Related Fatigue (CRF) is the most commonly reported long-term adverse outcome in 
men treated for prostate cancer. CRF is defined by the National Cancer Control Network as a 
“distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or 
exhaustion related to cancer or cancer treatment that is not proportional to recent activity and 
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interferes with usual functioning”24. It is considered as important as lower urinary tract 
symptoms (LUTS) in its influence on HRQoL during and after EBRT13 
The exact physiological cause of CRF is unknown, but it is thought to reflect central nervous 
system mechanisms15. It’s aetiology, correlates and prevalence in the context of cancer of the 
prostate are poorly understood by clinicians 25. To the best of the author’s knowledge, no study 
has examined the severity and correlates of fatigue in men receiving EBRT+ADT. 
Radiotherapy has been reported to induce acute fatigue (during or soon after EBRT) in up to 
80% of patients13. In general, during EBRT, CRF usually increases in severity and peaks at the 
completion of RT. It can have a profound effect on patients’ ability to function in their usual 
roles and activities25. In about 30% of cases, radiation induced fatigue can last long after 
completion of treatment and thus develop into chronic fatigue13,14. 
There appears to be no consensus on how cancer patients in general experience fatigue with 
respect to EBRT field size, radiation dose, number and frequency of treatment fractions and 
EBRT free days13. In addition, there is conflicting evidence relating to the relationship between 
fatigue and demographic and social factors, in particular age, gender and marital status26. 
However, there is evidence that suggests that treatment modality, e.g.  active surveillance, ADT, 
RT, and surgery, affect  prostate cancer patients’ fatigue levels, with the highest levels of fatigue 
measured in the RT+ADT group27. 
2.1.2. Androgen Deprivation Therapy  
Around 50% of prostate cancer patients will use ADT as part of their treatment15. While ADT 
has the beneficial effect of slowing down the growth of cancer by reducing the production of 
testosterone, this reduction leads to side effects that increase CRF and reduce HRQoL. 
Reductions in testosterone directly contribute to substantial declines in body composition. 
Galvao et al28 reported regional decreases in bone mineral density (1.3-3.9%) and muscle mass 
(1.4 -5.6%), and increases in fat mass (12.0 – 20.7%), after 36 weeks on ADT. These changes in 
body composition and CRF may contribute to significant reductions in aspects of physical 
fitness and functional performance. Prostate cancer patients on ADT have the physical fitness 
and functional performance ability of someone 10-20 years older15,29.   
These declines contribute to prostate cancer patients having up to four times more fall-related 
skeletal fractures (non-pathological) than aged matched controls15,30. Further, changes in body 
composition and reduced physical activity levels often lead to serious changes in blood 
pressure, blood lipid profile and other contributory factors for metabolic syndromes- a name for 
a group of risk factors that occur together and increase the risk for coronary artery disease, 
stroke and type-2 diabetes. Keogh et al 15 illustrate the relationship between changes in these 
measures (Figure 4) 
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Figure 4: Potential Interrelationships between Changes in Outcome that may Contribute to an Increased Risk 
of Metabolic Syndrome, Falls Related Fractures and Reduced QoL for PCa Patients Undergoing 
EBRT+ADT15 
Despite current multimodal approaches to ameliorate CRF and HRQoL including patient 
education, pharmaceutical agents, aetiology-specific interventions, and non-pharmacological 
therapies, patients in SLRON and other cancer centres continue to suffer from CRF and 
subsequent reductions in HRQoL.  
The literature strongly supports the conviction that as PCa patients are extremely likely to 
experience a diminished level of HRQoL that persists even after treatment finishes, intervention 
strategies that mitigate the effects of the associated CRF  and physical performance 
deterioration are essential 4,5,19,20. 
2.1.3. Physical Activity Interventions for Cancer Patients 
A number of QOL interventions for cancer patients have been reported. Meyer and Mark, as 
cited by Courneya and Friedenreich20, systematically reviewed the psychosocial therapies: 
cognitive behavioural therapies, informational and educational strategies, individual counselling 
or psychotherapy, social support and alternative treatments such as music therapy. They 
reported that these therapies are least likely to address the physical and functional problems 
encountered by cancer patients, which experts consider the most important dimensions of 
overall QOL. 
There is strong evidence to suggests that physical activity interventions offset many of the side 
effects of EBRT+ADT with few side effects itself4,5. Researchers suggest that physical 
deconditioning, as a consequence of diminished physical activity, resulting from either the 
cancer itself or its treatment, produces reductions in aerobic capacity and ultimately causes 
CRF14. CRF interferes with the ability to pursue occupational and social activities, consequently 
diminishing HRQoL.  
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A 2012 Cochrane review of 56 Randomised Controlled Trials (RCTs)  with 4068 patients 
examined exercise for the management of fatigue in patients with all cancer diagnoses4. Another 
2012 Cochrane review5 of 56 RCTs with 4826 participants examined exercise interventions on 
HRQoL for people with  all cancer diagnoses during active treatment. The findings of these 
reviews need to be considered cautiously because they looked at many different variables and 
there was no consistency in the tools used to measure primary endpoints (HRQoL or fatigue)5. 
The combined 81 interventions differ across 11 dimensions including cancer diagnosis, outcome 
measures, mode, frequency, duration, location and format of exercise intervention. 
Meta-analyses indicated that exercise interventions compared with control interventions had a 
positive impact on overall HRQoL and certain HRQoL domains including physical, functional 
and social functioning at varying follow-up periods for cancer patients. Fatigue data were 
independently assessed and synthesised in both systematic reviews.  Exercise interventions were 
statistically significantly more effective for reducing fatigue than the control intervention at the 
end of the intervention period and at 12 weeks’ follow-up. The Cochrane reviews also revealed 
insights such as:  
a) the benefits of exercise on fatigue were only observed for interventions during or post- 
adjuvant cancer treatment for prostate cancer patients,   
b) aerobic exercise significantly reduced fatigue but resistance exercise and other forms of 
exercise did not have a statistically significant effect,4 
c)  there was a greater improvement in HRQoL and physical functioning, and a greater 
reduction in fatigue when prescribed a moderate or vigorous versus a mild exercise 
program5 as compared with light exercise programs. 
 
 
In view of the above, section 2 aims to systematically review the literature regarding physical 
activity interventions for men with prostate cancer actively undergoing treatment with EBRT+ 
ADT and to contextualise the present study and provide justification for its research objectives. 
 This review will focus on examining the effectiveness of exercise interventions on CRF and 
HRQoL. To achieve this aim, study outcomes like changes in physical fitness and functional 
performance parameters (table 5), and exercise intervention related changes in quality of life 
(QoL) type measures (table 6) are examined. An examination of exercise intervention 
prescription and patient adherence will also be conducted. 
The findings of this review inform the current pilot exercise intervention study and potential 
clinical trial in the St Luke’s Radiation Oncology Network (SLRON).  
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2.2. Systematic Review 
Section 2.2 aims to systematically review the literature regarding physical activity interventions 
for men with prostate cancer actively undergoing treatment with EBRT+ADT and to 
contextualise the present study and provide justification for its research objectives. 
2.2.1. Literature Search Methods 
In order to systematically review the literature regarding physical activity interventions for men 
with prostate cancer actively undergoing treatment with EBRT+ ADT, PubMed, Medline, 
Cochrane Library, TRIP database and Google Scholar were searched using the key words: 
prostate cancer, radiotherapy, fatigue, cancer-related fatigue, exercise, physical activity, QoL 
and their derivatives. Additional searches were conducted using the reference list and 
appropriate MeSH terms from two Cochrane reviews identified in the original search and by 
contacting authors. To be considered eligible for inclusion articles had to be full articles 
published in peer-reviewed journals and include prostate cancer patients only or, if a mixed 
study, report outcomes for prostate cancer patients separately. In addition, only articles 
describing exercise intervention for patients actively undergoing EBRT+ADT were included. 
There were no restrictions on language or year published. To the best of our knowledge this is 
the only review of such studies. 
2.2.2. Data Analysis 
The design and methodological rigor of each study was critically evaluated using a modified 
version of Sackett’s method as described by Keogh and MacLeod15 and Megens and Harris31. 
The following criteria were adapted from Sackett's rules for scientific evidence: (1) inclusion 
and exclusion criteria were listed for the subjects and clearly stated whether patients were 
actively receiving radiotherapy (2) the mode of physical activity (aerobic and or resistance) was 
adequately described so as to be replicable, (3) the reliability of data obtained with outcome 
measures was investigated, (4) the validity of the outcome measures had been assessed, (5) the 
assessors were blinded to the treatment groups, and (6) all subjects enrolled in the study were 
accounted for in analysis. This method has been used in previous systematic reviews of 
intervention studies involving cancer patients and complies with the PRISMA statement on best 
practice for  reporting systematic reviews15.  
The five levels (1-5) of evidence devised by the University of Oxford’s Centre for Evidence 
Based Medicine (March 2009)32 were utilised in conjunction with Sackett to provide four grades 
(A-D) of recommendations for the benefits of aerobic and or resistance exercise interventions 
for prostate cancer patients actively undergoing EBRT+ADT. 
Grade A recommendations were given to studies with strong evidence supported by at least one 
Level I study e.g. An RCT involving > 100 participants. Grade B recommendation were given 
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to studies with  relatively strong evidence supported by at least one Level II study e.g. An RCT 
involving < 100 participants). Grade C recommendations were given to studies with 
moderate/moderately weak evidence supported by a corroborative study other than a RCT 
(Level III – IV studies). There were no Grade D recommendations i.e. studies with troublingly 
inconsistent or inconclusive studies at any level 
2.2.3. Results 
2.2.3.1. Description of Studies 
 
Figure 5: PRISMA Flow Diagram 
Ten studies involving prostate cancer patients receiving exercise interventions were identified. 
Of these ten, only four met the principal inclusion criteria for this review (actively undergoing 
EBRT+ADT). Of the four included studies one was categorised as level Ib33,  and the remaining 
three as level IIb34–36. All four studies were RCTs and had clearly outlined their inclusion and 
exclusion criteria (e.g. absence of distant metastasis and the ability to participate in an exercise 
intervention). All studies gave detailed descriptions of how they structured their exercise 
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interventions. Three studies investigated aerobic interventions only34–36 while one study 
investigated both aerobic and resistance interventions33.  
Two studies identified fatigue and/or HRQoL as their primary outcome33,34, the other two35,36 
did not specify primary outcomes. All studies used reliable and valid measures of fatigue and 
HRQoL. Fatigue was measured using the Functional Assessment of Cancer Therapy-Fatigue33,36 
(FACT-F), the Brief Fatigue Inventory35 (BFI) or Piper Fatigue Scale36 (PFS) instruments. 
HRQoL was measured using the Functional Assessment of Cancer Therapy-Prostate33,36 
(FACT-P) instrument.  
One study33 measured muscular endurance by assessing trends in participants’ performance of 
two sets of eight to twelve repetitions of ten different exercises using a weight of 60-70% of one 
repetition max (1RM). Aerobic endurance was measured in three studies using walking tests36, 
volume of oxygen consumed33 or shuttle walking tests35. Functional performance was only 
measured in one study and they used a sit-to-stand test36 which predicts physical function and 
falls risk15. 
None of the four studies used blind assessment of outcomes; this can be largely explained by the 
nature of interventions. Three of the four studies accounted for attrition33,34,36. A summary of 
this evaluation can be found in table 3. 
The level of demographic information and clinical description of participants’ prostate cancer 
and treatment varied greatly between the four studies. The average age of participants in 
intervention arms was 67 years. Only one study36 reported race and their intervention included 
27% white, 64% black and 9% Hispanic participants. Two studies reported education level with 
the majority of participant having achieved a college or University education33 or over 12 years 
in education36 Only one study reported working status and reported that 22% of the intervention 
arm were in full-time employment versus 34% in the control arm33.  The majority of patients 
presented with T1/2 and stage 2 tumours. Only one study reported the average risk category 
(high) and Gleeson score (7) of patients’ tumours and length of time on ADT (12 months)34.  
Two studies33,36 reported the average weight of participants (88.6 kg) while only one reported 
Body Mass Index (BMI) (28.9)33. Time since diagnosis and presenting psa level were not 
reported in any study. 
Two of the studies consisted of group-based exercise33,36 and two consisted of home-based 
exercise34,35. Aerobic exercise was the primary focus of three studies34–36 and comparing aerobic 
and resistance exercise was the focus of one study33. The results of the eligible studies are 
summarised in tables 4-6. 
Table 4 presents the results of the only study to assess a change in body composition. This 
group-based study compared aerobic versus resistance exercise for changes in body fat 
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percentage. It reported that resistance exercise caused a nonsignificant decrease in fat 
percentage while participants undergoing the aerobic exercise intervention actually increased 
the body fat percentage. From baseline to post-test (24 weeks) the % body fat change of 
participants was -0.4%, +1.4 % and + 1.6%33 for those in the Resistance exercise, Aerobic 
exercise, and control /usual care groups respectively. 
Table 5 presents the results of exercise intervention related changes in physical fitness and 
functional performance parameter measures for prostate cancer patients undergoing radiation 
therapy in the four studies. 
Only one study33, which was group-based, and compared aerobic to resistance exercise, assessed 
changes in muscle endurance. It reported a significant increase in the resistance exercise group 
and a nonsignificant increase in the aerobic exercise group. Three studies33,35,36 assessed aerobic 
endurance and reported significant increases for both home and group-based interventions and 
aerobic and resistance interventions. One group-based aerobic intervention observed 
nonsignificant results33. One study assessed functional performance and found a significant 
improvement in a sit-stand-test post a group-based aerobic exercise intervention. 
Table 6 presents the results of exercise intervention related changes in QoL type measures for 
prostate cancer patients undergoing radiation therapy. Significant increases in QoL were 
reported for both aerobic36 and resistance33 group-based interventions.  Only a group-based 
aerobic intervention showed a significant decrease in fatigue33. Home-based aerobic 
interventions showed increases in QoL34 and  significant decreases in fatigue post intervention35. 
Only one study, Truong et al34 considered adherence to exercise prescription. 
2.2.4. Grade Recommendations 
Based on the results summarised in table 4 “Exercise Related Changes in Body Composition for 
Prostate Cancer Patients Undergoing EBRT”, table 5, “Exercise Intervention Related Changes 
in Physical Fitness and Functional Performance Measures for PCa Patients Undergoing EBRT” 
and table 6 “Exercise Intervention Related Changes in Quality Of Life Type Measures for PCa 
Patients Undergoing EBRT” recommendations on the benefits of aerobic or resistance exercise 
as well as group- and home-based interventions are suggested in table 715. 
 18 
 
Table 3: Evaluative Criteria for the Exercise Intervention Studies Reviewed 
Study 
Level of 
Evidence 
Inclusion and 
Exclusion Criteria 
Treatment can be 
replicated 
Reliability of 
Outcome Measures 
Validity of 
Outcome Measures 
Blind assessment of 
Outcome measures 
Account for 
Attrition 
(reporting bias) 
        
Group-Based exercise        
        
    Monga et al36 Level II b Y Y Y Y N Y 
    Segal et al33 Level I b Y Y Y Y N Y 
        
Home-Based Exercise        
    Truong et al34 Level II b Y Y Y Y N Y 
    Windsor et al35 Level II b Y Y Y Y N N 
Y = Yes, N = No 
Note: Due to the nature of exercise interventions, all studies were at high risk for performance and detection bias 
 
Level   
1a Systematic Reviews (SRs) of Randomised Controlled Trials (RCTs)  
1b Individual RCT (with narrow Confidence Interval‡) 
2a SRs of cohort studies 
2b Individual cohort study (including low quality RCT; e.g., <80% follow-up) 
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Table 4: Exercise Related Changes in Body Composition for Prostate Cancer Patients Undergoing EBRT 
Study Participants (n) 
Mean Age (years) 
Form of Training Duration (Weeks) &  
Frequency (Per Week) 
Mean change in Body fat %  
from baseline to Post-Test  
(p-value) 
Adjusted* Group difference  
in mean change from  
baseline to post-test  
(p-value) 
Group-Based Exercise   
Segal et al33 
(41) 65 
(40) 66 
(40) 66 
UC 
RT 
AT 
24,3 
+1.60 (.003) 1 
-0.04 (.947) 
+1.40 (.016) 1  
RT vs. UC: -1.50 (.055) 
AT vs. UC: -0.15 (.847) 
UC: Usual Care; RT: Resistance Training; AT: Aerobic Training. 
* Adjusted for age, cancer stage, androgen deprivation therapy (yes/no), and Gleason score. 
1. Indicates significant (p<0.05) improvement. 
 
Table 5: Exercise Intervention Related Changes in Physical Fitness and Functional Performance Measures For PCa Patients Undergoing EBRT 
Study Participants 
(n) Age in 
Years 
Form of Training Duration (Weeks) 
Frequency (Per 
Week) 
Muscular 
Endurance 
Aerobic Endurance Sit to Stand 
       
Group-Based Exercise       
  Monga et al36 (11) 68 AT 8;3  +47% METS treadmill1 15% Faster in 5 STS1 
  Segal et al33 
  Segal et al33 
(40) 66 
(41) 66 
RT 
AT 
24;3 
24;3 
+24-25%1 
+3-7% 
+9% treadmill VO2max
1 
+5% treadmill VO2max 
 
 
Home-based exercise       
  Windsor et al35 (33) 68 AT 4; ≥3 encouraged  + 13 % shuttle walk1  
RT = resistance training; 5STS = five sit to stand test; AT = aerobic training; METS = metabolic equivalents during a treadmill test. VO2 max (is the maximum capacity of an individual's body to 
transport and use oxygen during incremental exercise, which reflects the physical fitness of the individual. The name is derived from V - volume, O2 - oxygen, max - maximum. 
1. Indicates significant (p<0.05) improvement. 
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Table 6: Exercise Intervention Related Changes in Quality Of Life Type Measures for PCa Patients Undergoing EBRT 
Study Participants (n) 
Age in Years 
Form of Training Duration 
(Weeks) 
Frequency (Per 
Week) 
Overall QoL Social Quality 
Of Life 
Physical QoL Fatigue 
        
Group-Based Exercise        
  Monga et al36 
 
(11), 68 AT 8;3 +10% FACT-P1 +14% FACT-P1 +15% FACT-P1 -179% PFS1 
  Segal et al33 
  Segal et al33 
(40) 66 
(41) 66 
RT 
AT 
24,3 
24,3 
+5% FACT-P1 
+3% FACT-P 
  -11% FACT-F 
-6% FACT-F 
 
Home-based exercise        
  Truong34 (50) 67 AT 12;3 Higher fatigue 
interference trends 
with QoL observed 
in control 
compared with 
exercise group 
  Stable mean total 
fatigue scores 
from baseline to 6 
mts post-EBRT 
FU (P=0.52) 
Fatigue in control 
subjects escalated 
from baseline to 6 
mts post-EBRT (P 
≈ 0.3) (BFI) 
 
  Windsor et al35 (33) 68 AT 4; ≥3 encouraged    -82%BFI1 
(estimated) 
RT = resistance training; AT = aerobic training; FACT-P = functional assessment of cancer therapy-prostate questionnaire; FACT-fatigue = functional assessment of cancer therapy-fatigue 
questionnaire; PFS = piper fatigue scale; BFI = brief fatigue inventory. 
1. Indicates significant (p<0.05) improvement. 
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Table 7: Summary of Recommendations from 4 Studies on the Benefits of Exercise Interventions for PCa Patients Undergoing EBRT 
 Group-based Exercise (n=2)33,36  Home-Based Exercise (n=2)34,35 Resistance Training (n=1)33 Aerobic Training (n=4)33–36 
Body Composition     
  Fat Mass NSE NA NSE NSE 
     
Physical Fitness     
  Muscular Endurance A NA A NSE 
  Aerobic Endurance A B A B 
     
Functional Performance     
  Sit to Stand B NA NA B 
     
Quality of Life     
  Overall A NSE A NSE 
  Social B NA NA B 
  Physical B NA NA B 
     
Fatigue B B NSE B 
Grade A recommendation = strong evidence supported by at least one Level I study e.g. An RCT involving > 100 participants 
Grade B recommendation = relatively strong evidence supported by at least one Level II study e.g. An RCT involving < 100 participants) 
Grade C recommendation = moderate/moderately weak evidence supported by a non-RCT that is Level III – IV studies) 
Grade D recommendation = troublingly inconsistent or inconclusive studies at any level 
NA = not assessed in any study in this category 
NSE = study (s) in this category reported no significant effect 
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2.2.5. Discussion 
A lack of research concerning PCa patients and the effects of EBRT+ADT is evident 
considering that there is only one relatively large study (100+ participants) and three smaller 
studies included in this review. This trend is also apparent from previous Cochrane reviews 
where the majority of studies focus on breast cancer patients, fatigue and QoL issues. 
 Applying the rules of evidence suggested by the University of Oxford’s Centre for Evidence 
Based Medicine, provides relatively strong (Grade B) to strong (Grade A) evidence that exercise 
interventions performed at least three times per week can significantly increase physical fitness, 
functional performance and QoL, and can decrease fatigue in prostate cancer patients actively 
undergoing RT+ADT. The strongest evidence for improved physical fitness and QoL came 
from group-based (Grades A and B) resistance exercise (Grade A) interventions A clear gap in 
the literature regarding scientific justification for exercise prescription and exercise adherence 
evaluation is apparent. 
2.2.5.1. Body Composition 
Changes in body composition (% body fat) was only reported in one group-based study33 and 
was non-significant for both aerobic and resistance interventions, compared to usual care, 
although the resistance exercise group did show a trend towards a small reduction in body fat 
(see Table 4). This lack of improvement is most likely as a result of muscle loss combined with 
weight gain due to hormone therapy15. Unfortunately this study does not provide details of 
length of time on ADT or type of ADT. Encouragingly both resistance and aerobic exercise had 
a more positive effect on the percent of body fat for patients on the exercise intervention group 
than for those in the control group. The ability to retard a percentage body fat increase, in this 
group of patients, can potentially provide significant public health benefits in the future, in 
particular by decreasing the risk factors of metabolic syndrome.  
2.2.5.2. Aerobic Vs. Resistance Exercise Interventions 
Aerobic exercise interventions provide level B evidence for improvements in functional 
performance and the social and physical domains of QoL. Authors of resistance exercise studies 
did not record these outcomes so a comparison is impossible. The lack of recorded/ reported 
data on functional performance outcomes and the social and physical domains of QoL outcomes 
in resistance exercise studies was unexpected. These outcomes are useful predictors of QoL and 
future health. 
Resistance training interventions provided Level A evidence for improvements in the physical 
fitness domains of muscle endurance and aerobic endurance compared with no significant effect 
and Level B evidence for aerobic exercise interventions. 
Resistance training provided Level A evidence for improvements in overall QoL whereas 
aerobic exercise surprisingly had no significant effect. On the other hand aerobic exercise 
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provided Level B evidence for an improvement in fatigue compared to resistance exercise 
which appeared to have no significant effect. 
2.2.5.3. Group-Based Vs. Home-Based Exercise Intervention 
Group-based exercise interventions provide level A and B evidence for improvements in 
physical fitness, functional performance and social and physical domains of QoL for men with 
prostate cancer actively receiving EBRT+ADT. It is not clear whether group-based or home-
based exercise interventions provide better improvements, as neither of the two home-based 
studies recorded these outcomes. Our limited evidence thus far demonstrates that group-based 
interventions provide greater improvements in overall QoL and both types of intervention 
provide Level B evidence for reductions in fatigue. 
The lack of recorded/ reported data on body composition, physical fitness and functional 
performance outcomes in home-based studies is also unexpected considering their importance in 
predicting overall QoL, metabolic syndrome and likelihood of fall- related fractures in this 
patient population, especially those patients also undergoing hormone therapy15. This is a clear 
gap in the literature. 
 
2.3. Exercise Prescription Best Practice 
Prescribing exercise to prostate cancer patients while they are undergoing EBRT+ADT is a 
relatively new approach to reduce CRF and improve HRQoL as demonstrated by the small 
number of studies in this review. A review of the  literature makes clear that exercise training is 
ideally prescribed according to the FITT acronym37, frequency, intensity, time and type.  
A. Frequency:  the number of physical training sessions during a specified time period 
B. Intensity: the physiological effort associated with participation in that exercise 
C. Time: the duration of execution of a single session 
D. Type: the exercise modality e.g. Aerobic, resistance/strength 
 
All four studies outline the expected frequency, time and type of exercise (table 6) but they do 
not provide a scientific justification for their chosen exercise prescriptions. The main weakness 
of all 4 studies is a failure to control for the key health benefit determining component of an 
exercise prescription; intensity.  
Two of the review studies looked at a home-based aerobic intervention for prostate cancer 
patients, Truong34 and Windsor35.  In Truong’s study patients walked for 20 min/day, 3 
days/week for 12 weeks whereas in Windsor’s study patients walked for 30mins/day, 
3days/week for each week of EBRT treatment. Neither author provides an explanation of why 
their exercise prescription is preferential for producing health benefits in this cohort of patients, 
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yet both authors agreed in their conclusions that their respective prescriptions reduced 
fatigue35,38 and improved HRQoL38. We have no understanding of how intensely patients 
exercised. Controlling and evaluating intervention intensity is paramount, as the health benefits 
of the intervention are dependent on exercise intensity. For example, there is strong evidence 
from  the American College of Sports Medicine recommendations for exercise interventions, the 
aforementioned Cochrane reviews,  and home-based interventions of ADT-only prostate cancer 
patients - that the physical activity intensity needs to be mild to vigorous (MVPA) to have any 
health benefits i.e. improving patients HRQoL or fatigue39. Considering the clear evidence for 
an intervention of MVPA intensity, what is an appropriate exercise prescription for prostate 
cancer patients undergoing RT+ADT? 
The frequency and time and type of physical activity are easy to prescribe and measure in an 
intervention, however intensity is difficult. Evidence suggests that many people struggle to 
subjectively measure their exercise intensity after only hearing or reading a description of what 
it should feel like i.e. using the popular Borg scale of perceived self-exertion. Perceived exertion 
is an individual's subjective rating of exercise intensity, formed by assessing their body's 
physical signs such as heart rate, breathing rate and perspiration/sweating. Participants hear or 
read a description of how they should feel when engaged in moderate intensity physical activity 
(11-15 on the Borg scale or 60% to 80% of max effort).  
The Irish national guideline of 150 min/week of MVPA is too abstract for most people to 
monitor and achieve. Participant potential difficulty in subjectively gauging exercise intensity 
presents a challenge in designing a home based walking intervention. We therefore need a valid, 
reliable and objective intensity monitoring tool that is affordable and easy to use. 
Accelerometers are perhaps the most common method of measuring physical activity directly in 
a laboratory setting  but these monitors are prohibitively expensive and not validated for special 
populations such as the sample in the current research40. The pedometer on the other hand is an 
objective activity monitoring tool which is affordable and more likely to be adopted for clinical 
and real world application40. 
2.3.1. The Pedometer: Measuring Exercise Intensity by Proxy 
A pedometer tracks the volume of daily activity by measuring steps per day. Marshall et al40 
translated current recommendations for Moderate to Physical Activity  (MVPA) into a 
pedometer- based step goal. Their evidence supports a public health recommendation/health 
promotion heuristic that walking at least 3000 steps in 30 minutes on 5 days each week,  i.e. a 
cadence of 100 steps/minute and accumulated in minimally 10 minute episodes be used to 
indicate the minimum value for MVPA41. This recommendation is based on research i.e. studies 
on  adults  that directly measured the number of steps and verified activity intensity in absolute 
terms of metabolic equivalents or METs (1 MET = 3.5 ml O2/Kg/min or 1 Kcal/Kg/hour)
41. To 
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be an accurate translation of public health guidelines these steps should be taken over and above 
baseline levels of daily activity/background activity, i.e. 15000 step/week at 100 steps/minute 
above baseline step/week. 
2.3.2. How Many Steps Are Enough for Prostate Cancer Patients? - 
Establishing Baseline Levels of Daily Activity/Habitual Steps/Day  
Quantifying baseline level of non-exercise PA (habitual steps) is considered problematic as it 
has been influenced greatly by reduction of PA in most jobs, a reliance on labour-saving 
devices, passive transport and passive recreational activities41. Quantifying baseline levels of PA 
is further complicated in older adults, particularly those suffering from a chronic condition such 
as cancer, since self-reported walking activity increases with age in older adults while 
objectively monitored PA decreases41. 
Tudor-Locke’s et al review42  of  28 objectively monitored studies of adults ≥ 50 years of age 
reported that step-defined PA ranged from 2000 -9000 steps/day for this group. In a similar 
review of 60 studies of special populations including breast cancer patients Tudor Locke et al43 
reported that older adults with disabilities took the fewest steps/day (1214 steps/day) followed 
by COPD suffers (2237 steps/day). The highest number of steps/day were taken by Type 1 
diabetes suffers (8008 steps/day).These broad ranges of steps/day reflect the natural diversity of 
abilities common to older adults and special populations especially given that not all chronic 
conditions impact physical mobility and/or endurance41. 
There is little evidence to inform our views on baseline steps/day for prostate cancer patients 
undergoing RT+ADT. Tudor Locke et al, 201141 identifies 10 pedometer based physical activity 
interventions involving cancer patients. Only one of these studies14 involved prostate cancer 
patients. It was a home-based intervention of the 19 patients in the intervention arm only 6 had 
prostate cancer and only one had or was currently receiving ADT. In the control arm 5 patients 
had prostate cancer and only 2 had or were currently receiving ADT. In this study, baseline 
steps/day for the control and intervention group were 5544± 2746 and 7222 ±2691 respectively. 
Post-treatment steps/day were 4796 ±2613 and 11200 ±5851. These figures represent a decrease 
in steps walked of 572± 2139 for the control group and an increase in steps walked of 3977 
±5959 for the intervention group14.  
Despite the limited similarities between the patient samples of the above study and the proposed 
study, it is encouraging to see the positive increase in daily steps in the intervention arm. These 
figures should be viewed with caution as it appears that baseline assessments of daily steps 
occurred after EBRT commenced and thus is not a true reflection of daily background 
steps/habitual steps. The process of being on treatment and the logistics involved may cause a 
natural increase or decrease in habitual steps/day. Consequently the success of the intervention 
may be inaccurate. The current study will control for this potential bias. 
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2.3.3. Calculating Exercise Prescription ExPx- Combining Habitual 
Activity with MVPA Prescription 
Consider a prostate cancer patient with a background daily activity of 7222 steps/day as in 
Mustian et al14, determined by a pedometer. His tailored exercise prescription would be 
calculated as follows: 
 MVPA days  
(steps) 
Background daily activity 7222 
MVPA (30min at 100 steps/min) 3000  
Total 10222 
 
The above table projects an estimated 10222 steps/day on the 5 days that include the goal of 30 
minutes of MVPA. Over the course of a week this averages out to 9364 steps/day (7 days at 
7222 added to 15000 MVPA steps). 
Despite prescribing tailor- made exercise interventions and controlling for intensity, the efficacy 
of the intervention is dependent on what many authors consider to be the “Achilles heel” of 
exercise intervention RCTs- adherence 
Getting people to Exercise-adherence- the Achilles heel of exercise RCTs44 
Adherence is defined by the World Health Organisation (WHO) as “the extent to which a 
behaviour - taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider45”  More specifically, exercise 
adherence may be defined as the extent to which the intervention group perform the exercise 
prescription. Conversely, exercise contamination refers to the extent which the control group 
has performed the exercise prescription46. The critical success determining components of 
RCT’s to test the efficacy of exercise interventions are high levels of exercise adherence in the 
intervention group and low levels of exercise contamination in the control group46.  
An insufficient investigation of exercise adherence and contamination is a key weakness of the 
four RCTs in this review. Only Truong et al34 considered exercise adherence in the intervention 
group, although not fully. They reported a reported protocol adherence of 84% (42/50 patients) 
with positive observations in fatigue reduction and QoL increases. Disappointingly, the protocol 
defined adherence by frequency, time and type (FTT) but did not factor in adherence to a 
prescribed exercise intensity (I). 
The speciality of Cardiology has the most experience in accessing adherence to exercise 
interventions. Only 20 years ago exercise was prescribed  in an experimental setting, today it is 
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a Class 1 recommended non-pharmacological treatment  for all stable heart failure patients37. 
However, despite its class 1 recommendation, implementation in clinical practice is low37.  
The European society of Cardiology suggests that low clinical implementation is as a result of 
underwhelming  results from large trials such as “Heart Failure: A Controlled Trial 
Investigating Outcomes of Exercise Training” . In this trial, 2331 patients were randomised to 
either aerobic exercise training or usual care to determine whether the intervention was able to 
reduce all-cause mortality/hospitalisation and improve QoL. While the results favoured the 
exercise intervention the effect size was less than expected. The authors conclude that the most 
likely explanation for these underwhelming results is the aforementioned “Achilles heel” of 
exercise training programmes that is non-adherence. Only 40% of patients in the exercise group 
reported weekly training volumes at or above those recommended. This is despite providing a 
supportive environment, a well-controlled RCT, formal education, activity logs, telephone 
contact, regular visits to the clinic, and heart rate monitors37. Considering the importance of 
adherence in determining the efficacy of exercise interventions in RCTs, it is crucial to monitor 
and improve adherence in both the exercise and control group44.   
What do we know about getting cancer patients to exercise? 
Most research on adherence has focused on cancer survivors after cancer treatment. A 
systematic review by Bourke et al47 (2014) “Interventions for promoting habitual exercise in 
people living with and beyond cancer”  reported that interventions to promote exercise in cancer 
survivors who report better levels of adherence share some common behaviour change 
techniques as defined by Michie et al48 i.e. setting programme goals, prompting practise and 
self-monitoring and encouraging participants to attempt to generalise behaviours learned in 
supervised exercise environments to other, non-supervised contexts47. 
They also reiterate  that prescriptions should be designed around individual capabilities, and 
frequency, duration and intensity or sets, repetitions, intensity or resistance training should be 
generated on this basis47. 
There is a gap in the literature regarding the adherence of patients receiving active cancer 
treatment who are likely to encounter disease and treatment-related side effects that might affect 
exercise behaviour44. To obtain the maximum health benefits of the proposed home-based 
walking exercise intervention, every effort must be made to achieve 100% adherence to the 
FITT prescription in the intervention group and 0% contamination in the control group46.  
Shang et al44 provide the most pertinent research to help us achieve this aim. Their RCT to test 
exercise intervention among patients with mixed cancer diagnoses and treatments, undergoing 
active treatment, reported how adherence significantly affected intervention efficacy. They 
analysed exercise-related adherence patterns and identified factors related to exercise adherence 
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in the intervention group and exercise contamination in the control group. Exercise non-
adherence in the intervention group was 32% while the exercise contamination rate in the 
control group was 12%. Independent predictors of adherence for the exercise group were 
baseline level of physical fitness, and pre-treatment fatigue (p< 0.01, < 0.01). Past exercise 
history significantly predicted exercise contamination (p<0.05) in the control group44. 
Considering this information, it seems pertinent to record these pre-treatment variables that are 
known to be significantly associated with fatigue and HRQoL44 for potential use in a future 
confirmatory trial. 
In addition to recording the above predictive factors, this study will incorporate the following 
evidence based behaviour change techniques; 
A. The home-based walking intervention will be prescribed according to the FITT ideal. 
B. Set programme goals (outcome), action planning, barrier identification, promote practise, 
encourage participants to attempt to generalise behaviours learned in supervised exercise 
environments to other, non-supervised contexts, provide instructions and how and where to 
perform the exercise, demonstrate the exercise, environment restructuring, and time 
management48. 
C. Self-monitoring48: i.e. the use of both subjective (log-books) and objective (pedometers) 
methods to assess adherence. 
D. Two baseline values of patient steps/day will be established. A “pre-treatment” and “on-
treatment” value. This distinction will enable us to distinguish the natural reduction in daily 
steps walked by patients when they undergo EBRT, and to minimise bias in pre/post 
treatment steps/day calculations. 
E. Distinct from previous exercise intervention with cancer patients where the exercise was 
carried out before or after medical treatment, our intervention concerns only prostate cancer 
patients currently undergoing EBRT+ADT. This has several adherence promoting 
advantages as it enables us to monitor and encourage patients daily (as in a hospital based 
intervention) as they attend for treatment, while at the same time providing a pragmatic, low 
resource home-based intervention. 
2.4. Conclusions From the Literature 
There is strong evidence that patients with localised prostate cancer undergoing RT+ADT will 
experience clinically significant adverse side effects like decreased physical and functional 
capacity and  fatigue which will diminish HRQoL and potentially increase the risk for coronary 
artery disease, stroke and type-2 diabetes. The public health burden of caring for prostate cancer 
survivors may therefore become even greater than caring for prostate cancer patients. 
Despite current multimodal approaches to ameliorate CRF and HRQoL including patient 
education, pharmaceutical agents, aetiology-specific interventions, and non-pharmacological 
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therapies, patients in SLRON and other cancer centres continue to suffer from CRF and 
subsequent reductions in HRQoL. Considering the lack of effective treatments, RCTs are 
needed to confirm the feasibility and efficacy of the most promising solution; moderate to 
vigorous physical activity. 
The literature on exercise interventions in men with prostate cancer undergoing RT+ADT 
represents less than 10% of all reported cancer related RCTs of exercise interventions. These 
RCTs have shown consistently that physically active prostate cancer patients have significantly 
greater QOL and less fatigue than those who are less active. The level A and B evidence for 
improvements in HRQoL and fatigue in these RCTs is consistent with both 2012 Cochrane 
reviews of exercise interventions for all cancer patients. 
Many patients believe that an increase in physical activity would provide many benefits 
including symptom relief15. Despite this belief, and evidence supporting exercise interventions, 
prostate cancer patients’ participation in physical activity is low.   Some researchers consider 
that  poor patient participation is a result of poor knowledge on the part of  health professionals 
and subsequent lack of physical activity prescriptions15,49. 
No authors to date have dealt with the practical issues of RCT feasibility e.g. resources, 
management and processes. Greater HRQoL benefits for prostate cancer patients have thus far 
been associated with facility-, rather than home-based interventions50. The cost and availability 
of human resources to provide exercise programs at radiotherapy centres is a barrier that 
severely limits programme delivery and access50. This is particularly relevant in the Irish health 
system at present as it is under extraordinary financial pressure. In addition, the patient related  
obstacles of extra time spent in a hospital per day, extra parking costs and negative treatment 
experience may reduce participation in a facility-based intervention50. Considering these 
potential barriers, a home-based intervention is the preferred option for maintenance of exercise 
adherence. 
A home-based intervention  is particularly appropriate for prostate cancer patients continuing 
ADT post treatment as the treatment and side effects may be experienced long term50. The most 
recent literature by Santa-Mina et al50 on ADT only patients provides further  evidence in favour 
of both aerobic as opposed to resistance, and home- as opposed to facility-based exercise 
interventions for prostate cancer patients. In addition they suggest that aerobic exercise  is more 
effective in stimulating long-term changes in exercise behaviour as patients are likely to be 
more familiar with AE such as walking than RE modalities50. 
The research to date has tended to focus on evaluating the efficacy of the exercise intervention 
but no study has controlled for the foremost health determining component of FITT exercise 
prescription “intensity” and the related  Achilles heel37 of exercise interventions “exercise 
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adherence”. The current research will prescribe tailored step/day based exercise prescriptions 
and measure adherence according to the best practice recommended FITT classification. To 
obtain the maximum benefit of the intervention we will employ objective pedometers and 
subjective logbooks to increase adherence in the intervention group and reduce contamination in 
the control group. Considering that, 
 there are numerous hospital and patient financial and logistical disadvantages with 
supervised,  facility-based group exercise interventions, 
 aerobic and home-based  interventions have demonstrated relatively strong evidence 
(Grade B) for improving HRQoL and reducing fatigue,  
 prostate cancer patients may find it easier to maintain a simple walking regime than a 
new resistance programme in the long-term,  
 exercise intensity is the most significant health benefit determining component of an 
exercise prescription 
 exercise adherence is the weak link of previous exercise RCTs 
 
there is a need to evaluate a pragmatic, tailored , moderate to vigorous intensity home-based 
aerobic exercise intervention for prostate cancer patients actively undergoing EBRT+ADT51 that 
encourages  maximum adherence in the intervention group and minimum contamination in the 
control group. 
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3. METHODS 
3.1. Pilot Study Objectives 
There is a clear gap in the literature concerning the feasibility of a home based MVPA aerobic 
exercise intervention to reduce fatigue and increase HRQoL for patients with localised prostate 
cancer actively undergoing EBRT+ADT.  
 
We hypothesise that in a proposed future confirmatory study, patients in Ireland and countries 
with similar treatment protocols, with localised prostate cancer undergoing radical EBRT+ADT 
randomised to the MVPA walking exercise intervention will experience less fatigue in 
comparison with the standard care control group over the period of radiotherapy treatment and 
at 1-month follow-up. 
 
The objectives of this pilot study are categorised as follows: 
 
1. Process- to assess the feasibility of the processes that are fundamental to the success of 
the main study. 
2. Resource- to assess the time problems that may occur during the main study. 
3. Management- to assess the potential human and data management problems. 
4. Scientific- to assess intervention safety and estimate the interventions effect size on 
cancer related fatigue and its variance. 
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3.2. Pilot Study Endpoints 
(See 3.7.3 for required feasibility criteria to proceed to a future confirmatory RCT at SLRON) 
Table 8 below outlines the specific pilot study endpoints associated with each of this studies 
process, resources, management and scientific objectives. 
 
Study objective Endpoint 
Process:  Baseline characteristics distribution 
 Eligibility criteria acceptability 
 Recruitment rates 
 Refusal rates/willingness to be randomised 
 Retention rates 
 Schedule of assessment distribution 
 Study questionnaire acceptability 
 Study tools acceptability 
 Satisfaction due to intervention 
Resources:  Key process times 
 Room and equipment availability 
Management:  Pilot study management issues 
 Data entry issues 
 Potential new data value 
Scientific:  Is it safe to use the study’s exercise intervention? 
 Exercise prescription adherence rates in the intervention group and exercise contamination 
in the control group 
 Determine the impact of a home-base walking exercise intervention and its effect on fatigue 
 What is the estimate of the treatment effect? 
 What is the estimate of the variance of the treatment effect? 
 HRQoL,  
 Anthropometric measure and 
 Physical Performance 
In patients with localised prostate cancer actively undergoing radical EBRT + ADT, and to use 
these data to assist in sample size estimates for a future confirmatory trial in an Irish setting. 
Table 8: Pilot Study Endpoints 
3.2.1. Proposed Future Confirmatory Study Endpoints 
Primary Endpoint 
 Patient assessed fatigue 
Secondary Endpoints 
 Patient assessed HRQoL                                                                                    
 Anthropometric measurements                                                
 Functional fitness measurements 
 Rate of adherence/contamination to exercise intervention                     
 Patient satisfaction with exercise intervention 
 
Intervention & control arm 
Intervention arm only 
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3.3. Pilot Study Design 
This pilot study is a comparative randomised trial designed to provide preliminary evidence on 
the clinical efficacy of our proposed exercise intervention. Also known as a “feasibility” or 
“Vanguard” study, it is designed to assess the safety of the intervention, recruitment potential, 
co-ordination of multicentre trial and to increase clinical experience with the exercise 
intervention2. It is the best way to assess feasibility of a large, expensive full-scale study2. 
Conducting this pilot study prior to the potential main study will enhance the likelihood of 
success of the main study in SLRON. 
 
This study is a two-arm, pilot, randomised controlled trial (RCT) of a home-based walking 
intervention. It consists of an intervention arm, in which patients adhered to a walking program 
for 6 weeks of their EBRT treatment and a control arm in which patients followed the standard 
treatment for their disease.  
 
A qualitative study was also nested within the RCT. After completion of the walking 
programme, participants in the intervention arm were invited to take part in an in-depth 
interview. The researcher endeavoured to uncover insights into barriers and facilitators for 
participation on the walking program. A saturation of information occurred at four patients. 
Considering no further interviews were justified. These insights will be used to aid the design of 
future patient–centric home-based exercise programs. Control group participants completed an 
exercise Knowledge, Attitude and Practices (KAP) questionnaire. The 3 trial co-ordinators (one 
at each centre) were also interviewed to gain an understanding of process, resource and trial 
management issues. This pilot study followed the CONSORT guidelines for reporting pilot 
studies. 
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3.4. Participant Flow 
Men with localised prostate cancer receiving radical EBRT+ADT were identified from CT 
schedules at each of the 3 SLRON centres, screened for eligibility (Section 3.8) and consented 
according to ICH-GCP protocols by a designated Registrar/Consultant and Trial Co-ordinator 
with ICORG GCP certification. All participants underwent baseline assessments at their 
planning CT appointment before randomisation and commencing EBRT including: 
Baseline assessments at planning CT appointment 
 
 Self-report questionnaires (Brief Fatigue Inventory [BFI] and Functional Assessment of Cancer 
Therapy-Prostate [FACT-P]) 
 Functional fitness (2 minute step test and 30 second chair-stand test) 
 Anthropometric measures (Height, weight, % , waist circumference, body fat, % muscle/bone 
mass) 
 Habitual/background steps/week measured using a pedometer given to patients at CT (A) 
 
Randomisation during week 2 of EBRT 
After completing all baseline assessments patients were randomised  centrally by the CTRU 
administrator using a randomisation scheme with blocks of four to a home-based walking 
program (intervention arm) or to follow standard treatment (control arm).  
Intervention arm: 
Starting in week two of EBRT, participants randomised to the intervention arm were given a 
tailored step/day target. Participants were also asked to walk for a minimum of 3000 steps/day, 
in 30 min sessions (duration), 5 times/week (frequency) at a rate of 100 steps/minute 
(MVPA intensity). In other words patients were asked to achieve 15000 steps/week measured 
using a pedometer in 150 minutes in total. The minimum time allowed per session was 10 
minutes. These 15000 MVPA steps were in addition to continuing to achieve their baseline 
steps/week (A below). 
 
Calculating individual exercise prescriptions ExPx- combining habitual activity with MVPA 
prescription 
Consider a prostate cancer patient with a background daily activity of 7222 steps/day as in 
Mustian et al14, determined by a pedometer. His tailored exercise prescription on each of the 5 
MVPA days would be calculated as 
follows: 
 
 
 
Participants were asked to continue with this programme throughout the course of their EBRT. 
The clinical research co-ordinator explained the home-based exercise program to the 
participants. To help improve adherence, a behavioural component exploring with patients how 
they could incorporate walking within their daily lives was carried out by the trial coordinator*. 
Patients were asked to fill in a log book to record the frequency, duration, and steps achieved for 
the 30 min MVPA intervention each day.  Patients completed an exercise satisfaction 
questionnaire at 4 weeks (Mid EBRT), 7-8 weeks (End EBRT/post intervention) and at 1 month 
 MVPA days 
(steps) 
Background daily activity (A) 7222 
MVPA Px (30min at 100 steps/min) 3000 
Total 10222 
 
Week -2 (CT)        -   -1      -1                      Start EBRT              +1 +1            +7 
Pedometer 
Steps/week 
Disregard 
(hawthorn effect) 
Background steps (A)  Natural decrease due 
to EBRT 
Intervention           Ex Px (A + 15000 MVPA 
steps/week)  
Control             usual care 
The table to the right projects an estimated 10222 
steps/day on the 5 days that include the goal of 30 
minutes of MVPA and 7222 steps/day on the other 2 days. 
Over the course of a week this averages out to 9364 
steps/day (7 days at 7222 added to 15000 MVPA steps). 
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follow-up. Four patients were also invited to take part in an in-depth interview after completion 
of the exercise intervention. 
*Behavioural Component 
The Trial co-ordinator (TC) explored the intervention design with participants to promote 
adherence. This involved 
 
1. Setting programme goals:  TC’s explained the individualised pedometer step target. As 
with all well-designed exercise programmes in any context, the exercise prescription (ExPx) 
was designed around the individual’s capabilities, and exercise frequency, duration and 
intensity. A balance between a safe yet effective exercise intervention47 can be achieved using 
these essential metrics of exercise prescription  
 
2. Prompting practise and self-monitoring: TC’S walked with the participant at a cadence 
of 100 steps/min to enable the patient to experience what MVPA felt like. In addition TC’s 
thoroughly explained how to monitor MVPA and regular steps on the pedometer. 
 
3. Encouraging participants to attempt to generalise behaviours learned in the supervised 
exercise environment at randomisation to other, non-supervised contexts: i.e. exploring when 
and how the participant would fit their walking prescription into their daily schedule. 
 
Control arm: 
Patients randomised to the control arm were asked not to join any new formal physical exercise 
program during the study intervention period. Participants wore a sealed pedometer. Control 
group participants also completed a short exercise KAP questionnaire upon completion at 1 
month follow up appointment. 
 
All patients were reminded to wear their pedometer each day by treating radiotherapists and 
reminded again by the trial co-ordinator at weekly assessment clinics (standard care). 
Follow-up schedule for all patients 
 
4 weeks (Mid EBRT) 
Repeat baseline assessments 
7-8 weeks (End EBRT/post intervention) 
Repeat baseline assessments 
1 month Follow-up 
Repeat baseline assessments 
 
Thereafter patients continued with standard follow-ups as determined by their treating Radiation 
Oncologist. The Clinical Research Co-ordinator collected all the self-reported questionnaires 
and carried out the objective test of functional fitness and anthropometric measures. The 3 trial 
co-ordinators were interviewed upon completion of recruitment and all assessments to gain an 
understanding of process, resource and trial management issues 
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3.5. Outcome Measurement 
1. Trial case report form (appendix A) 
This form captured each patient’s relevant medical history, disease characteristics, 
demographics and baseline and acute toxicities. 
 
2. Fatigue: (appendix B) 
To evaluate trends in fatigue, subjects in the control and exercise group were administered the 
Brief Fatigue inventory (BFI), a validated, self-complete fatigue assessment tool with 9 
questions to quantify the presence and severity of fatigue, and the interference of fatigue on 
function and QoL. The QoL domains in the BFI are general activity, mood, walking ability, 
normal work or daily chores, relations with others, and enjoyment of life. Each question 
required participants’ ratings from 0-10, with 0 indicating no fatigue and 10 indicating worst 
fatigue or interference. The maximum score is 90.  
3. HRQoL: (appendix C) 
To evaluate trends in Disease-specific HRQOL, subjects in the control and exercise group were 
administered the Functional Assessment of Cancer Treatment-Prostate (FACT-P). The minimal 
clinically important differences (MCID) on the FACT-P is 5.5.  This instrument included 27 
general questions that provide assessments of physical, social or family, emotional, and 
functional well-being. It also included 12 questions that queried “additional concerns” specific 
to prostate cancer and its treatment. The FACT-P has demonstrated construct validity and 
sensitivity and a test-retest reliability of 0.83. The maximum score is 156. 
4. Physical Performance: 
A. Cardiorespiratory Fitness: 2-Minute Step Test, the number of full steps completed in 
2 minutes, raising each knee to a point midway between the patella (kneecap) and iliac 
crest (top hip bone) was recorded. Score is number of times each knee reaches the 
required height. 
B. Functional Fitness: 30-Second Chair Stand test, measured the number of full stands 
that could be completed in 30 seconds without using arms for help. 
5. Logbook: (appendix D) 
To assess adherence to individualised exercise prescriptions, participants were asked to record 
the frequency and duration of each 30 minute session of MVPA. This was cross checked with 
daily and weekly step counts as recorded on participants’ pedometers. 
6. Patient acceptance of exercise intervention: (appendix E) 
This was evaluated using a self-reported questionnaire designed to elicit information on 
intervention participants’ attitude to, satisfaction with and convenience of the exercise program. 
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7. Insights into acceptance and adherence: (appendix F) 
Post intervention, insights into acceptance and adherence of the exercise intervention was 
explored utilising in-depth interviews.  An interview guide was employed to probe into possible 
barriers and facilitators to MVPA in the intervention group. 
 
8. Process, resource and trial management insights. (appendix H) 
A key informant interview with each trial co-ordinator in each of the three SLRON centres 
was conducted post trial. 
9. An on-line screening and recruitment log was maintained. 
10. Control Group, physical activity Knowledge Attitude and Practices questionnaire.  
This questionnaire was administered to control group participants at 1 month follow up 
appointments. (appendix I) 
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3.6. Table of Assessments 
Table 9 below outlines the range of assessments and assessment schedule of intervention and 
control group participants. 
Investigations 
Baseline Mid 
EBRT 
Last 
week/End 
EBRT 
1m FU 
All PARTICIPANTS 
On study case report form 
(Appendix A) 
Age, partnered status, job 
status, education ,relevant 
med history, baseline and 
weekly treatment toxicities 
x    
Steps/day (Pedometer) From 2 weeks before commencing EBRT (CT scan) until end of EBRT 
Anthropometric measures 
Including Bioelectric Impedance 
(italicised assessment) 
Height, weight, % body 
fat/muscle mass, waist 
circumference, bone mass 
x x x x 
Physical Performance A. 2 minute step test 
B. 30 second sit-stand test 
x x x x 
HRQoL 
 
Functional Assessment of 
Cancer Therapy-Prostate 
(FACT-P) 
x x x x 
Fatigue Brief Fatigue Inventory 
(BFI) 
x x x x 
Exercise intervention. 3000 steps in 30 min sessions (duration), 5 times per week (frequency) at a 
MVPA intensity of 100 steps/min. Sessions should last a minimum of 10 minutes i.e. 3 x10 minute sessions 
on MVPA days. These steps will be in addition to usual habitual steps as determined at baseline.  
INTERVENTION ARM ONLY 
Behaviour Change 
Section (sec 3.4) 
Explore common behaviour 
techniques 
After randomisation 
Goal setting, Prompting practise and self-
monitoring etc. 
Adherence Patient log book 
Frequency and duration of 
MVPA walking. Steps/day  
Completed after each walk 
Understanding  acceptance 
and adherence 
 
 
In-depth interviews of 4 
intervention arm 
participants 
–using interview guide - 
barriers and facilitators,  
  x  
    
Exercise satisfaction 
questionnaire 
Self-reported questionnaire 
evaluating attitude, 
tolerance and satisfaction 
with walking programme  
  x  
CONTROL ARM ONLY 
Exercise Knowledge attitude 
and practices 
Self-reported questionnaire 
KAPs of exercise during 
their EBRT 
  x  
Table 9: Pilot Study Assessment Schedule 
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3.7. Statistical Approach and Sample Size for Pilot and Main Study 
3.7.1. Pilot Study 
The target population for this study were men who received EBRT+ADT in the SLRON. 
Potentially eligible patients were identified from CT schedules. The first 24 eligible patients to 
consent constituted the study sample. Sample selection was based on the same intended 
inclusion and exclusion criteria as the main study. The sample used in the pilot study may be 
included in the main study, provided that the researcher can preserve key features of the 
proposed main study in the pilot 2. When pooling of pilot and main study data is done properly 
it can increase the efficiency of the main study2. 
 
Patients were recruited from the three centres which constitute the SLRON. The network is 
designed so that each patient receives identical treatment irrespective of treatment centre. Staff 
are trained and work using the same network standard operating procedures. Clustering of data 
was therefore not an issue. 
 
For pilot studies the recommendation is a sample size of 12 per group52. This sample size was 
considered large enough to provide useful information about the aspects of the pilot study that 
were being assessed for feasibility. 
 
This pilot study provided estimates of the mean fatigue in the control group and the standard 
deviation in each group in order to inform the sample size calculation for a future confirmatory 
RCT. At present we do not have any data on fatigue levels of Irish cancer patients receiving 
EBRT+ADT. Chang et al53 found that the BFI “usual” fatigue mean score was 5.0 (2.42) and 
BFI “worst” fatigue was 5.7 (±2.5) for cancer patients. Mendoza et al54. (1999) found that the 
BFI “worst” fatigue mean score was 4.7 (2.8) for cancer patients and 2.2 (1.8) for controls 
(p< 0.01). 
 
3.7.2. Main Study 
To increase the efficiency of the main study, the sample used in the pilot study will be included 
in the main study.  The key features of the main study were preserved in the pilot study and no 
potential bias is envisaged due to multiple testing or opportunistic actions since the pilot study is 
not using statistical tests.  
 
In the main study, the mean fatigue for the two groups of patients will be compared using a two-
sample t-test at the 5% significance level.  
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Sample size estimates for the main study are based on combinations of (i) differences in usual 
fatigue ranging from a minimum clinically important difference of 1 to a difference of 2 and (ii) 
variability estimates of 2.2 to 2.8.  Sample size estimates based on 80% statistical power to 
detect these differences between control and treatment groups using a two-tail two-sample t-test 
using a 5% significance level are presented in Table 10.   
 
 
 
 
 
 
 
 
 
 
*For 80% Statistical Power (assuming variability is equal in each group) 
 
Table 10 suggests that the numbers required to detect a minimum clinically important difference  
of 1 with a standard deviation of 2.6 or greater are impractical i.e. it would not be feasible to 
recruit such large numbers of patients. For the main study evaluable patients are defined as 
those for whom BFI at one month post RT is documented, as the primary endpoint is to show 
that fatigue as measured on the BFI scale is less at this time point in the intervention group. 
 
3.7.3. Feasibility Criteria 
The criteria below must be achieved in the pilot study at SLRON to recommend a future 
confirmatory RCT as feasible: 
 
1. At least 50% of all eligible patients are recruited 
2. A recruitment rate of 1 patient per centre per month  
3. Complete follow-up in at least 70% of all recruited patients 
4. ≤ 3 intervention related adverse events as specified by the study’s lead Clinician. 
5. 66% of the intervention group achieve an individual adherence rate of 66% 
6. Encouraging fatigue trends in the intervention arm 
 
 
 
 
Underlying 
Variability 
Mean difference between Control and Test groups 
1.0 1.4 1.8 2.0 
2.2 77 40 25 21 
2.3 85 44 27 22 
2.4 92 48 29 24 
2.5 100 52 32 26 
2.6  56 34 28 
2.7  60 37 30 
2.8  64 39 32 
Table 10: Future RCT Sample Size Estimate per Arm* 
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3.7.4. Calculating Exercise Prescription Adherence/Contamination 
A. Exercise Adherent (EA)            ≥ Individual Adherence Rate (IAR) of 66%   
 
B. Individual Adherence Rate (IAR) = 
𝐴𝑑ℎ𝑒𝑟𝑒𝑛𝑡 𝑊𝑒𝑒𝑘𝑠 (𝐴𝑊)
# 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑   𝐸𝑥 𝑊𝑒𝑒𝑘𝑠
 = 
𝑥
7
 
 
C. Adherent Weeks (AW) 
 
Exercise is prescribed according to Frequency, Intensity, Time and Type (FITT) and best 
practice is to measure adherence using the same criteria37. For a participant to achieve an 
Adherent Week (AW) they must fulfil the following criteria: 
a. Frequency (F); ≥ 66% of prescribed exercise sessions. 
b. Intensity (I); ≥ 66% of prescribed step/week target i.e. ≥66% of their baseline steps + ( 
≥ 66% of 15000) steps 
c. Time (T); ≥ 66% of prescribed time i.e. ≥66% of 150 minutes = at least 100 minutes 
d. Type (T): Walking. 
 
Similarly, exercise non-adherence or contamination in the control group was calculated by 
analysing steps/week. If a control group participant achieves their baseline steps + (≥ 66% of 
15000 steps in any week they will deemed non-adherent. 
3.8. Participants’- Selection and Recruitment 
All men with non-metastatic prostate cancer, booked for radical EBRT+ADT in the SLRON 
were screened for eligibility. Potential patients were screened prior to their planning CT scan. If 
deemed eligible, the clinical trial coordinator liaised with the patient’s Consultant to get 
permission to approach the patient at CT. Potential patients were provided with full written 
information (participation information leaflet and consent form) (Appendix G) on the details of 
the research study and deemed fit to take part in an exercise intervention by a Medical Doctor, 
prior to consent. Participants were consented according to ICH-GCP guidelines. A study 
screening and recruitment log was maintained by the study co-ordinator at each site, on a central 
share drive at SLRON. 
3.8.1. Inclusion Criteria 
1. Pathologically confirmed non-metastatic prostate cancer. 
2. Candidate for radical EBRT+ADT defined as curative intent treatment targeting the 
prostate or pelvis and prostate, fractionated once daily over 6-8 weeks. 
3. ADT for ≤ 1 year at 1 month Follow up. 
4. At least 30 scheduled radiation treatments (6 weeks). 
5. Sedentary lifestyle (no regular exercise, i.e. engaging in purposeful exercise or 
physical activity of moderate to vigorous intensity of 30 minutes or more, 3 times per 
week.)  
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6. Patient has read the participant information leaflet and signed the consent form.  
3.8.2. Exclusion Criteria 
1. Recurrent disease 
2. Contraindications prohibiting participation in a moderate intensity walking program as 
determined by the patient’s Radiation Oncologist or designated Registrar  
3. Inability to perform written consent. 
 
3.9. Participants Safety Risks, And Benefits 
Participants’ Consultant and General Practitioners were informed that their patients were taking 
part in this study. Participants were monitored during and after the study according to the same 
standard clinical guidelines as those choosing not to participate in the study. All participants 
underwent assessments at baseline, mid-EBRT, end of EBRT and at 4 week post-EBRT. 
Participants randomised to the exercise arm followed an individualised MVPA walking exercise 
prescription. 
 
Patients were monitored at their normal scheduled on-treatment check-ups by their Consultant 
and/or his/her team of doctors. The team watched patients closely to see if they had treatment- 
related side effects. Patients were given a physical exam by their Oncologist prior to consent 
(standard practise) to ensure that they are healthy enough to participate in a walking program.  
There was a small risk (less than 1%) that a patient could receive muscular injuries from the 
walking regimen.  There was also a small risk (less than 1%) that a patient may have suffered 
from heart problems due to increased exercise, but this risk was no greater than for the general 
public. 
 
Before consent patients were informed that there may or may not be direct benefits for 
participants. Participants in the intervention arm may benefit from increased physical fitness 
because of the walking exercise program.  Participants may or may not experience reduced 
fatigue resulting from participation. 
 
3.10. Administrative Responsibilities 
3.10.1. Data Management 
3.10.1.1. Media of Controlled Data 
Paper based data (questionnaires) were collected in this study and results entered into a 
computerised database. Individual in-depth interviews with the intervention group post 
intervention were recorded (Audio). 
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Medical records were accessed as they were integral to the study. Patient characteristics, disease 
characteristics, and follow-up information were important for the assessment of the study 
objectives. 
3.10.1.2. Data Access and Storage 
Consent to analyse the data was sought as part of the consent process outlined above. Only the 
study team had access to collected data. All data collected was analysed retrospectively and 
anonymously at the end of the study. Individual patients were offered the option of being 
informed of the study results. Data was coded and the trial coordinator retained the key to re-
identify the data. 
 
All data collected during the course of this research was stored on the trial coordinator’s 
password protected PC in the Clinical Trials Unit, St Luke’s Hospital Rathgar.  
 
Paper based data questionnaires were destroyed after being transferred to the electronic version 
using the shredding facilities provided by St Luke’s Hospital. The shredded paper was collected 
and recycled. Electronic data will be retained for a fixed period of 5 years at SLRON. 
3.10.1.3. Confidentiality 
The Principal Investigator is the only person with a key to the identity of the research 
participants. The named investigators had access to anonymised data and each patient’s study 
number. The key linking patient identity to study number was destroyed once all required 
follow-up information had been acquired so that only irrevocably anonymous data are retained. 
 
3.11. Good Clinical Practice 
The study was conducted in accordance with the EU Directive 2001/20/EC and International 
Conference on Harmonisation (ICH) for Good Clinical Practice (GCP) and the appropriate 
ethical requirement(s). The investigator was thoroughly familiar with the appropriate use of the 
study treatment as described in the protocol. Essential clinical documents were maintained to 
demonstrate the validity of the study and the integrity of the data collected. Master files were 
established at the beginning of the study, maintained for the duration of the study and retained 
according to the appropriate regulations. 
3.12. Ethical Considerations 
The study was conducted in accordance with ethical principles founded in the Declaration of 
Helsinki (Appendix J). The SLRON (21st March 2013 and 18th February 2014) and The London 
School of Hygiene and Tropical Medicine (LSHTM) (4th February 2014) ethics committees 
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reviewed all study documentation in order to safeguard the rights, safety and well-being of the 
patients. The study was only conducted at sites where full approval had been obtained. 
3.13. Patient Information and Informed Consent 
After the study was fully explained, written informed consent was obtained from the patient 
prior to study participation. The method of obtaining and documenting the informed consent 
and the contents of the consent complied with ICH-GCP and all applicable regulatory 
requirements.  The network also provides a range of allied health services at each site which are 
available to all patients, including counselling, psycho-oncology and physiotherapy. Study 
participants can avail of such services for the duration of their treatment/trial and while in 
follow up. 
3.14. Patient Confidentiality 
In order to maintain patient privacy, all case report forms, study reports and communications 
identified the patient by initials and the assigned trial number.  
3.15. Protocol Compliance 
The investigator conducted the study in compliance with the approved protocol (V 4.0). No 
changes to the protocol were required during the study.  
3.16. Project Organisation and Logistics 
This study was conducted in collaboration with the St Luke’s Radiation Oncology Network of 
cancer centres in Dublin, Ireland. As Principal Investigator, Ciarán Doyle had the overall 
responsibility for this research project. His academic supervisors: Dr Val Curtis, Dr Wolf-Peter 
Schmidt, Dr Alison Tree, Mary Dunne and Dr Pierre Thirion provided scientific and 
methodological guidance. The co-investigators at SLRON contributed to data analysis and the 
write-up of the results and conclusion. 
 
3.17. Communication Research Results 
The pilot study results will be reported using the CONSORT format and were presented in a 
report to the SLRON. It is planned to present the study findings at an appropriate conference, 
and to publish them in a suitable journal. Finally the study will be presented in partial fulfilment 
of a “Doctor of Public Health” thesis at the London School of Hygiene and Tropical Medicine. 
As part of the consent process, patients will be asked if they would like to be informed of the 
study results when they become available. 
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4. RESULTS 
4.1. Process 
This section assesses the feasibility of the processes that are crucial to the success of the main 
study. The results in this section come from a combination of quantitative and qualitative data 
collection methods. 
4.1.1. Consort Flow Diagram  
Figure 6 below is a Consort flow diagram of the progress through the phases of this randomised 
trial (that is, enrolment, intervention allocation, follow-up, and data analysis). 
 
CONSORT Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6: Consort Flow Diagram 
Eligible patients within 
screening period (n=30) 
Analysed (n=12) 
 
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention due to 
catheterisation (n=1) 
Allocated to intervention (n=12) 
 Received allocated intervention (n=12) 
 
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention due to 
exercise contamination (n=2) 
Allocated to control (n=12) 
 Received allocated intervention (n=12) 
 
Analysed (n=12) 
 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=24) 
Enrolment 
Excluded (n= 6) 
   Not meeting inclusion criteria (n= 2) 
   Declined to participate (n=2 ) 
   Other reasons (n=2) 
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4.1.2. Baseline Characteristics 
The distribution of anthropometric measures, time since diagnosis, baseline steps per day, 
functional fitness, age, T-stage, risk group, EBRT, ADT and social characteristics were similar 
in the intervention and control groups. the only major differences were that the  intervention 
group had more smokers and less drinkers that the control group. Intervention group 
participants were more fatigued but reported a greater HRQoL than control group participants’ 
pre randomisation. (Table 11) 
 
Variables Intervention (n=12)  Control (n=12) 
 Mean  SD  Mean  SD 
Anthropometric Measures        
Age (yr) 66  5.4  65.1  6.5 
Height (cm) 169.5  9.6  174.8  4.7 
Weight (kg) 82.5  18.8  84.2  9.8 
% Body fat 28.5  6.8  26.7  4.1 
% Muscle mass 68.3  6.5  69.5  3.9 
Bone mass (kg) 2.9  0.4  3.1  0.3 
Waist circumference (cm) 105.5  15.4  107.6  11.2 
        
Time since PCa diagnosis (mts) 8.6  6.5  8.1  3.4 
        
Habitual steps per week 45400.7  17751.9  42043.2  18185.8 
        
Functional Fitness        
2-min step test 150.5  62.8  147.6  46.9 
30 sec sit-stand test 15.7  6  15.4  4.3 
        
Fatigue (BFI) (0-90) 22.2  17.6  13.4  10.7 
HRQoL (FACT-P) (0-156) 126.7  19  126  15.5 
        
Referring PSA 9.9  5.8  14  22.8 
Gleason score (%)        
           7  4 (33.3)    7 (58.3)  
         >7  6 (50)    5 (41.7)  
T-stage (%)        
        T1  2 (16.7)    3 (25)  
        T2  4 (33.3)    4 (33.3)  
        T3,4  6 (50)    5 (41.7)  
DRE (%)        
Not assessed  2 (16.7)    0  
T1  4 (33.3)    4 (33.3)  
T2  3 (25)    6 (50)  
T3  3 (25)    2 (16.7)  
        
Risk category (%)        
  Intermediate risk  4 (33.3)    5 (41.7)  
  High risk  8 (66.7)    7 (58.3)  
        
Pre baseline ADT duration (%)        
ADT (0-6mts)   2 (16.7)    2 (16.7)  
ADT (3-6mts)  8 (66.7)    9 (75)  
ADT (6-9mts)  2 (16.7)    0  
ADT (9-12mts)  0    1 (8.3)  
Expected ADT duration (mts)         
LHRH 13.8  13.5  16  14.8 
Bical 7.5  9.2  7.8  9.1 
LHRH type (%)        
 47 
 
Decapeptyl  7 (58.3)    7 (58.3)  
Eligard  4 (33.3)    3 (25)  
Degarelix  1 (8.3)    0  
Prostap  0    2 (16.7)  
Anti-Androgen type (%)        
Casodex  11 (91.7)    12 (100)  
None  1 (8.3)    0  
        
Co morbidities (%)        
Hypercholesterolemia  4 (33.3)    5 (41.7)  
Hypertension  5 (41.7)    7 (58.3)  
Diabetes  2 (16.7)    0  
        
Current Smoker (%)  4 (33)    2 (16.7)  
  Pack years 13  14.4  20  18.5 
Current drinker (%)  6 (50)    11 (91.7)  
  Units per week 15.9  19.3  32.7  33.3 
Family Hx (%)        
Yes  6 (50)    4 (33.3)  
No  6 (50)    8 (66.7)  
Marital status (%)        
Married   9 (75)    8 (66.7)  
Partner  2 (16.7)    0  
Other  1 (8.3)    4 (33.3)  
Employment status (%)        
Employed  2 (16.7)    3 (25)  
Unemployed  2 (16.7)    1 (8.3)  
Retired  8 (66.7)    8 (66.7)  
Education (highest) (%)        
Primary  1 (8.3)    3 (25)  
Secondary  9 (75)    7 (58.3)  
Tertiary  2 (16.7)    2 (16.7)  
ADT = androgen deprivation 
therapy 
BFI= brief fatigue inventory DRE= digital rectal exam 
FACT-P = functional assessment 
of cancer therapy-prostate 
LHRH = Luteinizing Hormone 
Releasing Hormone 
SD = standard deviation 
Table 11: Participants Baseline Characteristics 
4.1.3. Eligibility Criteria Acceptability 
TCs reported no issue determining and recruiting eligible patients for this pilot study. One TC 
reported: “I found it very easy to read and, so, easy to understand. It was laid out very clearly. It 
was very clear on which patients were allowed to be recruited into the study and it was clear on 
what patients were not suitable. I didn’t find it restrictive at all55”. Another TC corroborated 
this point “I found the criteria pretty good. We got almost all our prostate patients who were on 
hormones onto the trial. That was very good. Very few patients were coming through with 
mobility issues, things that would make it unsafe for walking. So that was good to have that in it. 
Otherwise I didn’t see any reason to exclude other patients that fitted the treatment criteria56” 
 
One TC suggested that we should recruit patients at an earlier point in their treatment: 
“There is definitely enough information at CT to recruit patients in this centre. However, due to 
the nature of the study, I think it would be ideal if patients were recruited at an earlier stage…  
I think when their hormone prescription is being written and given to the patient, I think that 
would be a better time so that if there is an impact of the study on weight loss that that is 
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encompassed at the CT scan and when they go ahead for treatment… A true baseline, yes, when 
they start treatment,  because we did see patients on treatment, their contour changing towards 
the end of radiotherapy, which is very positive for the intervention. On a larger study it might be 
great to have that effect at the CT scan so it is more true for the patient… I think it would not be 
feasible to do the assessment in an outpatients clinic, not at all. The assessment itself would not 
be feasible, it would nearly need to be a separate appointment if that was the case…  I would be 
very reluctant to delay the start of hormone treatment but I would be very keen to start the 
exercise intervention in advance of CT. They’d be the two things I’d be trying to match up56” 
4.1.4. Recruitment Rates 
From 24/2/14 to 7/4/14, 28 eligible patients were approached for recruitment, 24 patients 
accepted. This represents a recruitment rate of 86% and an average recruitment rate of 4 patients 
per week. No patients were recruited in St Luke’s Hospital as SLRON treatment booking policy 
over this period dictated that prostate patients be treated in either Beaumont or St James’s 
centres. 17 patients were recruited in St James’s hospital and 7 in Beaumont Hospital. 
4.1.5. Refusal Rates 
Only two eligible patients refused to participate in the study i.e. 7%. A participant in screening 
week three suffered from anxiety and decided that the intervention would be “too much” for 
him. The other patient in screening week four was “not interested in anything extra” on top of 
his standard treatment. 
4.1.6. Retention Rates 
The retention rate was 96%. One patient in the intervention arm had to withdraw from the study 
as he had grade 3 urinary pain and retention. This resulted in him needing a supra pubic 
catheter, that made it too uncomfortable for him to walk. This patient was assesses and followed 
up as per protocol. 
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4.1.7. Schedule of Assessments 
The schedule of assessments (Table 12) appears evenly distributed between groups. Participants 
were assessed at roughly the same fractionation and days between assessments in each group. 
Variables Intervention (n=12)  Control (n=12) 
 Mean  SD  Mean  SD 
 Fractionation  Fractionation 
Total #s 38.9  3.6  37.7  3.7 
Randomisation (R) # 6.5  1.2  6.9  1.8 
Mid EBRT ass # 21.2  2.3  20.4  2.4 
End EBRT ass # 36.8  4.0  36.1  3.9 
 Days  Days 
BL-R 23.6  2.6  24.9  3.5 
BL-Mid 46.3  4.5  45.7  4.1 
BL- End 69.8  6.1  69.8  6.8 
BL-1mt FU 99.6  10.9  97.5  7.0 
R-Mid 22.8  3.1  20.8  2.8 
R-Mid #s 14.8  2.0  13.5  2.0 
R-End 46.2  5.8  44.9  7.8 
R-End  #s 30.3  4.6  29.2  4.7 
R-last#/Intervention duration 
(days) 
49.6  4.9  47.7  8.2 
R#-last#/Intervention duration #s 32.5  4.1  30.8  4.8 
R-1 Mt-FU 76.0  10.3  72.6  7.8 
Mid-End 23.4  7.4  24.2  6.6 
Mid-1mt FU 53.3  11.7  51.8  6.6 
End-1 Mt Fu 29.8  6.3  27.7  0.7 
Last#-1mt FU 26.3  7.1  24.9  2.4 
# = “fraction” e.g. #7 is patients 7th treatment 
BL= Baseline assessment 
 
Mid = Mid EBRT assessment 
End = End of EBRT assessment 
1 mt Fu = 1 month FU assessment 
Table 12: Distribution of Trial Assessments 
 
 
 
 
 
 50 
 
4.1.8. Study Questionnaires Acceptability 
TCs had no issues administering the main study questionnaires (BFI and FACT-P) to all 
participants or the exercise KAP questionnaire to the control group. 
“I found both of them fine. I have a lot of experience of administering questionnaires, quality of 
life questionnaires, things like that. There was no problem; they are very similar to other quality 
of life questionnaires. The questions were very familiar; the format was very familiar, so due to 
my familiarity I found it very simple. I think most trial coordinators would use questionnaires so 
I can’t imagine anyone having difficulty with that56.”  
 
“The questionnaires were fine. I thought they were of a reasonable length, not too long or 
conversely short. I suppose patients find filling out questionnaires monotonous but I think there 
would be no benefit to changing the questionnaires to resolve that57.”  
 
TC also explained how study participants responded to the questionnaires. When given the 
option to self-complete or have the questionnaires read to them, in all cases patients chose the 
latter. This is common among trial patients in the SLRON network as explained by the TC56 
below: 
 
R: In general I found that a lot of them liked to have the questions read out to them and shown 
to them.  I: How does that compare to other studies we have? Is it unusual? R: Yes, it is. For 
this study, your study here, a lot of the fellas would have had poor eyesight, not reading 
difficulties but poor eyesight, with small print. It’s all very unfamiliar so they would say, ‘Would 
you just read it out, it’s easier’. And I have found the same with two palliative trials.  I: So you 
think it is the patient population, as they are usually gentlemen in their sixties, that is the reason 
they prefer to have the questions read out to them?  R: I don’t know. I wouldn’t pigeon-hole 
them as much as that because much older patients and much more sick patients of both genders 
I find very similar. I think in general maybe they just like to be talked to, maybe it makes it less 
like a formal exam. I don’t know. But even in the DCIS, which is more younger females, some of 
them will want you to read them out, some don’t.  I: Because the questionnaires, both of them, 
are designed that they can be self-administered or they can be administered through a 
coordinator. R: Yes.  I: Do you think it is good to have the option or just have all coordinators 
ask the questions?  R: I think it is good to have the option. For two reasons: some patients will 
have reading difficulties and they will want you to read it out but, conversely, some of the 
questions are very personal, very sensitive topics are addressed and some patients will want to 
do that themselves and not have it spoken out, particularly if the patient is accompanied by a 
family member or a friend they don’t want knowing all the answers to the questions. I think it is 
great because you can still provide them with privacy while not isolating them from their family 
members.  
 
Another TC explained that: 
“They (participants) didn’t seem to have any issues once you took the time to explain what they 
were for and explained that it was their own opinion55.” 
 
4.1.9. Study Tools Acceptability 
4.1.9.1. Log Book 
TCs had mixed experiences administering the log books to intervention patients: 
“I found the log book very straightforward but I found patients got really confused by the whole 
thing. It took a few times of explaining to them and which number to write in which box and 
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when but, in general, once they got it, they got it. I found very few people coming back having 
done it wrong56.”  Another TC had no such issues: “No, that was very clear. Again, once 
everything was explained thoroughly to them at the beginning, they seemed to get a good handle 
on it and it seemed to work out well55.” 
4.1.9.2.  Body Composition Monitor 
The bioelectric impedance scales proved problem free. One TC reported that: 
“The Tanita scales that we have here, the little stand-on one, I found that very straightforward 
to use. I just used it under the guest profile, I didn’t save any of the profiles, but it was fine. 
Patients were able to get on it, no one every fell, there were no problems there. Tape measure, 
obviously measuring the circumference of the waist, was very straightforward56.” Another TC 
agreed with this sentiment:“the scales was very easy to use. It was very simple with very clear 
instructions to use it55.” 
4.1.9.3. Pedometer 
TCs had contrasting views on the pedometers, for example: 
“No, no issues came up, which was great and I think the fact that they didn’t have to actually do 
anything with the pedometer was the main benefit of it, otherwise, you may run into problems. It 
turned out very well55.” 
 
In addition one TC was concerned with the user friendliness and quality of the pedometers: 
“You would need a lot more pedometers and, if possible more user-friendly pedometers and 
ones that were easier to use and maybe more reliable. There was an odd one. The string broke 
on one; one of them got wiped one day, we’re not sure why. There are a couple of little issues 
with them that, even though they said when we bought them the spec was quite high and they 
were quite expensive for clinical trial purposes, in reality when they were tried and tested they 
weren’t quite as good quality as we were expecting…   my biggest requirement would be ones 
that aren’t affected by mobile phone signals because, no matter how many times you tell 
patients… 56” 
 
4.1.10. Potential Future Process Issues for a Future Confirmatory RCT 
 
TCs were in agreement that the existence of this pilot study will eliminate a lot of the usual 
process issues that SLRON encounter with new RCTs. For example when asked the following 
question: 
I: Do you think this feasibility study will make the process of rolling out a future confirmatory 
randomised control trial easier? 
R: Oh yes, definitely. I think especially for the trial coordinators it is not a new thing to them so 
they are very familiar with the workings of the equipment and the assessments and they are used 
to explaining the trial to the patients. So, I don’t see an issue with those who are most involved 
with the study55.  
However the TC makes a valid point that with any new study even with the benefit of a pilot 
“there are always going to be issues with studies in terms of the coordination of the study and 
the organisation of the study and making sure everybody knows what they’re doing and are well 
informed of what is going on and they are all trained up in the study. So, in general, I think once 
the planning phase is done correctly, I don’t envisage any issues with the study55 “   
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4.2. Resources 
 
This section deals with assessing time and resource problems that can occur during the main 
study. The results in this section come from a combination of quantitative and qualitative data 
collection methods. 
 
4.2.1. Key Process Times 
4.2.1.1. Participant Recruitment Duration 
The average time to recruit a patient at their CT appointment was 53.8 minutes (SD = 18.2) 
4.2.1.2. BFI and FACT-P Completion Time 
The average time to complete the BFI questionnaire was 93 seconds (SD 60.2, Range 30-351) 
and FACT-P 367.9 seconds (SD 205, Range 57-1315). We can see from Figure 7 below that it 
takes the intervention group on average longer to complete the BFI questionnaire at each 
assessment after recruitment. In contrast it takes them less time on average to complete the 
FACT-P questionnaire at each assessment (see Figure 8) 
behaviour 
 
 
 
 
 
 
 
 
 
 
 
MID EBRT END EBRT 1 MT FU
Intervention 369.2 314.3 285.6
Control 507.5 406.2 324.8
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Figure 7: BFI Completion Times 
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4.2.2. Room and Equipment Availability 
TCs reported no issues with either room or equipment availability: 
“There are two lovely little rooms beside our CT and they are not always but available the 
majority of the time to use. Thankfully, in this centre we are very lucky with rooms that way56.”  
 
“there was always a room available and the scales are very transportable so we were able to 
move it from room to room and the measuring tape we had anyway57” 
 
“Room availability worked out perfect because the clinics were running at the same time mostly 
so we tried to coordinate the patients with clinics. You probably could see in general with 
studies that sometimes, if it is a very busy clinic, it may be an issue trying to get a room so a 
patient may be waiting a bit longer but, as it turns out, they are probably waiting to see a doctor 
anyway so you can fit them in55”  
 
“because the PI had actually purchased scales especially for this and a tape measure and 
pedometers for all the patients, because all the actual equipment was purchased and I already 
have a desk and a computer and rights for computer access and things like that, that was all 
fine. There was nothing additional, there was nothing asked of the centre to provide56 
4.2.3. SLRON Multi-Centre Willingness and Capacity 
TCs at the three sites reported that they had no issues at their centres with respect to initiating 
and coordinating this pilot study. 
“I think it had very little impact on the centre because everything about the study works around 
a normal radiotherapy pathway. It fits in. You can do it on the CT day, or whatever day. We 
didn’t delay CT, we didn’t delay treatment appointments, we didn’t delay patients. Occasionally 
patients were asked to check in with reception to tell us when they were here, reception were 
very good at letting us know. We didn’t delay follow-ups or anything like that. So the centre, I 
think, didn’t have much hassle because they basically just transferred the patient to us and then 
the workload was just done by the coordinators. There is a lot of work for the coordinator from 
certainly the initial appointments but I don’t think the centre felt the impact of that. But that 
would be standard for any clinical trial56”   
 
At one of the centres a TC raised the issues of staffing a future confirmatory future trial: 
 
“I would say that you could have a greater rate of recruitment but you’d still have to look into 
issues of staffing. Staffing is always going to be an issue no matter what study you are doing. At 
Figure 8: FACT-P Completion Times 
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the moment we are probably not fully staffed but if you were to roll out a bigger study, of 
course, staffing would have to be adequate for you to recruit adequate numbers…, 55” 
 
4.2.4. Potential Future Resource Issues for a Future Confirmatory RCT 
While TCs agreed that there were no capacity issues for the pilot study they are concerned that 
at current staffing levels we would not be able to continue at the current rate of recruitment. 
“the only thing would be if you were to go forward with it, two patients a week amounts to quite 
a number of patients on review at any one time so you would probably need some extra staff. In 
a small pilot setting it’s not too bad but on-going in a larger trial you would need more staff 
available to do the assessments, particularly the longer assessments with the steps, they do take 
a little bit of time. You wouldn’t be able to do two or three too quickly57” 
This point is further reinforced by the other TCs: 
 
“I think the main thing is staffing and just making sure as well, obviously, that your consultants 
or medical teams who are involved in the study are all on board with you55” and 
 
“We definitely do not have the capacity to recruit all the eligible patients. Well, in saying that, 
in general the centre runs about four or five clinical trials with one trial coordinator. So if this 
study is effectively 20% of your week, if you have only one dedicated day for this trial, that’s not 
enough for the number of eligible patients coming through because you do need a good bit of 
time for those initial assessments and follow-up assessments. It is easy to get patients on the 
trial but once the mid-radiotherapy assessments and post-radiotherapy assessments start 
clashing with new patients coming on the study that is when it gets really busy so you would 
need either another coordinator or fewer studies. I think you would easily have two and a half 
days a week worth of work with this study for one person, if you were to go for every person and 
it was long-term56”   
 
The TC goes on to explain exactly where the capacity issue would arise: 
 
“it’s not the initial assessment that is such a big deal but doing the initial assessments and then 
four weeks later doing the mid-radiotherapy assessments and eight weeks later you would have 
patients doing all three types of assessment. It’s when you have all three; you actually have six 
appointments on that day. Six appointments on one day is a lot, you wouldn’t want to be doing 
more than six patients in one day56” 
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4.3. Management 
This section of the pilot study explores potential human and data management 
problems that could adversely affect a future RCT.  All data in this section comes 
from in-depth interviews with each trial co-ordinator. 
 
4.3.1. Pilot Study Management Issues 
All three trial Co-Ordinators (TCs) reported that they had no issues managing this feasibility 
study and that: “Everything seemed to run smoothly55”. One TC summarised, 
 “I think this study is great because it does pilot the study and I think that’s really important, 
that’s not usually done. What usually happens is what looks great on paper doesn’t always work 
in practice. You just don’t know what you’re going to come up against. In reality we end up 
changing CRFs or retrospectively trying to grab data that we didn’t grab or collecting data that 
we don’t need or we’d plan things that are more inefficient than they could be. I think, if it’s 
going to be a long-term study or a longitudinal design, it really should be piloted and I think it’s 
something that should be done more”56  
 
4.3.2. Data Entry Issues 
TCs found data entry for the trial non-problematic overall. The only issue to emerge 
concerns the process of calculating intervention patients’ step targets 
“There was a spread sheet that was to calculate the step targets and I found that really 
complicated even though I shouldn’t have. There was a calculation that you could do out 
manually and that would have been fine but then there was a spread sheet as well that 
calculated it. You put in a couple of different numbers from the pedometer but I copied and 
pasted them and actually deleted some of the formulae from the spread sheet which was a bit of 
a risk if you were collecting data in the future. To just try and test it on a few dummy run 
patients, either dummy run the Excel spread sheet or do a pilot study, or lock it, if there was 
some way of locking the spread sheet, or do them manually, I don’t know. But just to be aware 
that that is something that someone could mess up”56 
 
4.3.3. Potential New Data Values  
TCs main concern was that we need to capture if and how intervention participants 
weight loss impacts on their EBRT treatment and dosimetric distribution in any future 
study. One TC commented: 
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“The only thing would be if you were to capture maybe whether weight loss required any of the 
patients to have their treatment re-planned. If they lost a significant amount of weight, it may 
result in a change in the patient’s contour and subsequently a change in their dosimetric 
distribution of their treatment. Obviously, you would like to avoid that because it is more 
workload on the department and it also involves more radiation dose to the patient as they are 
having extra scans. So, it is not an ideal situation. I: Roughly, what kind of a contour change in 
the patient?  In excess of 1cm in any one direction”57.  
 
Another TC further added to this point while commenting how Radiation Therapists were not 
fully aware that a patient was on an exercise trial initially: 
 
“The girls in the units were amazed by the visible [weight loss], although they actually didn’t 
realise that was what it was from because they weren’t totally in tune with the study in this 
particular case but they couldn’t understand why the patient’s contour had changed so 
dramatically. Eventually I mentioned, ‘actually, they are on the study, the exercise intervention, 
they’re walking, they’re trying to keep healthy, get healthy.’ So there was a very dramatic, 
noticeable increase not just in our own weekly assessments but other staff around the 
department noticed the improved health and fitness of the patients. That was great and 
something to be aware of, that it might work more than you would expect. I: Because weight 
loss is not always a good thing for a radiotherapy patient. That’s it, in terms of consistency and 
planning. From a radiotherapy perspective, it might be too good. It might not seem like they are 
being asked to do a lot but people who are so sedentary to begin with, it’s ideal. They can 
manage it but it definitely works”56  
 
One TC also though that it would be useful to record physiological and biochemical tests to the 
study’s outcomes. 
 
“I think it would have been great or in future it would be really interesting to look at a patient’s 
blood pressure and maybe their liver function tests because we could definitely see the physical 
impact but it would be lovely to know did we actually improve heart health in these patients”56 
 
4.3.4. Potential Future Management Issues for a Future Confirmatory 
RCT 
 
TCs expressed no obvious management concerns. The consensus was that: 
 
 “it was a very well-coordinated trial, very easy to do.57” Another co-ordinator commented that 
“we are well used to doing studies.., and think it follows, really, the manner in which many of 
our studies would follow. It doesn’t stand out as being different in terms of how it would run or 
how we would actually go about setting up the study55.”  
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4.4. Scientific 
This section deals with the assessment of the interventions safety, adherence and effect on 
outcomes of interest. 
4.4.1. Intervention Safety 
There were no trial related serious adverse effects recorded. One patient in each of the 
intervention and control groups developed urinary issues that indicated catheterisation. 
Patient #4 (intervention) underwent a procedure to have a suprapubic catheter during 
week four of the intervention and thus could not continue with his exercise prescription. 
He was still followed up at the appropriate times. Patient #17 (control) had a urethral 
catheter inserted. This did not affect his ability to continue as a trial participant. 
4.4.1.1. Treatment Toxicities 
The following table (table 13) demonstrates the change in adverse events (AE) from 
baseline assessment to highest recorded toxicity grade throughout the intervention. For 
example, there was a 25% increase in grade 1 diarrhoea from baseline assessment in 
the intervention group compared with 16.7% in the control group. 
 
 Intervention Control 
Toxicity Grade  1  2 3  1  2  3  
 % change % change 
Urinary Incontinence 0 0 8.3 0 0 8.4 
Urinary Frequency/Urgency 16.7 0 8.3 16.7 8.4 8.2 
Dysuria 25 0 8.3 50 0 8.3 
Haematuria 0 0 8.3 8.3 0 8.3 
Urinary Retention 25 0 8.3 25 0 8.4 
Diarrhoea 25 0 0 16.7 0 0 
Proctitis 25 0 0 0 0 0 
Rectal Bleeding 8.3 0 0 0 0 0 
Constipation 8.3 0 0 8.3 -25 0 
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 Intervention patients demonstrated higher rates of grade 1 diarrhoea, proctitis, rectal 
bleeding and hot flushes, and grade 2, erectile impotence and gynecomastia (in red) 
than the control group. However intervention patients demonstrated lower rates of 
grade 1, dysuria and haematuria and grade 2, urinary frequency/urgency (in blue) than 
the control group.  Both groups were comparable on all other measures AE’s 
Table 13: Intervention VS Control Participants change in adverse events from baseline assessment to highest 
recorded toxicity grade throughout the intervention 
 
4.4.2. Intervention Adherence/Contamination Rates  
 
 Calculating Exercise Prescription Adherence/Contamination 
A. Adherent Weeks (AW) 
 
Exercise prescription was prescribed according to Frequency, Intensity, Time and Type (FITT) 
and it is best practice is to measure adherence using the same criteria37. For a participant to 
achieve an AW they must fulfil the following criteria: 
a. Frequency (F); ≥ 66% of prescribed exercise sessions. 
b. Intensity (I); ≥ 66% of prescribed step/week target i.e. baseline steps + ( ≥ 66% of 
15000) steps 
c. Time (T); ≥ 66% of prescribed time i.e. ≥66% of 150 minutes = at least 100 minutes 
d. Type (T): Walking. 
 
B. Exercise Adherent (EA)            ≥ Individual Adherence Rate (IAR) of 66%   
 
C. Individual Adherence Rate (IAR) = 
𝐴𝑑ℎ𝑒𝑟𝑒𝑛𝑡 𝑊𝑒𝑒𝑘𝑠 (𝐴𝑊)
# 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑   𝐸𝑥 𝑊𝑒𝑒𝑘𝑠
 = 
𝑥
𝑦
% 
 
Similarly, exercise non-adherence or contamination in the control group was calculated by 
analysing their steps/week. If a control group participant achieved their baseline steps + (≥ 66% 
of 15000 steps in any week they will deemed non-adherent or an exercise contaminant. 
Individual contamination rates in the control group were calculated using the same logic as 
adherence rates in the intervention group. 
 
There was an overall exercise adherence was 81.8% in the intervention group and exercise 
contamination was high at 33.3% in the control group. 
4.4.3. Steps/Day Trends  
 
Erectile Impotence 0 8.7 0 0 0 0 
Libido 0 0 0 0 0 0 
Hot Flushes 8.4 0 0 0 0 0 
Gynecomastia 0 16.7 0 0 0 0 
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Figure 9: Group Steps/Day Trends from Baseline to 1 Month Follow-Up 
Figure 9 above demonstrates that both intervention and control patients had similar average 
habitual steps/day before beginning EBRT (previous 7 days), 6505 and 6230 respectively. Both 
groups increased their average daily steps from commencing EBRT to randomisation at on 
average # 7. The intervention group increased their average daily steps by 16% while the control 
group increased their average daily steps by 15.8%.  
 
After randomisation, the intervention group increased their average daily steps 3460 (53%) 
steps and the controls increased their average daily steps 649 steps (10%) compared to average 
habitual steps/day. 
 
The intervention group maintained their increased average steps/day from completion of the 
intervention to 1 month FU, intervention participants only decreased their average steps/day by 
-2.6%. Control participants decreased their average daily steps by 9.5%. 
4.4.4. Fatigue 
Table 14 outlines Mean and SD of Overall Fatigue Scores of Both Groups from CT i.e. 
“Baseline” to 1 Month Follow-Up. Figure 10 demonstrates both groups mean fatigue scores of 
each assessment. 
4.4.4.1. Overall Fatigue 
 
 
 
 
 
 
Pre EBRT
Habitual Steps
#1 EBRT -
Randomisation
at #7
Intervention
End EBRT-1 MT
FU
Intervention 6505 7545.5 9965.2 9704.6
Control 6230 7182.2 6879.1 6225.1
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 Intervention Control 
 Mean SD Mean SD 
CT “Baseline” 22.2 17.6 13.4 10.7 
Mid EBRT 10.9 17.7 13.4 13.4 
End EBRT 7.4 11.9 15.5 13.7 
1 MT FU 2.0 4.1 19.2 20.0 
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           Table 14: Mean and SD of Overall Fatigue Scores of Both Groups from Baseline to 1 Month Follow-Up 
.  
Figure 10: Mean Overall Fatigue Scores of both Groups from Baseline to 1 Month Follow-Up 
We intended to calculate sample size estimates for the main study based on combinations of (i) 
differences in BFI fatigue scores ranging from a minimum clinically important difference of 1 to 
a difference of 2 and (ii) variability estimates of 2.2 to 2.8.  Sample size estimates based on 80% 
statistical power to detect these differences between control and treatment groups using a two-
tail two-sample t-test using a 5% significance level are presented in Table 10 (chapter 3).  
However we underestimated the magnitude of the intervention effect. 
 
The data in table 10 (chapter 3) suggested that the numbers required to detect a minimum 
clinically important difference of 1 with a standard deviation of 2.6 or greater are impractical. 
For the main study evaluable patients are defined as those for whom BFI at one month post RT 
is documented, as the primary endpoint is to show that fatigue as measured on the BFI scale is 
less at this time point in the intervention group. 
 
In the process of determining a sample size for the future larger study, we discovered that our 
pilot study was adequately powered to determine if there was statistically significant difference 
between groups. 
 
The mean fatigue score difference from CT/baseline to 1 month follow-up in the intervention 
group was (M = -20.17, SD =15.86) and (M = 5.75, SD = 15.30) in the control group (Table 
14). These means and standard deviations give an anticipated effect size (Cohen's d) of 1.67. At 
a desired statistical power level: 0.80 and probability level less than or equal to 0.05, a total of 
14 patients is sufficient. The probability is 82 percent that the study will detect a treatment 
difference at a two-sided 0.05 significance level, if the true difference between treatments is 26 
units. This is based on the assumption that the standard deviation of the response variable is 
15.5. A similar one-tailed hypothesis predicts that 12 patients would be sufficient. 
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The dependent variable; fatigue score difference from baseline to 1-month follow-up was 
assessed for normality using descriptive statistics (skewness, kurtosis and distribution shape) 
and deemed normally distributed. The Shapiro-Wilk statistic result was also > 0.1, this non-
significant result also indicates normality. 
 
An independent samples t-test was conducted to compare the differences in fatigue scores from 
baseline to 1 month follow up in the intervention and control group. 
There was a significant difference in scores for intervention participants (M = -20.17, SD 
=15.86) and control participants (M = 5.75, SD = 15.30; t (22) = -4.07, p= .001 (two tailed). The 
magnitude of the differences in the means (Mean difference =25.92, 95% CI: -39.11 to -12.72) 
was very large (eta squared = 0.43) 
 
Additionally because of the small sample size a Mann-Whitney test was also performed.  This 
test also gave a statistically significant result (p< .0005) 
 
4.4.4.2. Fatigue Interference with 6 BFI QoL Domains 
Table 15 (below) outlines fatigue interference with each of the BFI questionnaire’s 6 QoL 
domains. A higher score indicates greater interference. Fatigue interference with each QoL 
domain is discussed in detail after the table. 
 Baseline (CT) Mid-EBRT End-EBRT 1 MT FU 
 Mean SD Mean SD Mean SD Mean SD 
General Activity         
Control 0.5 1.2 0.5 1.4 1.1 1.7 2.0 2.9 
Intervention 2.3 2.8 1.2 2.4 0.6 2.0 0.1 0.3 
Mood         
Control 1.8 2.1 0.8 1.6 0.6 1.4 1.2 1.9 
Intervention 1.9 2.4 1.6 3.5 0.7 1.8 0 0 
Walking Ability         
Control 0.8 1.8 1.6 2.4 1.9 3.0 1.1 2.7 
Intervention 2.4 2.8 0.7 2.3 0.4 1.2 0.2 0.6 
Normal Work, 
daily chores 
        
Control 0.8 1.3 0.8 1.6 1.2 2.0 1.8 2.8 
Intervention 1.8 2.3 1.3 2.7 0.1 0.3 0.2 0.6 
Relations with 
others 
        
Control 1.1 2.1 1.1 2.1 0.6 1.0 1.1 2.2 
Intervention 1.3 1.9 1.1 2.6 0.5 1.7 0 0 
Enjoyment of 
Life 
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a. Fatigue interference with General Activity 
At CT/Baseline fatigue interfered with intervention participants’ general activity more than 
control group participants. However it can be seen from Figure 11 that upon 
commencement of the exercise intervention fatigue began to interfere less with 
interventions participants’ general activity. The opposite is true in the control group where 
fatigue gradually interferes more and more with control group participants. 
 
 
 
 
b. Fatigue interference with Mood 
Fatigue interferes with both groups’ mood less and less as they progress through EBRT. 
However upon completion of EBRT it can be seen that fatigue continues to decrease its 
interference with intervention patients whereas it increases its interference in the control 
group as demonstrated in Figure 12. 
 
c. Fatigue interference with 
Walking Ability 
Fatigue can be seen to decrease its interference with intervention group participants’ 
walking ability from baseline to the end of the intervention (Figure 13). In the control 
group, fatigue increases its interference from baseline to the end of EBRT. From the end of 
EBRT to the 1 month follow-up fatigue can be seen to decrease its interference with 
walking ability. 
 
d. Fatigue interference with Normal Work/Chores 
Fatigue interferes less with intervention patients’ normal work/chores as they progress 
through EBRT. This decrease coincides with starting the exercise intervention. There is a 
slight increase in interference from the end of EBRT to 1 month follow-up (0.1- 0.2). 
However interference at 1 month follow-up is still 9 times less than at baseline. Fatigue 
interferes more with control group participants’ normal work/chores as they progress 
through EBRT (Figure 14). This interference mirrors the accepted patient fatigue 
experience, i.e. patient begin to experience fatigue around the middle of EBRT which 
continues to increase after EBRT if not treated. 
 
Control 0.8 1.2 0.6 1.7 1.2 2.4 1.3 2.6 
Intervention 1.9 2.5 0.3 1.2 0.4 1.4 0.1 0.3 
Table 15: Between Group Fatigue Interference with 6 QoL Domains 
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e. Fatigue interference with Relations with Others 
Fatigue appears to interfere with both intervention and control groups patients’ relations 
with others to the same effect from baseline to the end of EBRT. However after EBRT 
fatigue interference decreases in intervention participants and increases in control 
participants (Figure 15). 
 
f. Fatigue interference with Enjoyment of Life 
Fatigue’s interference with intervention participants’ enjoyment of life decreases to coincide 
with participation in the exercise intervention (Figure 16). There is a slight increase from 
the end of EBRT to 1 month follow-up (0.1- 0.2) which coincides with finishing the 
intervention. Fatigue interferes more with control group participants’ enjoyment of life as 
they progress through EBRT. This interference mirrors the accepted patient fatigue 
experience, i.e. patient begin to experience fatigue around the middle of EBRT which 
continues to increase after EBRT if not treated. 
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4.4.5. HRQOL 
HRQoL was assessed at CT/Baseline, Mid EBRT, End EBRT and at 1 MT FU using the FACT-
P questionnaire. The questionnaire is composed of 5 sections: Physical wellbeing (PWB), social 
wellbeing (SWB), emotional wellbeing (EWB), functional wellbeing (FWB) and a prostate 
specific additional concerns section (PCS). The maximum score possible is 156. A higher score 
represents a greater HRQoL. Three scores can be determined from this questionnaire by 
including or excluding any of the 5 sections, e.g. 
 
a) FACT-P (Overall) Total score (0-156) 
           = (PWB score) + (SWB score) + (EWB score) + (FWB score) + (PCS score)   
b) FACT-P Trial Outcome Index (TOI) Total score (0-104) 
           = (PWB score) + (FWB score) + (PCS score)  
c) FACT-G Total score (0-108)  
           = (PWB score) + (SWB score) + (EWB score) + (FWB score) 
 
Figures 17-19 demonstrate trends in FACT-P, TOI and FACT-G scores. It is clear that both 
groups had similar HRQoL at baseline however the intervention group participants reported a 
better HRQoL from Mid-RT to 1 month follow-up across all three measures of HRQoL. These 
three scores are discussed in more detail below.  
 
a) FACT-P (Overall) Total score (0-156) = (PWB score) + (SWB score) + (EWB score) + (FWB score) + (PCS 
score)   
Table 16 outline how exercise intervention participants HRQoL increased from M = 126.7 (SD 
19) at baseline to M = 135.8 (SD= 17.6) at 1MT FU. Control groups participants HRQoL 
remained almost the same over the same time period. M= 126 (SD= 15.5) to M= 129.1 
(SD=20.7). Figure 17 graphically demonstrate between groups FACT-P Total Score over the 4 
assessments. 
 
FACT-P (Overall) Baseline (CT) Mid EBRT End EBRT 1 MT FU 
 Mean SD Mean SD Mean SD Mean SD 
Intervention 126.7 19.0 133.3 15.3 130.6 20.8 135.8 17.6 
Control 126 15.5 129.5 22.7 128.6 19.1 129.1 20.7 
(PWB score) + (SWB score) +  (EWB score) + (FWB score) +  (PCS score) = FACT-P Total score 
Table 16: Mean and SD of FACT-P Overall Scores of Both Groups from Baseline to 1 Month Follow-Up 
 67 
 
 
Figure 17: Between groups FACT-P Total Score 
 
b) FACT-P Trial Outcome Index (TOI) Total score (0-104) = (PWB score) + (FWB score) +  (PCS score)  
Exercise intervention participants FACT-P TOI increased from M = 84.6 (SD 11.2) at baseline 
to M = 89.2 (SD= 11.8) at 1MT FU. Control groups participants HRQoL remained almost the 
same over the same time period. M= 82.9 (SD= 13) to M= 83.8 (SD=15.8) (Table 17). Figure 
18 graphically demonstrates between groups FACT-P Trial Outcome Index Score over the 4 
assessments. 
 
 
TOI Baseline (CT) Mid EBRT End EBRT 1 MT FU 
 Mean SD Mean SD Mean SD Mean SD 
Intervention 84.6 11.2 87.7 10.3 85.7 11.8 89.2 11.8 
Control 82.9 13 82.4 17.1 83.2 14.8 83.8 15.8 
(PWB score) + (FWB score) +  (PCS score) = FACT-P TOI Total score 
Table 17: Mean and SD of FACT-P TOI Scores of both groups from Baseline to 1 month follow-up 
Baseline Mid EBRT End EBRT 1 MT FU
Intervention 126.7 133.3 130.6 135.8
Control 126 129.5 128.6 129.1
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Figure 18: Between Groups FACT-P Trial Outcome Index Score 
 
c) FACT-G Total score (0-108) = (PWB score) + (SWB score) +  (EWB score) + (FWB score)  
Exercise intervention participants FACT-G increased marginally from M = 94 (SD 17.1) at 
baseline to M = 97.3 (SD= 12.7) at 1MT FU. Control groups participants HRQoL increased by a 
similar amount over the same time period. M= 89.7 (SD= 12.3) to M= 92.8 (SD=14.1) (Table 
18). Figure 19 graphically demonstrates between groups FACT-G Score over the 4 assessments. 
 
Table 18: Mean and SD of FACT-G scores of both groups from Baseline to 1 month follow-up 
 
Figure 19: Between Groups FACT-G Score
Baseline Mid EBRT End EBRT 1 MT FU
TOI Intervention 84.6 87.7 85.7 89.2
TOI Control 82.9 82.4 83.2 83.8
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Baseline Mid EBRT End EBRT 1 MT FU
Intervention 94 96 94 97.3
Control 89.7 95.7 92.6 92.8
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FACT-G Baseline (CT) Mid EBRT End EBRT 1 MT FU 
 Mean SD Mean SD Mean SD Mean SD 
Intervention 94.0 17.1 96.0 10.4 94.0 17.1 97.3 12.7 
Control 89.7 12.3 95.4 17.3 92.6 12.6 92.8 14.1 
(PWB score) + (SWB score) +  (EWB score) + (FWB score) = FACT-G Total score 
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4.4.6. Anthropometric Measures 
Table 19 outlines changes in control and intervention groups’ anthropometric measures across Baseline, Mid EBRT, End EBRT and 1 Mt Follow-Up. 
Variables Baseline (CT) Mid EBRT End EBRT 1 MT FU CT-MID EBRT CT-END CT-1 MTFU End -1 MT FU 
 Mean SD     Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Weight (kg)                 
Control 84.3 9.8 85.4 11.1 85.4 11.4 86.0 11.1 1.1 1.6 1.1 2.3 1.7 1.8 0.7 1.3 
Intervention 82.3 18.8 81.9 18.4 81.6 18.3 80.6 17.2 -0.5 2.0 -0.9 2.2 -1.7 3.3 -0.8 1.9 
% Body fat                 
Control 26.6 4.1 28.4 4.5 28.1 5.6 27.7 5.4 1.8 3.3 1.4 5.9 1.1 3.8 -0.4 2.1 
Intervention 28.7 6.8 28.1 6.3 28.7 6.6 27.6 6.9 -0.6 2.3 0 2.1 -1.1 2.7 -1.2 1.4 
% Muscle mass                 
Control 69.5 3.9 68.4 5.0 68.3 5.3 68.8 5.5 -1.1 3.9 -1.2 3.6 -0.8 3.8 0.4 1.8 
Intervention 68.2 6.5 68.2 5.9 67.7 6.2 68.7 6.6 0 2.5 -0.5 2.5 0.5 3.2 1.0 1.4 
Bone mass (kg)                 
Control 3.1 0 3.1 0.3 3.0 0.3 3.0 0.2 0 0.1 0 0.2 0 0.1 0 0.1 
Intervention 2.9 0.4 2.9 0.5 2.9 0.4 2.9 0.4 0 0.2 -0.1 0.1 0 0.1 0 0.1 
Waist circumference (cm)                 
Control 107.7 11.2 110.6 10.9 111.5 10.6 111.1 11 2.8 4.0 3.8 2.9 3.4 3.3 -0.4 1.4 
Intervention 105.3 15.4 106.3 15.5 105.4 15.5 104.5 15.8 1.0 3.2 0.0 3.0 -0.9 2.9 -0.9 2.4 
         Table 19: Mean and SD Anthropometric Scores of Both Groups from Baseline to 1 Month Follow-Up 
a) Weight (KG): Intervention participants lost M= 1.7 Kg (SD 3.3) form Baseline to 1 MT FU. Control participants gained M=1.7 Kg (SD= 1.8) over the same time period (Figure20) 
b) % Body Fat: Intervention participants lost M= 1.1% body fat (SD 2.7) form Baseline to 1 MT FU. Control participants gained M=1.1% body fat (SD= 3.8) over the same time 
period (Figure21) 
c) % Muscle Mass: Intervention participants gained M= 0.5% muscle mass (SD 3.2) form Baseline to 1 MT FU. Control participants lost M=0.8% muscle mass (SD= 3.8) over the 
same time period (Figure22) 
d) Bone Mass (KG): Bone mass remained unchanged in both groups from Baseline to 1 MT FU (Figure23) 
e) Waist Circumference (cm): Intervention participants lost M= 0.9cm (SD 2.9) of waist circumference form Baseline to 1 MT FU. Control participants gained  M=3.4cm   (SD= 3.3) 
over the same time period (Figure24) 
Figures 20-24 below demonstrate changes in all anthropometric measures across the 4 assessments 
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Figure 21: Mean Body Fat % of Both Groups from Baseline to 1 Month Follow-Up Figure 20: Mean Weight of Both Groups from Baseline to 1 Month Follow-Up 
Figure 22: Mean Muscle Mass of Both Groups from Baseline to 1 Month Follow-Up Figure 23: Mean Bone Mass of Both Groups from Baseline to 1 Month Follow-Up 
 
Figure 24: Mean Waist Circumference of Both Groups from Baseline to 1 Month Follow- 
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4.4.7. Physical Performance 
Variables* Baseline (CT) Mid EBRT End EBRT 1 MT FU CT-MID EBRT CT-END CT-1 MTFU End -1 MT FU 
 Mean SD     Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
2 Min Step Test                 
Control 147.5 46.9 164.7 43.9 178.9 46.0 182.3 48.1 17.2 35.2 31.4 27.3 34.8 40.7 3.4 26.5 
Intervention 150.8 62.8 206.1(10) 40.4 215.4 (11) 51.3 234.9 (11) 51.8 59.6 50.5 67.2 53.9 86.7 62.3 17.9 26.2 
30 Sec Sit-to-Stand Test                 
Control 15.4 4.3 15.7 4.8 16.3 5.5 16.8 5.3 0.3 2.1 0.8 2.9 1.3 3.0 0.5 1.6 
Intervention 15.8 6.0 17.5 (11) 4.5 18.8 (11) 7.3 19.8 (11) 7.4 1.5 3.9 3.3 2.7 4.4 3.5 1.1 1.7 
          Table 20: Mean and SD Physical Performance Scores of Both Groups from Baseline to 1 Month Follow-Up 
        *All participants completed both physical performance tests except where indicated by number in brackets 
a) 2 Min Step Test: Intervention participants increased their steps by M= 86.7 (SD 62.3) form Baseline to 1 MT FU. This represents an increase of 55.8%.  Control 
participants also increased steps but by M=34.8 (SD= 40.7) over the same time period i.e. an increase of 30 %. (Figure 25) 
b) 30 Sec Sit-to-Stand Test: Intervention participants increased their STS by M= 4.4 (SD 3.5) form Baseline to 1 MT FU. This represents an increase of 25.3%.  
Control participants also increased steps but by M=1.3 (SD= 3.0) over the same time period i.e. an increase of 9.0 %. (Figure 26) 
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Figure 25: Mean 2 Minute Step Test Scores of both Groups from Baseline to 1 Month 
Follow-Up 
 
Figure 26: Mean 30 Second Sit-To-Stand Test Scores of both Groups from Baseline to 1 Month 
Follow-Up 
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4.4.8. Intervention Participants 
4.4.8.1. Intervention Satisfaction  
Intervention participants were invited to complete a four question survey at the end of EBRT. 
The questions, scales and results are displayed in table 21. 
 Intervention 
(N=12) 
 Mean SD 
Pain or discomfort performing the walking intervention 
(0 = No pain or discomfort,  5 = severe pain or discomfort) 
1.1 0.3 
Programme convenience 
(0= Not convenient, 5 = Extremely convenient) 
4.8 0.4 
Overall level of satisfaction 
(0 = Not satisfied, 5 = Extremely satisfied) 
4.8 0.4 
Willingness to continue walking programme independently after intervention 
finishes (Yes or No) 
100% Yes 
Table 21: Intervention Group Participants Intervention Satisfaction Scores 
 
4.4.8.2. Intervention Barriers and Facilitators 
From the literature we know that exercise interventions for patients with all types of cancer that 
report the highest exercise adherence rates have three intervention components in common, 
they: 1) set programme goals, 2) promote practise and self-monitoring, and 3) encourage 
participants to attempt to generalise behaviours learned in the supervised exercise environment 
at randomisation to other, non-supervised contexts. This intervention integrated these 3 
components into its methodology. To investigate further potential exercise facilitators or 
barriers for PCa patients specifically, a convenience sample of 4 intervention participants were 
invited take part in an in-depth interview exploring barriers and facilitators to completing the 
intervention. 
 
Intervention patients gave very positive feedback about their experiences participating in the 
intervention:  
“I think the programme is of benefit to anyone because, especially with the weight, it keeps it 
level and it doesn’t increase during that time. It would be of benefit to your overall health and 
fitness58” 
 
“It was satisfying and I enjoyed the walking, it’s good for you and I want to keep that up59” 
 
“I found it satisfying… I enjoyed it. I was glad of the experience60” 
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“At the beginning I found it a bit difficult, I wasn’t really used to the procedure, but then when 
it was explained to me that you could do it in two different sections rather than all in the one go 
it made life a bit easier61” 
 
Intervention participants were generally clear of the advantages of their involvement in 
the exercise programme; one participant explained how it made him feel: 
 
“Because it was benefiting myself and my own level of fitness and exercise, I didn’t regard it as 
an inconvenience. I accepted that it was for a purpose… I feel fitter and my mood is better that 
it would have been without it, in my opinion… that (intervention) was a help, to take my mind 
off it (cancer) and concentrate on doing the exercise and just basically forgetting about the 
cancer58” 
Another participant who unknown to himself at the time had increased his average weekly steps 
from a baseline of 43349 steps to an intervention weekly average of 73719 steps i.e. +70.1% 
said the following: 
“Did it help me at all? I couldn’t say. I’d probably have done as much walking if I was never on 
the programme, I think… Or maybe I wouldn’t have done as much but I’d have tried to do as 
much anyway61” 
 
No intervention participants had an overall negative experience on the trial. One 
participant did find the recruitment process “upsetting”: 
“Well I’ll tell you what upset me in the beginning, do you remember the day when I was here 
for my first scan (recruitment)?.. I was to meet you as well. So, I wasn’t up to date with this 
water drinking and I got no information on that until my CT scan was over but what I found 
annoying, although I didn’t relate it at the time, what I found later was because you came on in 
the meantime and dragged me over to the far side of the hospital and I was up here, wherever, 
getting the CT scan and I was after drinking three mugs of water and then I was swept off over 
there, ‘C’mon over there, you’ve one in your hand there, you have to drink six more,’ you said 
to me. And I was thinking, if I’d been left alone without being dragged over there and back, you 
know what I mean. I’m not saying you, you were probably busy. If I could’ve just concentrated 
on the CT scan first and then go and do the other business... Get one thing out of the way first 
and then go and do the other thing61” 
 
Intervention participants had generally positive feedback regarding the pedometer and logbook: 
“At first I was a bit frightened I would lose it “pedometer”! But I got used to it, I used it every 
day, I got used to it and it wasn’t a problem... It did motivate me a bit. I exercise regularly but it 
was interesting to have a look at it60”, “Yes, it was (easy to use)58” and “no bother61”.The 
logbook also received positive reviews: “I just got used to it60”  and it was “Very clear 59” 
 
Interventions participants gave very informative answers about the exercise barriers they faced 
throughout the intervention: 
“There would be a few days that you wouldn’t feel like doing it but I forced myself to do it, I 
was glad afterwards58” 
 
“R: you might want to get it out of the way and you might be rushing, you might only get in in 
time to drink your water and stuff. I: And that’s because you decided to do your walking before 
treatment.  R: Before treatment, yes.  I: Do you think if you had to do it again you’d do your 
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walking after treatment?  R: No, I’d do it the same way. I did do it after treatment sometimes. 
Depending on what time the treatment was at61”  
“I: On the days that you didn’t achieve it, which are relatively few, were there specific reasons 
that you couldn’t do it? R: Generally, two reasons: 1) I would be travelling in a car, long 
journeys; and 2) weather, when it was raining. I: And on the rainy days, were they days you 
were getting treatment or were they weekend days? R: Generally, weekend days59” 
 
“The only problem was the traffic. One part has heavy traffic on the roads61” 
 
Intervention participants also had interesting things to say about what facilitated their exercise 
each day: 
“The programme, the study you are doing. That was the motivation60” 
 
“Well, because the walking in St Luke’s was somewhat level, you know that was a help to me. 
There wasn’t much hills and hollows. And also, when I went home the same would apply 
because I walked on the road because it was fairly flat and it was a help58” 
 
“Yes (the walking fitted into my treatment schedule)…  It was on my mind all the time. I was 
trying to get the 8,000 or 9,000 every day59 
 
The different environment of each hospital also had a part to play in facilitating the exercise 
intervention: SJH 
“For me, it was very simple because I got off the train at Heuston and walked up to here. I 
probably would have got 15 minutes, 15-20 minutes in there. Then I walked around the grounds 
of the hospital outside in general and I got the 30, 35 minutes…Then I would walk at home or 
do something at home and get it up to the 7,000 or 8,00059” 
 
“Coming up on the train was handy because you could walk up from the station, that was 10 
minutes or a quarter of an hour out of the way. Then you had another 15 minutes maybe around 
the hospital. I used to get a lift in to Portlaoise with the wife, she works in Portlaoise and some 
days I walk from where she works down to the station but I wouldn’t include that. If I was going 
to do the walk, if I had time, I’d do the walk before the train, I’d walk around Portlaoise for half 
an hour…. Mostly, I’d come up to Dublin and walk from the station up to here…   . I’d walk 
around the hospital and finish the half an hour before I’d have my treatment I: Were there ever 
days where it was raining and stuff like that? How did you handle that? R: I walked inside the 
hospital, yes. I: How did you find that? Was that harder? R: No, no bother, no. I: Just up and 
down the long corridors? R: All around the bottom, the far end over the other side near the 
restaurant, all down around there61” 
 
“Most of the time from 10 o’clock in the morning and it would take me about an hour and a half 
to get to 9000. I walked from A to B and in near enough the half hour I would have 3000 plus 
steps. And then it would take another hour61” 
 
SLH 
“I chose to do the exercise in the grounds of St Luke’s in Rathgar, which is a Slí na Sláinte 
[walk way]1km per lap. I usually did three laps of that which is 30 minutes. Sometimes I did 
four58” 
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“It only rained say about twice while I was over there and it started during, during my 30 
minute walk and I continued, continued as though it wasn’t raining. So I finished even though I 
got wet but that was only about two days58” 
“If my treatment is in the morning, I did it in the afternoon and if my treatment was in the 
morning, I did it in the afternoon58” 
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4.4.9.  Control Participants 
 
4.4.9.1. Exercise Knowledge, Attitude and Practices (KAP) in the control group  
 
Only 42% (5/12) of the control group were aware of the correct recommended weekly MVPA guidelines (Figure 27). 33% of control group participants were 
unaware of the adverse event reducing effect of MVPA during EBRT (Figure 28) but 92% did agree that it could improve their HRQoL (Figure 29). 58% incorrectly 
thought that there are genuine risks associated with MVPA during EBRT (Figure 30). 100% of the control group felt confident that they knew how to keep 
physically active (Figure 31) and only 50% were interested in learning more about physical activity (Figure 32). 
 
Only 33% patients remembered a health care professional discuss the role of exercise during and after EBRT (3 Consultant, 1 Nurse) (Figure 33). 58% of patients 
had not changed their exercise regime from baseline to end of EBRT, 25% decreased their exercise and 17% increased their exercise (Figure 34). 
 
Since completing EBRT 67% have not charged their exercise regime. 17% say they have decreased exercise and 17% say they have increased exercise (Figure 35).   
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Figure 27: Control Group Participants Responses to KAP Questionnaire Q1 Figure 28: Control Group Participants Responses to KAP Questionnaire Q2 
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 78 
 
 
 
3 x Consultant
1 x Nurse
0
1
2
3
4
5
6
7
8
9
Yes No
A
xi
s 
Ti
tl
e
Were You Advised to Exercise by Any Member of your 
HealthCare Team Since entering the SLRON System
No
Decreased
habitual activity
Increased Walking
Participants 7 3 2
0
1
2
3
4
5
6
7
8
C
o
n
tr
o
l P
ar
ti
ci
p
an
ts
Have You Changed your Physical Activity Regime Since 
Diagnosis or  Starting EBRT
No Increased PA Decreased PA
Participants 8 2 2
0
1
2
3
4
5
6
7
8
9
C
o
n
tr
o
l P
ar
ti
ci
p
an
ts
Has Your Exercise Regime Changed Since Finishing EBRT
Figure 34: Control group participants’ Responses to KAP questionnaire Q6b (i) Figure 33: Control group participants’ Responses to KAP questionnaire Q6a 
Figure 35: Control group participants’ Responses to KAP questionnaire Q6b (ii) 
 79 
 
 
5. DISCUSSION 
 
This pilot study was designed to establish the feasibility of a home-based MVPA aerobic 
exercise intervention to reduce fatigue and increase HRQoL for patients with localised prostate 
cancer actively undergoing EBRT+ADT before proceeding with a future confirmatory  RCT. 
 
Similar to previous systematic reviews4,5,15,18 , this study further adds to the existing evidence  to 
suggest that physical activity interventions offset many of the side effects of EBRT+ADT with 
few side effects itself4,5.  
This is the first study to demonstrate that a home based MVPA walking exercise intervention 
during EBRT is safe and associated with high compliance and reduced fatigue among patients 
undergoing radical EBRT for PCa. These findings support the hypothesis that in any proposed 
future confirmatory study, patients in Ireland with localised prostate cancer undergoing radical 
EBRT+ADT randomised to the MVPA walking exercise intervention will experience less 
fatigue in comparison with the standard care control group over the period of radiotherapy 
treatment and at 1-month follow-up. 
 
This pilot study was planned as a preparatory study designed to test the feasibility of the  
processes, resources and management issues under consideration for use in a future 
confirmatory RCT62. It has comfortably satisfied the feasibility criteria for SLRON to 
recommend a future RCT. In advance of a discussion on the scientific outcomes of this pilot 
study, firstly we will discuss the process, resource and management outcomes and subsequent 
issues that could create obstacles to completing a future confirmatory RCT.  Finally we will 
discuss the pilot study results in the context of the feasibility or “stop/go” criteria, and interpret 
whether it is feasible to proceed to the main study. 
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Processes 
We assessed the feasibility of the steps that need to take place as part of the main study2. 
86% of eligible participants were recruited to the pilot intervention (Satisfying feasibility 
criteria 1).The target accrual of 24 participants was achieved in 6 weeks, well in advance of 
schedule (Satisfying feasibility criteria 2). Unfortunately no patients could be recruited in the 
SLH centre as network policy during this time determined that all radical PCa patients be 
treated at the BH and SJH centres. A greater number of patients were recruited at SJH as more 
PCa patients were referred there for treatment. The issue of referring patients to each centre is 
decided by a central booking office and is dictated by the availability of treatment slots. This 
system is independent of the Clinical Trials Unit. 
 
Trial co-ordinators (TC) reported no issues understanding the trial eligibility criteria and 
determining patient eligibility. TCs found the criteria in keeping with the ICH-GCP guidelines 
and would not recommend any changes for a future confirmatory RCT. 
 
One TC did suggest that we should consider recruiting patients earlier than at their CT scan as 
patients’ have already begun ADT by this time. They suggested that participant recruitment 
should happen at the same appointment as their ADT is prescribed.  While this would be a true 
pre-hormone baseline assessment, it would not be feasible to carry out the functional fitness or 
anthropometric assessments at these appointments for a number of reasons. Namely, patients are 
often prescribed ADT in hospitals outside the network prior to referral to SLRON. Clearly it 
would not be feasible recruit these particular patients as we have no staff or authority in these 
centres. Additionally it would be unethical to ask Radiation Oncologist or Urologists to hold off 
on prescribing ADT until patients attend the SLRON for the sole purpose of potential 
recruitment to a clinical trial. 
 
Participant refusal to participate rate was very low at 7%. No recruited patient refused to be 
randomised or withdrew from the study after allocation to either the intervention or control arm. 
The retention rate was very high at 96% (Satisfying feasibility criteria 3). Only one patient 
could not complete his prescribed exercise prescription due to treatment related grade 3 urinary 
pain and retention. This adverse event resulted in the patient undergoing a procedure to insert a 
supra-pubic catheter. Grade 3 urinary pain and retention are both rare side effects of EBRT. 
 
The baseline distribution of anthropometric measures, time since diagnosis, baseline steps per 
day, functional fitness, age, T-stage, risk group, EBRT, ADT and social characteristics (table 
11) were similar in both groups. These measurements are also similar to four previous 
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EBRT+ADT studies. Intervention group participants were slightly more fatigued than the 
control group (by chance as participants were randomised) but reported a similar HRQoL as 
control group participants’ pre-randomisation. These patient characteristics are comparable to 
other studies looking at the effects of exercise intervention and are representative of radical 
prostate cancer patients across the network. 
 
The schedule of assessments (table 12) appears evenly distributed between groups. Participants 
in each group were assessed at roughly the same fraction and with roughly the same amount of 
days between assessments. 
 
TCs had no issues administering the study questionnaires. Both the BFI and FACT-P are 
designed for either self or co-ordinator administration. When given the choice, all participants 
choose to have the co-ordinator administer the questionnaire.  This is in keeping with other 
studies in the SLRON network. According to TCs there are several reasons why participants 
like to have the questions read to them, in particular poor eyesight and unfamiliarity with 
completing questionnaires. In SLRON all trial co-ordinators are experienced researchers and 
receive specialised training from ICORG in how to administer questionnaires in a way that will 
not bias participant responses. In addition co-ordinators are trained to recognise courtesy bias 
i.e. the tendency for respondents to give answers that they think the interviewer wants to hear, 
rather than what they really feel. 
 
TCs checked log books weekly for data quality and reported that some intervention participants 
found the log book hard to follow at first and required further instruction, after which they had 
no difficulty. Other TCs reported that participants had no issues at all.  In a future confirmatory 
study participants would benefit from more education and training in how to complete the log 
book. 
 
TCs are used to operating high-tech machinery on a daily basis and thus had minimal issues 
operating the body composition analyser. TCs had mixed experiences with the pedometers. In 
the majority of cases both the coordinator and participants had no issues using them. In some 
cases coordinators found them difficult to program and not very user friendly. Despite receiving 
clear verbal and written instruction not to keep the pedometer near cell phones some participant 
did. Participants were constantly reminded that this could affect data storage. Fortunatly there 
were no issues. In a future RCT both coordinators and participants would benefit from further 
training in pedometer use. It would also be worthwhile investigating the availability of radio 
frequency (RF) resistant pedometers or RF resistant cases for the existing pedometers. 
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TCs were very supportive of this pilot study and how it served to bring to light potential process 
issues for a future confirmatory RCT. They were appreciative for the opportunity to increase 
their familiarity with the trial processes which will increase their confidence and efficiency in 
the future confirmatory RCT. Indeed they suggest it would be sensible to carry out pilot studies 
for all future RCTs in the SLRON network. 
 
Resources 
The researcher assessed the time and resource issues that could occur as part of the main study. 
A key component in planning a future RCT is estimating the necessary resources. Recruiting 
patients to a clinical trial is time consuming and often a limiting factor in patient accrual. The 
average time to recruit a patient to this pilot study was 53.8 minutes (SD 18.2). This is in 
keeping with recruitment times to other trials in the network. TCs did not find the recruitment 
process unnecessarily time consuming or in need of change for the large RCT. 
 
Completing questionnaires is often the most time consuming component of a clinical trial 
assessment. The sample population in this pilot opted to have a trial coordinator talk them 
through the questionnaires. This is common in clinical trials in the SLRON network, and 
highlights the necessity of questionnaires that are validated for both self and trial coordinator 
administration.  
 
The average time to complete the BFI questionnaire was 1.55 minutes (SD 1) and FACT-P 6.13 
minutes (SD 3.42). No other studies have reported on completion times so we cannot make a 
comparison. TCs felt that these are reasonable completion time for such questionnaires and not 
of concern for trial coordinators. Patients became progressively slower completing the BFI 
questionnaire as they progressed through the study. We can also see that in general intervention 
participants took slightly longer to complete the BFI than control participants. In contrast, 
patients became progressively faster completing the FACT-P questionnaire and control 
participants took slightly longer to complete the FACT-P than intervention participants.  
 
Usually patients are recruited to clinical trials at out-patient visits and on-treatment trial 
assessments coincide with patients’ daily EBRT appointment. In both instances, appointment 
times change regularly for a number of reasons, namely machine breakdowns or services. 
During such unforeseen changes to scheduled appointments, TCs need to have quick access to a 
room and the necessary equipment to complete the trial assessment. 
 
As this is a multi-centre trial each centre has its own unique challenges. Fortunately, TCs 
reported no issues accessing clinic rooms for either recruiting patients or on-treatment 
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assessments. Likewise, there were no issues accessing the necessary equipment i.e. body 
composition analyser, tape measure and PC. 
 
Hospitals are busy settings in which to carry out research. Research like the current pilot study 
requires the cooperation and willingness of a multi–disciplinary team i.e. Doctor, Nurses, 
Radiotherapists, and administrative staff. It is the trial coordinators responsibility to synchronise 
these staff to ensure patients are recruited to studies in a controlled manner. In this instance, 
Consultant Radiation Oncologists backed the study and enthusiastically consented patients. This 
willingness filtered down through the rest of the allied health professions and made coordination 
easier. 
 
TCs reported that this enthusiasm developed as a result of the minimal impact that the trial had 
on the normal patient pathway. In-depth knowledge of how the SLRON works regarding patient 
referral and treatment planning pathways played a major role in the design of this study. 
 
As with any study with a high recruitment rate, staffing is an issue. TCs were in agreement that 
while we had sufficient TC staff to manage 24 patients we would need more staff at each centre 
for a larger RCT even at the same rate of recruitment.  Recruiting 2 patients a week for a 7 week 
study would mean you would have 14 patients at various stages after 7 weeks. This number 
escalates week after week. There are an insufficient number of TCs in the network to recruit 
patients at the current rate for a larger study.  The SLRON would need to either recruit more 
staff or limit the rate of recruitment.  
 
Management 
The researcher assessed the potential personnel and data management issues at each of the three 
participating centres. 
 
This study was designed around the SLRON’s existing clinical trial systems and structure. In 
doing so, the researcher was able to minimise potential trial management issues. All three TCs 
reported that they had no major issues managing patients on this trial. One TC suggested that we 
should pilot all our studies in future as what “looks great on paper doesn’t always work in 
practice56”. 
 
TCs had no issues with data entry except for calculating intervention participants step targets. 
This calculation is done using an excel spread sheet. While the process is simple, it appears that 
it is not user friendly. TCs suggested that either this spread sheet is simplified or TC’s should 
receive more training on its use. 
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Weight loss in the intervention group was an unexpected outcome. At best we had anticipated 
no weight gain. While weight loss as a result of MVPA is beneficial for a patient’s health, too 
much weight loss may become problematic from an EBRT treatment and dosimetric distribution 
point of view. As a patient loses weight his external contour decreases. As a consequence, the 
distance from the patient surface to the prostate decreases. As this distance changes from that of 
the planned distance, the distribution of radiation to the prostate and organs at risk also changes. 
Weight loss also has implications for radiotherapists trying to get the patient into the treatment 
position daily using external skin tattoos. A contour change of 1 cm in any direction as verified 
using the linear accelerator’s (treatment machine) on-board imaging facility would require the 
patient to undergo a treatment “re-plan”. This should be avoided as the patient would be 
subjected to more scans and thus unnecessary radiation exposure. The added workload would 
also be a drawback. 
 
Intervention patients lost an average of 0.9 kg (SD 2.2) from their CT scan to the end of EBRT. 
Fortunately this did not translate into a contour decrease of ≤ 1cm. In one case it was necessary 
for a Consultant to assess a patient’s scans. The Consultant determined that it was safe to 
proceed. In a future trial, there would need to be a provision for this situation. For example; if 
the radiotherapist identifies that a patient’s contour is decreasing (visually or imaging), they 
should immediately notify the TC. The TC should then reassess the volume of MVPA 
prescribed to the patient and reduce as appropriate. There are three key points to note: firstly, 
the principal investigator should ensure that all radiotherapists are aware that the patient is on an 
exercise trial, secondly; a contour change is a possibility, and finally, a system to communicate 
efficiently with the TC is important.   
 
It was also suggested that we consider a translational component in any future trial. This would 
involve regular blood and/or urine sample collection. The samples would then be analysed in a 
lab to investigate how proteins or other markers of interest change with respect to exercise. 
Other physiological measurements could also be considered such as blood pressure. 
 
The overall TC consensus was that this pilot study integrated seamlessly into the existing 
management structures of SLRON. It is not anticipated that there will be any future 
management issues. 
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Scientific 
The following section contains a discussion on intervention safety and participant adherence, 
fatigue, HRQoL, anthropometric measures and functional fitness. We will then discuss 
intervention participants’ acceptance of the intervention and potential issues for future 
intervention participants, followed by a discussion of control participants’ exercise KAP.  
 
Safety 
As with any treatment, adverse effects and safety are key concerns63 for exercise interventions 
There were no exercise related adverse or serious adverse events reported for this pilot study 
(Satisfying feasibility criteria 4)  . It would appear that the individualised step-based MVPA 
exercise prescription used in this study is safe and well tolerated by patients undergoing 
EBRT+ADT. This outcome is similar to other intervention for PCa patients undergoing ADT 
and EBRT+ADT. 
 
Gardner63 (2014) in his review “the effects of exercise on treatment-related adverse effects for 
patients with prostate cancer receiving ADT” reported that exercise interventions were well 
tolerated by participants, with a low frequency of adverse events. In addition, he also reported 
that exercise did not seem to affect PCa progression or ADT efficacy63. However the current 
research is more concerned with PCa patient undergoing EBRT+ADT. 
 
One supervised and one home-based exercise intervention33,34 included in this pilot study’s 
review of patients undergoing EBRT+ADT looked at exercise related adverse events. Segal et 
al33 reported that two patients without a cardiac history experienced adverse events (syncope 
and acute myocardial infarction) related to supervised aerobic exercise (cycling, jogging or 
cross training). Only the acute myocardial infarction was deemed a serious adverse event 
(requiring hospitalisation or disability). Both participants made a full recovery. Truong et al34 
reported that there were no cardiovascular complications, musculoskeletal injuries, or other 
adverse events related to their home-based walking exercise. This study adds further to Truong 
et al34 evidence that a pragmatic home-based aerobic exercise is safe and well tolerated by PCa 
patients undergoing EBRT+ADT.  
 
Treatment Related Adverse Events 
To the best of the author’s knowledge, this is the first study to record and report radiotherpy 
treatment related adverse events for patients undergoing an exercise intervention. Intervention 
participants experienced slightly higher rates of grade 1 diarrhoea, proctitis, rectal bleeding, and 
hot flushes and grade 2 erectile impotence and gynecomastia. However they demonstrated lower 
rates of grade 1 dysuria and haematuria, and grade 2 urinary frequency/urgency. Both groups 
were comparable on all other measures of adverse events. There was no clinically significant 
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difference in adverse events experienced between groups. The rates of adverse events are 
comparable to the non-trial population. This evidence suggests that the MVPA exercise 
prescribed in this intervention does not affect the rate of treatment related adverse events 
experienced by PCa patients undergoing EBRT+ADT. 
 
Intervention adherence/contamination rate 
Adherence to exercise is often considered the Achilles heel of an exercise intervention37 and is a 
key weakness in previous EBRT+ADT studies. Exercise adherence has been defined as the 
degree to which a person completes a given exercise prescription.  Most authors of both ADT 
and EBRT+ADT exercise intervention do not describe the intervention’s adherence criteria. In 
fact none of the previous four EBRT+ADT interventions controlled for adherence to “exercise 
intensity” the most crucial health determining component of physical activity. In addition, in 
most interventions it appears that adherence is recorded using patient reported subjective tools 
e.g. a logbook. 
 
This study was informed by research carried out on cardiology patients37 and took an abstract 
public health heuristic of walking for 150 min/week  at a MVPA and transformed it into a real 
step target. We considered the total amount of exercise performed i.e. frequency, intensity (steps 
and time). An individualised pre-specified threshold was identified for each patient and the 
percentage of participants achieving that threshold was determined64. There was an overall 
exercise adherence of 81.8% in the intervention group (Satisfying feasibility criteria 5) and 
exercise contamination was 33.3% in the control group. 
 
Home-based programs are particularly subject to questions about whether participants adhere to 
exercise recommendations during the intervention in the absence of direct supervision. This 
issue is important since adherence to exercise recommendations in RCTs is critical to the 
validity of the outcomes64. We employed a number of evidence based measure to encourage 
adherence as outlined previously in section 2.3.3 
 
ADT 
The self- reported adherence to supervised exercise for prostate patients undergoing ADT 
treatment  ranges from 78% to 100%63. Of these ADT-only interventions, only Bourke et al51 
reported adherence to unsupervised exercise. As part of a supervised aerobic and resistance 
exercise intervention for metastatic prostate cancer patients,  participants were asked to 
undertake at least one self-directed 30 minute independent exercise session in week 1-6 and two 
independent sessions in weeks 7-12 of the intervention using the skills taught in the supervised 
sessions. Adherence was reported as 82% however it is unclear how adherence was assessed. 
There are three potential explanations for such high adherence rates for these ADT only studies: 
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1) They are self-reported, 2) They are predominantly supervised and 3) patients are not 
undergoing EBRT concurrently. One would expect lower adherence to home-based exercise 
interventions. 
 
EBRT+ADT 
Three exercise interventions for PCa patients undergoing EBRT+ADT reported adherence to 
prescribed exercise. The three studies appear to have used entirely subjective methods of 
exercise adherence assessment.  Segal et al33 reported a median adherence of 85.5 % to a  
supervised 24 week exercise intervention of either aerobic (cycle ergometer, treadmill, or 
elliptical trainer beginning) or resistance exercise (leg extension, leg curl, seated chest fly, 
latissimus pulldown, over- head press, triceps extension, biceps curls, calf raises, low back 
extension, and modified curl-up). No adherence criteria are reported, however we do know that 
it was subjectively assessed by exercise specialists. 
 
In the Windsor et al35 home-based, moderate intensity intervention, intervention participants 
were prescribed continuous walking for 30 minutes on at least 3 days of each week of 
radiotherapy at a target heart rate of 60–70% calculated maximum heart rate (as a guide to the 
intensity of the activity). The duration of activity and the heart rate before and at completion of 
activity were recorded using a wrist-band heart-rate monitor. Patients in the control group were 
not discouraged from performing normal activities but were advised to rest and take things easy 
if they became fatigued. 
 
Adherence was self-assessed. All patients kept a patient-activity diary during radiotherapy 
detailing the frequency and duration of the walking intervention together with the heart rate 
achieved (exercise group) or the frequency and duration of everyday aerobic activity (control 
group). The control group showed a small, non-significant decline in hours of reported aerobic 
activity per week during radiotherapy. All patients in the exercise group recorded at least 1.5 
hours of aerobic exercise at the recommended percentage maximum heart rate per week 
throughout radiotherapy. The increase in hours of prescribed exercise during radiotherapy did 
not achieve statistical significance (Week 1 compared with Week 5: P=0.056). 
 
Truong et al 34 asked participants to walk for at least 20 minutes/day, 3 days/week over 12 
weeks at a perceived moderate intensity of 60%-70% of age-predicted heart rate, starting one 
week prior to commencing EBRT. They reported a study completion rate of 84%. Of the 84 
participants to complete the intervention 88% met or exceeded the exercise requirements with 
respect to frequency, intensity and/or duration of exercise. As in Windsor’s study above, 
adherence was self-reported using subjective tools such as a log book. 
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None of the three exercise interventions for PCa patients undergoing EBRT+ADT, whether 
supervised (Segal) or home-based (Windsor and Truong), used an objective tool to measure 
adherence or provided enough detail to allow comparison to the current study. 
 
Current Research 
In this pilot study, exercise was prescribed according to the F.I.T.T acronym and adherence was 
determined in a similar manner. We used a stricter adherence criterion than previous studies. 
We also utilised a pedometer as an objective tool in conjunction with the subjective logbook to 
measure adherence. Despite using more stringent criteria there was an overall exercise 
adherence of 81.8% in the intervention group and exercise contamination was 33.3% in the 
control group 
 
To the best of the author’s knowledge this is the first exercise study either supervised or home-
based to include a step based target as an objective assessment of adherence. It is also the first 
study to use a pedometer as an objective measurement tool. As opposed to the heart rate monitor 
used by Windsor et al, the pedometer records data that can be independently verified by the 
researcher.  
 
This is the first home–based walking exercise intervention using tailored step based exercise 
prescriptions. Using strict and objective adherence criteria based on the F.I.T.T. principles, we 
have demonstrated adherence rates in the intervention group that are comparable to supervised 
exercise programs.  
 
This is also the first exercise study for patients undergoing EBRT+ADT, to assess exercise 
contamination in the control group.  Truong et al 34  recognise that their lack of data on 
contamination in the control group is a limitation of their research. A 33% exercise 
contamination rate in this study demonstrates the need to assess this outcome and regularly 
remind control participants not to purposefully increase their volume of exercise as per the trial 
protocol. 
 
Steps/day 
It is evident from the literature review that there is little evidence to inform researchers about 
baseline/habitual steps/day for PCa patients. This is, to the best of the author’s knowledge, the 
first study to do so. Independently recorded pedometer data demonstrated that both groups of 
patients had similar habitual steps/day before EBRT. Contrary to our expectations both groups 
of patients increased their average daily steps by a similar amount during the first week of 
EBRT (#1- #7). We had expected that patients’ average daily steps would decrease upon 
commencing EBRT due to increased travel and the actual treatment process each day. This is 
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the first study to investigate and indeed report that EBRT patients increase their average daily 
steps upon commencing EBRT. 
 
During the study, the intervention group increased their average daily steps by 3460 steps (53%) 
to 9965 steps per day. We can logically assume that this increase is as a result of the exercise 
intervention and that at least 3000 of these steps are at a moderate to vigorous intensity. On 
average, intervention patients exceeded their weekly step target by 15.3%. This increase in steps 
almost brings the intervention group in line with the internationally recognised steps/day 
guideline of 10000 steps per day. 
 
Again, contrary to our expectations, control participants increased their average daily steps by 
649 steps (10%) to 6879 steps per day compared to average habitual steps/day during the pilot 
study. We cannot make any assumption as to the intensity of these steps. It is important to note 
that this average is well below the internationally recognised steps/day guideline of 10000 steps 
per day. 
 
It is perhaps most satisfying that at 4 weeks post intervention (1 month FU assessment) the 
intervention group generally maintained their increased average steps/day. Intervention 
participants only decreased their average steps/day by -2.61%. Control participants decreased 
their average daily steps by 9.5% from an already lower baseline. 
 
 
Fatigue 
Data has emerged in recent years advocating the superior effects of exercise over other therapies 
in reducing cancer related fatigue in patients with different malignancies. To date the majority 
of research has involved breast cancer patients, with relatively little data specific to men with 
localised prostate cancer34.  Of the data that is available, interventions that include PCa patients 
undergoing ADT only dominate. Evidence shows that patients undergoing a combined 
treatment of EBRT+ADT suffer more adverse effects than ADT-only patients. This is 
particularly true with respect to cancer related fatigue. 
 
ADT 
Three RCTs, included in Gardner’s review of  the “effects of exercise on treatment-related 
adverse effects for patients with prostate cancer receiving androgen-deprivation therapy”, 
included fatigue measures63. Bourke et al51 and Segal et al65 reported clinically and statistically 
significant reductions in fatigue with exercise training compared with control63.In contrast, 
Culos-Reed et al39 found no benefits of their home-based intervention with regard to fatigue 
compared with usual care63. 
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EBRT+ADT 
For several reasons, patients undergoing EBRT+ADT typically experience worse fatigue than 
patient undergoing ADT only. All four interventions included in this study’s review of exercise 
interventions for PCa patients undergoing EBRT+ADT reported fatigue outcomes. Two 
supervised aerobic interventions report reductions in fatigue, Monga36 reports a significant 
reduction of 79%, and Segal33 reports a non-significant reduction of 11%. 
Two home-based aerobic interventions also report reductions in fatigue. Windsor35 reports a  
significant reduction in fatigue of 82%, Truong34 reports stable mean total fatigue scores from 
baseline to 6 months post-EBRT FU (P=0.52) in the intervention group while fatigue in control 
subjects escalated from baseline to 6 months post-EBRT (P ≈ 0.3).  Both Windsor and Truong 
used the BFI questionnaire to estimate fatigue. 
 
Current research 
The decline in fatigue in the exercise group in this study is distinct from the rising fatigue scores 
in the control group which remained elevated at one month post EBRT.  In addition trends for 
higher fatigue interference with six QoL domains were observed in the control group compared 
with the exercise group (Satisfying feasibility criteria 6). 
 
The current intervention demonstrates a mean fatigue reduction of 91% from baseline to 1 
month follow-up in the intervention group and a mean fatigue increase of 43% in the control 
group over the same time period. The mean fatigue score difference from baseline to 1 month 
follow-up was (M = -20.17, SD =15.86) in the intervention group and (M = 5.75, SD = 15.30) in 
the control group. This difference was statistically significant (p=.001). The magnitude of the 
differences in the means was very large (eta squared = 0.43) 
 
As in Truong’s34 home-based aerobic exercise intervention, higher fatigue interference trends 
with the 6 QoL domains (general activity, mood, walking ability, normal work/daily chores, 
relations with others and enjoyment of life) were observed in control compared with exercise 
group. 
 
Despite patients in the current study receiving higher average doses of radiation at 75 Gy (SD 
3.9) over a greater average number of fractions 38 (SD 3.7), this study has demonstrated 
comparable and, in most cases, greater reductions in patient fatigue than other ADT or  
EBRT+ADT  supervised or home-based exercise interventions. These improvements remained 
even after the completion of EBRT and the intervention. This further supports the 
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recommendation of home-based aerobic exercise as a self-help measure to manage fatigue 
during and after EBRT34. 
 
HRQoL 
Several complimentary interventions have been reported that may help patients cope with 
cancer and its treatment. Most of these interventions include cognitive behavioural therapies, 
individual counselling, or psychotherapy and social support36. Meyer and Marks systematic 
review reports that these types of interventions have no effect of the physical and functional 
domains of QoL. It is these domains that clinicians consider the most important. Exercise 
interventions are now seen as the most promising intervention to both maintain and improve 
PCa patients HRQoL. The current intervention is the first home-based walking intervention to 
examine and report QoL outcomes. 
 
Four RCTs included in Gardner’s review of effects of exercise on treatment-related adverse 
effects for patients with prostate cancer receiving ADT included QoL measures. Segal et al65 
demonstrated that resistance training improved PCa-specific QoL, compared with a decline in 
the control group. Similarly, Galvao et al66 found that exercise training was superior for certain 
components of QoL, including general health, vitality, physical health, sexual activity, cognitive 
function, fatigue, nausea, and dyspnoea.  In contrast, two RCTs39,51 observed no significant 
effects of exercise on general or cancer-specific QoL 
 
Two of the four interventions included in this study’s review of exercise interventions for PCa 
patients undergoing EBRT+ADT reported HRQoL type outcomes. Monga et al36  aerobic 
intervention demonstrated statistically significant improvements in overall QoL (+10%) as well 
as in the  physical (+15%) and social (+14%) domains of QoL using the FACT-P questionnaire 
compared with a decreases in the control group. Segal et al33 aerobic intervention demonstrated 
a non-statistically significant increase of 3% in overall QoL using the FACT-P questionnaire. 
 
The current intervention is the first home-based walking intervention to examine and report 
QoL outcomes. Similar to Monga36 and Segal’s33  supervised interventions above, we employed 
the FACT-P questionnaire. Our results show that both groups scored similarly at baseline 
however minor increases in overall QoL, as well as the physical, functional and prostate cancer 
specific domains of QoL were demonstrated in the exercise group. Control group participants 
QoL scores remained stable over the same time period. These improvements remained beyond 
the completion of EBRT and the intervention. This results further support the recommendation 
of home-based aerobic exercise as a self-help measure to manage maintain and improve HRQoL 
during and after EBRT34. 
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Anthropometric Measures 
 
Body composition 
ADT alters body composition, substantially increasing abdominal adiposity and decreasing lean 
body mass within 3 to 12 months of initiation of treatment. This loss of muscle mass is 
associated with reduced muscular strength, increasing falls and fracture risk, and impairment of 
physical performance of everyday activities. Furthermore, increased adiposity is also implicated 
in a range of chronic health problems. There is accumulating evidence suggesting an association 
between ADT and elevated cardiometabolic risk. This is particularly concerning given that 
among men with PCa, cardiovascular disease accounts for a proportion of mortality similar to 
that of PCa itself18. 
 
This is the first home-based interventions for PCa patients undergoing EBRT+ADT to report a 
measure of body composition. Exercise interventions for patients undergoing ADT only 
regularly record body composition measures. 
 
All studies included in Gardner’s review, of effects of exercise on treatment-related adverse 
effects for patients with prostate cancer receiving androgen-deprivation therapy, included body 
composition measures. Resistance training seems effective at preserving or even increasing total 
and regional lean body mass. In fact, no study reported reductions in lean body mass with 
exercise, despite skeletal muscle loss being a well-documented adverse effect of ADT. Unlike 
lean body mass, however, most studies did not observe a benefit of exercise regarding measures 
of adiposity18. 
 
Only one of the interventions included in this studies review of exercise interventions for PCa 
patients undergoing EBRT+ADT reported body composition type measures. Similarly to the 
ADT studies reported above, Segal et al33 reported that both control and aerobic training groups 
showed  a statistically significant increase in % body fat over 24 weeks. Resistance training 
participants showed a non-significant decrease in % body fat.  
 
It is possible that previous interventions did not achieve adequate energy expenditure for weight 
loss. At least 150 minutes per week of moderate-intensity exercise is recommended for weight 
loss18. Of note, the three studies in Gardner’s review that reported slight reductions in adiposity 
were among those prescribing higher training volumes18.  
 
In this study, on average, intervention participants decreased their weight while control 
participant gained weight. Intervention participants lost M= 1.7 Kg (SD 3.3) form Baseline to 1 
MT FU. Control participants gained M=1.7 Kg (SD= 1.7) over the same time period. It also 
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demonstrates that intervention participants’ % body fat decreased while on the intervention 
however control participants’ increased. Intervention participants lost M= 1.1% body fat (SD 
2.7) from Baseline to 1 MT FU. Control participants gained M=1.1% body fat (SD= 3.8) over 
the same time period. 
 
Control participants’ waist circumference also increased while intervention participants’ 
decreased. Intervention participants lost M= 0.9cm (SD 2.9) of waist circumference from 
Baseline to 1 MT FU. Control participants gained M=3.4cm   (SD= 3.3) over the same time 
period.  
 
Muscle mass increases were observed in the intervention groups, in comparison muscle mass 
decreases were in the intervention group. Intervention participants gained M= 0.5% muscle 
mass (SD 3.2) from Baseline to 1 MT FU. Control participants lost M=0.8% muscle mass (SD= 
3.8) over the same time period 
 
Intervention participants fare better on every objective measure of body composition compared 
to control participants. This is in contrast to previous aerobic exercise interventions either 
supervised or home-based. One possible explanation for these positive results is that  this study 
prescribed a 150 min/week of MVPA. This volume of MVPA is recommended for weight loss 
and is more than in previous aerobic exercise interventions. This exercise was in addition to 
participants’ habitual exercise. We also employed more rigorous measures to ensure adherence. 
 
Bone Health 
A recent study by Mennen-Winchell et al67 summarises the  the effects of ADT on bone health 
and the public health burden these effects have. The aim of ADT is chemical castration by 
decreasing patients’ testosterone levels below 50 ng/mL to suppress cancer tumour growth. 
However, this lack of testosterone impairs the cellular replication of new osteoblasts, decreasing  
bone mineral density BMD and increasing the risk for osteoporosis and bone fracture67.  During 
the first year of receiving ADT for prostate cancer, possibly two thirds of men will develop 
osteopenia or osteoporosis of the hip or spine67. BMD can decrease by up to 2.4% and 7.6% 
during years 1 and 2 of treatment with continuous decrease with each additional year of 
treatment. In the first year of ADT, fracture risk is 1.5 times greater than the norm, primarily in 
hip and spine. Recent interventions have demonstrated that BMD can be increased with 
exercise, which may decrease the risk for osteoporosis fractures. The effects of exercise training 
on bone health in patients with PCa receiving ADT are yet to be determined18.  
 
Galvao et al68 UCT investigated the effects of exercise on bone health, observing no change in 
hip BMD or total-body bone mineral content in a single cohort of 10 men after 20 weeks of 
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resistance training. The authors suggested this result may have represented an attenuation of 
ADT-induced bone loss. 
 
To the best of the author’s knowledge this is the first exercise intervention in PCa patients 
undergoing ADT+EBRT to report on any aspect of bone health. Participants’ bone mass was 
recorded at each of the four study assessments. There was no change from baseline to one 
month follow up in either group. However the limitations of the BIA scales to assess bone mass 
and the short time frame has to be considered. Dual-energy x-ray absorptiometry (Dexa) scans 
are considered the gold standard and should be considered in the future RCT. 
 
Physical Performance 
Decreases in cardiorespiratory and functional fitness are common in men undergoing ADT or 
EBRT+ADT.  These decreases combined with worsening anthropometric measures and fatigue 
put patients at a higher risk of metabolic syndrome as its associated conditions i.e. 
cardiovascular disease. 
 
This home-based MVPA exercise intervention improved participants’ physical performance. 
Both groups improved their cardiorespiratory fitness and functional performance from baseline 
to 1-month follow up. A greater increase was observed in the intervention group. 
 
Cardio respiratory fitness 
Cardiorespiratory fitness is a useful diagnostic and prognostic health indicator for patients in 
clinical settings. It is a strong and independent predictor of all-cause and cardiovascular disease 
mortality, but its importance is often overlooked. Several prospective studies indicate that CRF 
is at least as important as the traditional risk factors (hypertension, diabetes, smoking, or 
obesity), and is often more strongly associated with mortality69.  
 
Three of the RCTs included in Gardner’s review of the effects of exercise on treatment-related 
adverse effects for patients with prostate cancer receiving androgen-deprivation therapy, 
investigated changes in cardiorespiratory fitness. Bourke et al51 reported a significant 
improvement in cardiorespiratory fitness for the exercise group compared with controls63. 
Similarly, Galvao et al66 noted a borderline significant (P=.080) between-group difference in 
400-m walk time, favouring exercise63. In contrast, Culos-Reed et al39 reported no difference in 
6-minute walk test performance between groups63.  
 
Three of the interventions included in this study’s review of exercise interventions for PCa 
patients undergoing EBRT+ADT investigated changes in cardiorespiratory fitness. Segal et al33 
unexpectedly found an statistically significant increase in cardiorespiratory fitness in the 
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resistance group compared with a smaller non-significant increase in the aerobic group.  Monga 
et al36 and Windsor et al35 also demonstrated statistically significant increases in cardio 
respiratory fitness as measured using  metabolic equivalents during a treadmill test (METS) and 
shuttle runs test respectively. 
 
This is the only the second home-based aerobic exercise intervention to include a measure of 
cardiorespiratory fitness. It is the first intervention to use a standardised 2 minute step test. Both 
groups of patients in the current study demonstrated almost identical levels of cardiorespiratory 
fitness at baseline. Unexpectedly, both groups increased their cardiorespiratory fitness from 
baseline to 1 month follow up. Intervention participants increased their steps by M= 86.7 (SD 
62.3) from Baseline to 1 MT FU. This represents an increase of 55.8%.  Control participants 
also increased steps but by M=34.8 (SD= 40.7) over the same time period i.e. an increase of 30 
%. 
 
It was surprising to observe the progressive increase in 2-minute step test scores in the control 
group. Control group patients’ anthropometric measures progressively declined from baseline to 
1 month follow up. It is reasonable to assume that cardiorespiratory fitness would have followed 
a similar trend. One potential explanation may be that all patients were hesitant to push 
themselves to the maximum effort at baseline. We recruited patients at their CT scan and for 
most patients it was their first real interaction with SLRON staff. As patients became more 
familiar with the building and staff they may have felt more comfortable completing the test, 
hence, improving scores from assessment to assessment. It is also reasonable to deduce that 
intervention participant scores increased by nearly twice that of control participants as a result 
of the exercise intervention. This increase in cardiorespiratory fitness is consistent with 
observation from previous supervised aerobic ADT and EBRT+ADT interventions. It is 
encouraging to observe a similar increase in a simple home-based walking exercise intervention. 
 
Functional Fitness 
Intervention patients’ improvements in cardiorespiratory were accompanied by improvements in 
performance of a functional task i.e. 30 sit-stand test. These changes are important because they 
may contribute to preserving a patient’s capacity for independent living. In addition, 
improvements in functional task performance has been shown to protect against falls and 
fractures63. Overall, the effects of this home-based exercise intervention on physical 
performance in EBRT+ADT treated patients with PCa were similar to those observed in more 
costly supervised interventions63.  
 
Two of the RCTs included in Gardner’s review of effects of exercise on treatment-related 
adverse effects for patients with prostate cancer receiving androgen-deprivation therapy 
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investigated changes in functional tasks. Galvao et al66 reported superior performance in 6-m 
walk and 6-m backward walk in the exercise group, with borderline improvement in sit-to- 
stand performance (P=.074). No between-group differences existed for the 6-m fast-walk or 
stair-climb task63. Bourke et al51 also reported better sit-to-stand performance with exercise63. 
 
Only one of the interventions included in this study’s review of exercise interventions for PCa 
patients undergoing EBRT+ADT reported a measure of functional fitness. Monga et al36 
reported a 15% speed increase in completing the 5 sit-to-stands test (STS). 
 
In contrast to Monga et al36 above, in this study participants were asked to complete as many 
STS as possible in 30 seconds. Intervention participants increased their STS by M= 4.4 (SD 3.5) 
from Baseline to 1 MT FU. This represents an increase of 25.3%.  Control participants also 
increased steps but by M=1.3 (SD= 3.0) over the same time period i.e. an increase of 9.0 %. 
 
Considering that functional fitness is among the outcomes considered the most clinically 
significant by clinicians and cancer researchers alike, it is surprising that only three studies of 
any type included a measure of functional fitness. To the best of the author’s knowledge this is 
the first home-based intervention to include a functional fitness measure. Functional fitness 
score patterns mirror cardiorespiratory scores above. A similar explanation may also help to 
explain the increase in control group participant scores from baseline to 1 month follow-up. 
 
It is encouraging to see both measures of physical performance increase in this pragmatic home-
based walking exercise intervention considering the importance clinicians attribute to their role 
in treatment tolerance and recovery. 
 
Intervention Participants Acceptance of the Exercise Intervention 
No RCT for patients with prostate cancer receiving androgen-deprivation therapy investigated 
intervention satisfaction. Only one of the interventions included in this study’s review of 
exercise interventions for PCa patients undergoing EBRT+ADT reported a measure of 
participants’ acceptance of the exercise intervention. Truong et a38 carried out a home-based, 20 
minute/day, 3 days/week, 12 week moderate intensity walking intervention. Their intervention 
was rated as “convenient to extremely convenient” by 73% of intervention participants. 
Satisfaction was also rated as “good-excellent” by 92% of participants. 
 
In this pilot study, intervention patients gave very positive feedback about their experiences 
participating in the intervention and were generally clear about the advantages of their 
involvement in the exercise programme. No intervention participant had an overall negative 
experience on the trial. One participant did find the recruitment process “upsetting” as he felt we 
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rushed his CT appointment unnecessarily. He would have preferred to have been recruited at a 
separate appointment. However upon explanation he understood the logic and necessity to 
recruit patient at their CT appointment. In general patients had no issues with either the 
pedometer or the logbook. 
 
Intervention patients’ acceptance of the exercise intervention was evaluated using a self-
reported questionnaire in addition to in-depth interviews with four participants to elicit 
information on the subjects’ attitude, tolerance and satisfaction with the prescribed exercise. 
 
Intervention participants average convenience and satisfaction scores were 4.8/5 (SD=0.4) i.e. 
“extremely convenient” and 4.8/5 (SD=0.4) i.e. “extremely satisfied” respectively. It is 
encouraging to report convenience and satisfaction levels as high as Truong et al34, considering 
that we prescribed 2.5 times the volume of exercise per week and at a greater intensity. 
 
Intervention participants also reported experiencing no pain or discomfort participating in the 
exercise intervention. Reassuringly, 100% of intervention participant said they would be willing 
to continue with the intervention independently when they finished EBRT. 
 
Barriers and facilitators 
To the best of the author’s knowledge this is the first exercise intervention to investigate barriers 
and facilitators to completing an exercise intervention.  The research to date has focused on PCa 
survivors. The determinants of physical activity in prostate cancer survivors has been most 
commonly assessed using the Theory of Planned Behaviour-based questionnaires. These studies 
demonstrated that theory of behaviour constructs, that is, attitude, subjective norms and 
perceived behavioural control explain a moderate amount of the variance in physical activity 
intentions, with the intentions being a good predictor of physical activity levels70. As the focus 
of these studies has often been on the perceived physical and psychological benefits of physical 
activity much less is known about their barriers and facilitators to physical activity70. 
 
Recently, Zimmer et al70 investigated the  perceived barriers and facilitators to physical activity 
in men with prostate cancer. However none of these patients were on an exercise intervention. 
Facilitators to physical activity for cancer survivors undergoing ADT but not on an exercise 
intervention included clinician and spousal involvement, personal involvement/ownership of 
survivorship and group support. Fatigue, pre-existing co-morbidities, increased age and a lack 
of specific advice from their clinician were cited as barriers70.  
 
Two themes emerged as facilitators to completing prescribed exercise. The main facilitator was 
“convenience”. “The exercise then became part of their daily routine or as one patient put it 
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“the walking fitted into my treatment schedule58”  The second facilitator was “centre 
environment”. One centre was roughly a 15 minute walk from the train station.  Intervention 
patients’ decided independently to walk to and from the station to accumulate the 30 minutes 
MVPA, “Coming up on the train was handy because you could walk up from the station, that 
was 10 minutes or a quarter of an hour out of the way61” Another centre was located on a nice 
grounds with lots of green areas that patients took advantage of, “I chose to do the exercise in 
the grounds of St Luke’s in Rathgar, which is a Slí na Sláinte 1km per lap. I usually did three 
laps of that which is 30 minutes. Sometimes I did four58” 
 
Two themes also emerged as barriers to completing prescribed exercise. Time was a common 
barrier as most patients had to use public transport to get to their treatment centre. However 
patients appreciated the flexibility of the intervention and managed to fit in the 30 minutes 
walking at some stage during the day. Poor weather was also a barrier however we provided an 
indoor route as an alternative. Patients had no issues using the indoor routes throughout the 
SLRON network.  
 
The above investigation of barriers and facilitators to completing an exercise intervention 
demonstrate that in a future confirmatory RCT we need to continue to liaise with patients to 
make the intervention as convenient as possible. The importance of utilising the surrounding 
environments of each centre to facilitate the exercise has also been highlighted. In contrast, we 
need to continue to aid patients in planning when and how they will fit the prescribed exercise 
into their daily schedule. We also need to ensure patients are familiar with alternate indoor 
routes for use during times of poor weather. 
 
Control Participants Exercise KAP. 
This study provides further preliminary evidence that physical activity KAP of PCa patients is 
poor and exercise advice may not be provided routinely to prostate cancer patients undergoing 
EBRT+ADT. Control participants walked an average 45900 steps/week while undergoing 
EBRT. Chippererfield71 et al 2013  reported that of 356 men with PCa they surveyed, less than 
half were meeting the National Physical Activity Guidelines of Australia (41.9%). The Irish 
national physical activity guideline of 10000 steps/day is the same as Australia’s. Unfortunately 
only 17% of our control patients reached this target. 
 
Clinicians have been described as among the most influential promoters for encouraging 
behaviour change. The period of transition from a PCa patient to survivor has been described as 
a ‘teachable moment’, in which people are motivated to make positive lifestyle changes such as 
increasing MVPA. This period is one that clinicians should optimise without overwhelming the 
patient with excessive information72.  Our research further corroborates Zimmer et al70, 2014 
study outcome that there is a lack of specific advice from their clinician and this acts as barrier 
to physical activity. 
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Jones et al73 investigated the attitudes of radiation and medical oncologists in Canada about 
promoting physical activity to cancer survivors and most respondents agreed that exercise is 
helpful, important and safe. 
 
Research to date suggests that physical activity is not routinely discussed by clinicians with 
cancer survivors72.  Daley et al74  investigated the role of medical and clinical oncologists and 
surgeons in promoting physical activity to breast cancer patients in the U.K. and found that 
44.1% of clinicians reported giving physical activity advice routinely. In terms of prostate 
cancer survivors, research form Australia shows that most prostate cancer survivors do not 
recall receiving information from clinicians about physical activity75. A 2014 study by Spellman 
et al72 reported that although clinicians recognized the benefits of physical activity for their 
patients, few gave advice about physical activity. Over half of the clinicians (55%) reported that 
advising patients on physical activity was not part of their role75. 
 
Only 33% of patients in the control arm could recall a health care professional discuss the role 
of exercise during or after EBRT (3 Consultant, 1 Nurse). Subsequently patients had a poor 
knowledge of exercise. Only 42% of the control group were aware of the correct recommended 
weekly MVPA guidelines. 33% of control group participants were unaware that MVPA during 
EBRT may reduce treatment related adverse effect. 58% incorrectly thought that there are 
genuine safety risks associated with MVPA during EBRT. 92% agreed that exercise could 
improve HRQoL. 
 
It is worrying that despite their poor exercise knowledge, 100% of the control group felt 
confident that they knew how to keep physically active (practice) and only 50% were interested 
in learning more about physical activity (attitude). 
 
Since completing EBRT 67% of intervention participants have not charged their exercise 
regime. 17% say they have decreased exercise and only 17% say they have increased exercise. 
This evidence highlights the importance for future research to address the involvement of 
clinicians and other health care professions in physical activity promotion so that a more 
complete service is provided. 
 
This pilot study has comfortably satisfied the 6 feasibility criteria that had to be achieved for 
SLRON to recommend a future confirmatory RCT. The data from this pilot study will serve to 
inform the design and conduct of a  future RCT to confirm the role of a home-based MVPA 
intervention in improving fatigue, HRQoL, anthropometric measures and physical performance 
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for patients with prostate cancer undergoing EBRT+ADT. Finally this pilot intervention 
provides justification for proceeding to a confirmatory trial. 
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6. LIMITATIONS 
Although we feel that our results have many important implications for any future confirmatory 
RCT and how cancer clinicians prescribe exercise to PCa patients in general, the results and 
conclusions from this feasibility trial should be interpreted in the context of a number of 
limitations. 
 
The high rate of compliance and low loss to follow-up may not be achievable in a larger RCT or 
in clinical practice where the coordinator to participant ratio is decreased. 
 
The absence of more precise anthropometric measures (e.g., DEXA, MRI) limits any 
conclusions that can be drawn about changes in body composition. Bioelectric impedance 
analysis (BIA) may not be the ideal method of measuring body composition, since hydration 
status can affect findings; however, this method of body composition has been  used 
successfully in previous clinical trials with cancer patients and survivors.14 
 
Participants may have been particularly receptive to exercise particularly walking, creating a 
self-selection bias and the results may not be applicable to those less amenable to exercise in 
general or specifically walking. 
 
Pedometers are limited as physical activity measurement devices because they capture 
movement only of the lower body in the vertical plane and cannot distinguish between walking 
on different gradients. Although evidence does support a public health recommendation of 
walking at least 3000 steps in 30 minutes on 5 days each week to help meet current MVPA 
recommendations. This recommendation should not be used as a precise criterion as pedometer-
assessed step rates serve as a proxy for the metabolic equivalent energy expenditure of walking 
(METs). However, there is substantial error in predicting METs from step rate alone. Rather, it 
should be used as a public health promotion heuristic to help people lead more active 
lifestyles40. 
 
The sample was based in one large geographical region (Dublin hospitals and their catchment 
areas) and consisted of predominantly public healthcare patients. The men also appeared 
relatively physically active and were motivated enough to participate in this study. Thus, future 
studies in this area may wish to preferentially recruit patients undergoing EBRT+ADT who are 
not physically active to gain additional insight into their barriers and facilitators to physical 
activity. Future RCTs should consider longer-term follow up. 
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Finally, as with the previous four EBRT+ADT exercise intervention studies this study was 
neither fully blinded nor placebo-controlled; this can be largely explained by the nature of 
interventions. It is therefore possible that the benefits reported from the intervention were due to 
experimenter bias, or participant expectancy effects. However every reasonable precaution was 
taken to minimise such bias. 
 
7. CONCLUSION 
 
This preliminary evidence suggests that a pragmatic home-based MVPA walking exercise 
intervention is feasible and has the potential to evoke improvements in fatigue, in addition to 
other important health outcomes in men with PCa undergoing EBRT+ADT. 
 
In Ireland and indeed globally, the incidence of PCa is increasing. In addition, the number of 
men living as prostate cancer survivors is increasing thanks to improved treatment and 
management. This simultaneous increase in incidence and survivorship has focused researchers’ 
and clinicians’ efforts on improving CRF and HRQoL of both prostate cancer patients under 
active treatment, and prostate cancer survivors.  
 
Patients with localised prostate cancer undergoing EBRT+ADT in the SLRON experience 
clinically significant adverse events like CRF and decreased physical and functional capacity 
that diminish HRQoL and potentially increase the risk for  falls related fractures, coronary 
artery disease, stroke and type-2 diabetes. The public health burden of caring for prostate cancer 
survivors may therefore become even greater than caring for prostate cancer patients. 
 
Considering the lack of effective pharmacological and complementary treatments, RCT’s  like 
the current intervention are needed to confirm the feasibility and efficacy of the most promising 
solution; moderate to vigorous physical activity (MVPA). 
 
MVPA  interventions offset many of the side effects of EBRT and ADT with few side effects 
itself,4,5 however there is limited evidence and consequently a gap in our knowledge regarding 
the effects of an exercise intervention on treatment-related adverse effects and HRQoL for 
patients with PCa actively undergoing EBRT+ADT. 
 
Previous research tended to consider only the intervention efficacy and not with the practical 
issues of RCT feasibility. We know that greater HRQoL benefits for prostate cancer patients 
have thus far been associated with supervised combined aerobic and resistance facility based 
interventions, rather than home-based aerobic interventions50. The cost and availability of 
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human resources to provide exercise programs at radiotherapy centres is a barrier that severely 
limits programme delivery and access50. This is particularly relevant in the Irish health system at 
present. In addition, the patient related  obstacles of extra time spent in a hospital per day, extra 
parking costs and negative treatment experience may reduce participation in a facility-based 
intervention50.  
Considering these potential barriers, a home-based aerobic intervention is the preferred option 
as aerobic exercise  is safer and more effective in stimulating long-term changes in exercise 
behaviour as patients are likely to be more familiar with aerobic exercise such as walking than 
resistance modalities i.e. weight lifting50. 
Our research evaluated the feasibility and efficacy of a pragmatic, tailored, moderate to 
vigorous intensity home-based aerobic exercise intervention for prostate cancer patients actively 
undergoing EBRT+ADT before proceeding with a confirmatory RCT. 
 
This is the first home based exercise intervention to utilise a pedometer as an objective tool to 
both encourage and evaluate exercise adherence. It is also the first home based exercise 
intervention to assess participants' physical performance, and barriers/facilitators to completing 
exercise while undergoing EBRT. 
 
The exercise intervention group showed greater improvements in fatigue (much greater than 
anticipated), quality of life, anthropometric measures and physical performance compared to 
standard care controls. These improvements were sustained beyond the intervention period. 
Programme convenience and treatment centre environment emerged as exercise facilitators. 
Intervention participants average convenience and satisfaction scores were 4.8/5 (SD=0.4) i.e. 
“extremely convenient” and 4.8/5 (SD=0.4) i.e. “extremely satisfied” respectively. A lack of 
time and poor weather emerged as exercise barriers. Standard care controls had poor exercise 
KAP post EBRT, e.g. only 42% of the control group were aware of the correct recommended 
weekly MVPA guidelines.  
 
In conclusion, this study provides evidence that a pragmatic home-based MVPA walking 
exercise intervention is feasible and has great potential to evoke improvements in fatigue, 
HRQoL, anthropometric measures and physical performance in PCa patients undergoing 
EBRT+ADT. 
 
Our results suggest that a future definitive confirmatory RCT should:  
 Continue to concentrate on providing an intervention that builds on existing structures and 
processes in SLRON, 
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 Utilise each centres’ natural environment to provide both indoor and outdoor options should 
patients wish to complete their exercise independently around treatment times,  
 Spend more time exploring with patients how and when to fit exercise into their daily 
routines,  
 Give clearer instructions to coordinators on how to calculate step targets  and to patients on 
how to utilise the logbook and pedometers,   
 Research the availability of radio frequency resistant pedometers,  
 Consider recruiting more trial coordinators or limit the rate of recruitment, 
 Create a Standard Operating Procedure (SOP) with Radiotherapist, Treatment planners and 
Consultants detailing the management of patient contour reductions of ≥1 cm. This should 
include both imaging and visual inspection guidelines. 
 Consider recording physiological measurements i.e. heart rate and blood pressure at each 
assessment, 
 Consider utilising more sophisticated methods to assess bone mass i.e. a DEXA scan. 
 
The researcher can conclude that this intervention is effective and has achieved its: process, 
resource, management and scientific feasibility criteria and should proceed to a confirmatory 
RCT with 9 patients per arm to try replicate fatigue effect sizes. Sample size estimates are based 
on an effect size of 1.67 at 90% statistical power to detect fatigue differences between control 
and treatment groups using a two-tail two-sample t-test using a 5% significance level. This 
confirmatory trial should only include two assessment appointments for participants, one at 
baseline and one at the end of the intervention. If the results of the confirmatory trial replicate 
the pilot study, SLRON should introduce walking prescriptions into clinical practice.
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9.1. APPENDIX A: Exercise Study Case Report Form 
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Acute Toxicity Form – Exercise Study 
 
Please Grade Using CTCAE Version 3.0 
WEEK No: 1 2 3 4 5 6 7 8 9 
No of Treatments          
DATE /   / /   / /   / /   / /   / /   / /   / /   / /   / 
KPS %          
Fatigue          
          
BOWEL          
Diarrhoea          
Constipation          
Rectal Pain          
Proctitis          
Rectal Bleeding          
Number of 
BMs/Day 
         
Mucous Discharge Yes  No
  
Yes  No
  
Yes  No
  
Yes  No
  
Yes  No
  
Yes  No
  
Yes  No
  
Yes  No
  
Yes  No
  
          
BLADDER          
Urgency/ Frequency          
Dysuria          
Haematuria          
Urinary Retention          
Incontinence          
Nocturia 
(Number per night) 
         
          
SKIN          
Radiation 
Dermatitis 
         
SEXUAL 
DYSFUNCTION 
         
Erectile 
Dysfunction 
        
Libido         
          
HORMONAL  
TREATMENT     
         
Gynaecomastia         
Hot Flushes         
          
Unexpected Event 
 
Yes  No
 
Yes  No
 
Yes  No
 
Yes  No
 
Yes  No
 
Yes  No
 
Yes  No
 
Yes  No
 
Yes  No
 
If YES: 
State Event and 
Grade 
 
        
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9.2. APPENDIX B: Brief Fatigue Inventory 
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9.3. APPENDIX C: Functional Assessment of Cancer Therapy - Prostate  
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9.4. APPENDIX D: Log Book 
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9.5. APPENDIX E: Satisfaction Questionnaire 
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6. Did you find the study questionnaires easy to understand and complete? 
     Yes        No       (if no please explain) 
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9.6. APPENDIX F: In-Depth Interview Guide 
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9.7. APPENDIX G: Patient Information Leaflet and Informed Consent Form 
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9.8. APPENDIX H:  Key Informant Interview Guide for Trial Co-ordinators 
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9.9. APPENDIX I: Control Group Physical Activity KAP 
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9.10. APPENDIX J: World Medical Association Declaration of Helsinki 
 
Ethical Principles for Medical Research Involving Human Subjects 
 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000  
53th WMA General Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 
55th WMA General Assembly, Tokyo 2004 (Note of Clarification on Paragraph 30 added) 
59th WMA General Assembly, Seoul, October 2008 
 
 
A.  INTRODUCTION 
 
1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a 
statement of ethical principles for medical research involving human subjects, including 
research on identifiable human material and data. 
 
 The Declaration is intended to be read as a whole and each of its constituent paragraphs 
should not be applied without consideration of all other relevant paragraphs. 
 
2. Although the Declaration is addressed primarily to physicians, the WMA encourages 
other participants in medical research involving human subjects to adopt these principles.  
 
3. It is the duty of the physician to promote and safeguard the health of patients, including 
those who are involved in medical research. The physician's knowledge and conscience 
are dedicated to the fulfilment of this duty.  
 
4. The Declaration of Geneva of the WMA binds the physician with the words, “The health 
of my patient will be my first consideration,” and the International Code of Medical 
Ethics declares that, “A physician shall act in the patient's best interest when providing 
medical care.” 
 
5. Medical progress is based on research that ultimately must include studies involving 
human subjects. Populations that are underrepresented in medical research should be 
provided appropriate access to participation in research. 
 
6. In medical research involving human subjects, the well-being of the individual research 
subject must take precedence over all other interests. 
 
7. The primary purpose of medical research involving human subjects is to understand the 
causes, development and effects of diseases and improve preventive, diagnostic and 
therapeutic interventions (methods, procedures and treatments). Even the best current 
interventions must be evaluated continually through research for their safety, 
effectiveness, efficiency, accessibility and quality. 
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8. In medical practice and in medical research, most interventions involve risks and burdens. 
 
9. Medical research is subject to ethical standards that promote respect for all human 
subjects and protect their health and rights. Some research populations are particularly 
vulnerable and need special protection. These include those who cannot give or refuse 
consent for themselves and those who may be vulnerable to coercion or undue influence.  
 
10. Physicians should consider the ethical, legal and regulatory norms and standards for 
research involving human subjects in their own countries as well as applicable 
international norms and standards. No national or international ethical, legal or regulatory 
requirement should reduce or eliminate any of the protections for research subjects set 
forth in this Declaration.  
 
B. PRINCIPLES FOR ALL MEDICAL RESEARCH 
 
11. It is the duty of physicians who participate in medical research to protect the life, health, 
dignity, integrity, right to self-determination, privacy, and confidentiality of personal 
information of research subjects. 
 
12. Medical research involving human subjects must conform to generally accepted scientific 
principles, be based on a thorough knowledge of the scientific literature, other relevant 
sources of information, and adequate laboratory and, as appropriate, animal 
experimentation. The welfare of animals used for research must be respected.  
 
13. Appropriate caution must be exercised in the conduct of medical research that may harm 
the environment. 
 
14. The design and performance of each research study involving human subjects must be 
clearly described in a research protocol. The protocol should contain a statement of the 
ethical considerations involved and should indicate how the principles in this Declaration 
have been addressed. The protocol should include information regarding funding, 
sponsors, institutional affiliations, other potential conflicts of interest, incentives for 
subjects and provisions for treating and/or compensating subjects who are harmed as a 
consequence of participation in the research study. The protocol should describe 
arrangements for post-study access by study subjects to interventions identified as 
beneficial in the study or access to other appropriate care or benefits.  
 
15. The research protocol must be submitted for consideration, comment, guidance and 
approval to a research ethics committee before the study begins. This committee must be 
independent of the researcher, the sponsor and any other undue influence. It must take 
into consideration the laws and regulations of the country or countries in which the 
research is to be performed as well as applicable international norms and standards but 
these must not be allowed to reduce or eliminate any of the protections for research 
subjects set forth in this Declaration. The committee must have the right to monitor 
ongoing studies. The researcher must provide monitoring information to the committee, 
especially information about any serious adverse events. No change to the protocol may 
be made without consideration and approval by the committee. 
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16. Medical research involving human subjects must be conducted only by individuals with 
the appropriate scientific training and qualifications. Research on patients or healthy 
volunteers requires the supervision of a competent and appropriately qualified physician 
or other health care professional. The responsibility for the protection of research subjects 
must always rest with the physician or other health care professional and never the 
research subjects, even though they have given consent. 
 
17. Medical research involving a disadvantaged or vulnerable population or community is 
only justified if the research is responsive to the health needs and priorities of this 
population or community and if there is a reasonable likelihood that this population or 
community stands to benefit from the results of the research.  
 
18. Every medical research study involving human subjects must be preceded by careful 
assessment of predictable risks and burdens to the individuals and communities involved 
in the research in comparison with foreseeable benefits to them and to other individuals or 
communities affected by the condition under investigation. 
 
19. Every clinical trial must be registered in a publicly accessible database before recruitment 
of the first subject. 
 
20. Physicians may not participate in a research study involving human subjects unless they 
are confident that the risks involved have been adequately assessed and can be 
satisfactorily managed. Physicians must immediately stop a study when the risks are 
found to outweigh the potential benefits or when there is conclusive proof of positive and 
beneficial results.  
 
21. Medical research involving human subjects may only be conducted if the importance of 
the objective outweighs the inherent risks and burdens to the research subjects. 
 
22. Participation by competent individuals as subjects in medical research must be voluntary. 
Although it may be appropriate to consult family members or community leaders, no 
competent individual may be enrolled in a research study unless he or she freely agrees.  
 
23. Every precaution must be taken to protect the privacy of research subjects and the 
confidentiality of their personal information and to minimize the impact of the study on 
their physical, mental and social integrity.  
 
24. In medical research involving competent human subjects, each potential subject must be 
adequately informed of the aims, methods, sources of funding, any possible conflicts of 
interest, institutional affiliations of the researcher, the anticipated benefits and potential 
risks of the study and the discomfort it may entail, and any other relevant aspects of the 
study. The potential subject must be informed of the right to refuse to participate in the 
study or to withdraw consent to participate at any time without reprisal. Special attention 
should be given to the specific information needs of individual potential subjects as well 
as to the methods used to deliver the information. After ensuring that the potential subject 
has understood the information, the physician or another appropriately qualified 
individual must then seek the potential subject’s freely-given informed consent, 
preferably in writing. If the consent cannot be expressed in writing, the non-written 
consent must be formally documented and witnessed. 
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25. For medical research using identifiable human material or data, physicians must normally 
seek consent for the collection, analysis, storage and/or reuse. There may be situations 
where consent would be impossible or impractical to obtain for such research or would 
pose a threat to the validity of the research. In such situations the research may be done 
only after consideration and approval of a research ethics committee.  
 
26. When seeking informed consent for participation in a research study the physician should 
be particularly cautious if the potential subject is in a dependent relationship with the 
physician or may consent under duress. In such situations the informed consent should be 
sought by an appropriately qualified individual who is completely independent of this 
relationship.  
 
27. For a potential research subject who is incompetent, the physician must seek informed 
consent from the legally authorized representative. These individuals must not be 
included in a research study that has no likelihood of benefit for them unless it is intended 
to promote the health of the population represented by the potential subject, the research 
cannot instead be performed with competent persons, and the research entails only 
minimal risk and minimal burden.  
 
28. When a potential research subject who is deemed incompetent is able to give assent to 
decisions about participation in research, the physician must seek that assent in addition to 
the consent of the legally authorized representative. The potential subject’s dissent should 
be respected.  
 
29. Research involving subjects who are physically or mentally incapable of giving consent, 
for example, unconscious patients, may be done only if the physical or mental condition 
that prevents giving informed consent is a necessary characteristic of the research 
population. In such circumstances the physician should seek informed consent from the 
legally authorized representative. If no such representative is available and if the research 
cannot be delayed, the study may proceed without informed consent provided that the 
specific reasons for involving subjects with a condition that renders them unable to give 
informed consent have been stated in the research protocol and the study has been 
approved by a research ethics committee. Consent to remain in the research should be 
obtained as soon as possible from the subject or a legally authorized representative. 
 
30. Authors, editors and publishers all have ethical obligations with regard to the publication 
of the results of research. Authors have a duty to make publicly available the results of 
their research on human subjects and are accountable for the completeness and accuracy 
of their reports. They should adhere to accepted guidelines for ethical reporting. Negative 
and inconclusive as well as positive results should be published or otherwise made 
publicly available. Sources of funding, institutional affiliations and conflicts of interest 
should be declared in the publication. Reports of research not in accordance with the 
principles of this Declaration should not be accepted for publication. 
 
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE 
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31. The physician may combine medical research with medical care only to the extent that the 
research is justified by its potential preventive, diagnostic or therapeutic value and if the 
physician has good reason to believe that participation in the research study will not 
adversely affect the health of the patients who serve as research subjects.  
 
32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against 
those of the best current proven intervention, except in the following circumstances: 
 The use of placebo, or no treatment, is acceptable in studies where no current proven 
intervention exists; or 
 Where for compelling and scientifically sound methodological reasons the use of 
placebo is necessary to determine the efficacy or safety of an intervention and the 
patients who receive placebo or no treatment will not be subject to any risk of serious 
or irreversible harm.  Extreme care must be taken to avoid abuse of this option. 
 
33. At the conclusion of the study, patients entered into the study are entitled to be informed 
about the outcome of the study and to share any benefits that result from it, for example, 
access to interventions identified as beneficial in the study or to other appropriate care or 
benefits.  
 
34. The physician must fully inform the patient which aspects of the care are related to the 
research. The refusal of a patient to participate in a study or the patient’s decision to 
withdraw from the study must never interfere with the patient-physician relationship. 
 
35. In the treatment of a patient, where proven interventions do not exist or have been 
ineffective, the physician, after seeking expert advice, with informed consent from the 
patient or a legally authorized representative, may use an unproven intervention if in the 
physician's judgement it offers hope of saving life, re-establishing health or alleviating 
suffering. Where possible, this intervention should be made the object of research, 
designed to evaluate its safety and efficacy. In all cases, new information should be 
recorded and, where appropriate, made publicly available.  
 
